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“Nein”, erwiderte der Alchemist. „Was du noch wissen musst, ist folgendes: Immer, 
bevor ein Traum in Erfüllung geht, prüft die Weltenseele all das, was auf dem Weg 
gelernt wurde. Sie macht das nicht etwa aus Bosheit, sondern damit wir gemeinsam 
mit unserem Traum auch die Lektionen in Besitz nehmen, die wir auf dem Pfad 
dorthin gelernt haben. […] Eine Suche beginnt immer mit dem Anfänger Glück. Und 
sie endet immer mit der Prüfung des Eroberers.“ 
- Paulo Coelho, Der Alchemist –  
 
 
 
 
Für meinen Vater 
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SUMMARY 
Hematopoietic stem cell (HSC) research largely relies on cell culture models or 
mouse transplantation studies. Moreover, HSCs are rare and immunophenotypic 
definitions are incomplete, rendering the characterization of HSCs difficult. In this study, 
we circumvented these restrictions using >180,000 γ-retroviral (γRV) integration sites 
(ISs) from a gene therapy trial on 10 Wiskott-Aldrich-Syndrome patients. γRV ISs leave a 
unique tag to hematopoietic stem and progenitor cells (HSPCs) that engraft in patients, 
which are passed on to all progeny, making them suitable to track clonal reconstitution 
dynamics. Moreover, γRV ISs can be used to map active promoters and enhancers, due 
to their predilection to integrate at such sites. ISs recovered during stable long-term 
hematopoiesis would therefore point towards active promoters and genes that originate 
from true repopulating long-term HSCs. However, due to the genotoxic potential of 
γRVs, ISs are often regarded as molecular tags that point towards proto-oncogenes. 
To examine this in more detail, we first cloned 20 protein-coding genes that 
showed a large number of ISs in their vicinity and established a pooled lentiviral 
overexpression library to study their influence on proliferation, self-renewal and 
differentiation of HSPCs. Although the characterization of individual candidate genes 
was limited by transduction efficiencies and library representation, we observed that not 
a single candidate gene led to clonal expansion or measurable increase in self-renewal 
during both in vitro and in vivo experiments, suggesting that γRV genotoxicity is less 
universal than expected. 
Based on this, we assessed the cumulative number of ISs per gene over time and 
statistically compared γRV IS pattern before and after transplantation, demonstrating 
that the clonal skewing of IS pattern is indeed restricted to only few known 
leukemogenic loci. We next modeled the hematopoietic reconstitution after 
transplantation in humans and used these insights to define long-term HSC specific ISs, 
which confirmatively showed the highest ATAC-seq signal intensity at HSC specific peaks, 
efficiently enriched for HSC specific gene sets and strongly correlated with 
hematopoietic risk variants. Finally, through integration of publicly available ATAC-seq, 
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ChIP-seq, capture Hi-C as well as GWAS SNP data, we were able to create the first 
genome wide map for active gene-regulatory regions in functionally defined human 
repopulating long-term HSCs. 
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ZUSAMMENFASSUNG 
Forschung an hämatopoetischen Stammzellen (HSZ) basiert weitgehend auf 
Zellkulturmodellen oder Maus Transplantationsstudien. Darüber hinaus sind HSZ sehr 
selten und deren immunphänotypische Aufreinigung oft unzureichend, was die 
Charakterisierung von HSZ zusätzlich erschwert. Durch die Verwendung von mehr als 
180,000 γ-retrovirale (γRV) Integrationsstellen (IS) aus einer Gentherapie-Studie an 10 
Wiskott-Aldrich-Syndrom Patienten konnten wir jedoch die vorher genannten 
Einschränkungen umgehen. Dies ist möglich, da die γRV IS eine unverwechselbare 
Markierung in hämatopoetische Stamm- und Vorläuferzellen (HSVZ) hinterlassen, die an 
alle Nachkommen weitergegeben wird. Da γRV präferentiell in aktiven regulatorischen 
Einheiten integrieren, können mithilfe der genomischen Positionen von IS nicht nur 
klonale Rekonstitutionsdynamiken analysiert werden, sondern auch aktive Promotoren 
und Enhancer kartografiert werden. IS die während der stabilen Langzeit-Hämatopoese 
detektiert wurden, weisen daher auch auf aktive Promotoren und Gene hin, die von 
repopulierenden Langzeit-HSZ abstammen. Allerdings werden γRV IS aufgrund ihres 
genotoxischen Potentials auch oft als molekulare Markierungen für Proto-Onkogene 
angesehen. 
Um dies weiter zu untersuchen, klonierten wir zunächst 20 Protein-kodierende 
Gene, die eine große Anzahl von IS in ihrer Nähe aufwiesen, in eine lentivirale 
Überexpression Bibliothek um deren Einfluss auf Proliferation, Selbsterneuerung und 
Differenzierung in HSVZ zu untersuchen. Obwohl die Charakterisierung einzelner 
Kandidatengene durch Transduktionseffizienzen limitiert war, konnten wir weder 
klonale Expansion oder messbare Zunahme der Selbsterneuerung während der in vitro 
noch der in vivo Experimenten feststellen. Dies lies vermuten, dass γRV Genotoxizität 
weniger universal ist als bisher angnommen. 
Basierend darauf haben wir sowohl die zeitliche Zunahme an IS pro Gen 
gemessen, als auch das IS Muster vor und nach der Transplantation statistisch 
verglichen. Diese Analysen zeigten ebenfalls, dass klonale Verzerrungen des IS Musters 
tatsächlich auf einige bekannte leukämogene Loci beschränkt sind. Als nächstes 
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modellierten wir die hämatopoetische Rekonstitution nach Transplantation bei 
Menschen und nutzten diese Erkenntnisse, um HSZ-spezifisches IS zu definieren. Die 
HZS-Spezifität konnte weiterhin sowohl durch eine hohe Korrelation mit 
HSZ-spezifischen „ATAC-Seq“ Signalen gezeigt werden, als auch durch signifikante 
Anreicherung von IS an HSZ-spezifischen Genen und hämatopoetischen Risiko-
Genomvarianten. Zusammenfassend konnten wir durch die Integration von öffentlich 
verfügbaren Hochdurchsatz-Sequenzdaten (ATAC-seq, ChIP seq, HiC, GWAS-SNP) die 
erste genomweite Karte für aktive regulatorische Regionen in funktionell definierten 
humanen repopulierenden HSZ erstellen.  
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1 INTRODUCTION 
1.1 Hematopoiesis – the producOon of blood 
The term hematopoiesis describes the production of the cellular components of 
the blood system, one of the most regenerative tissues in the body. Every day, 1012 - 1013 
blood cells are produced in the human body, which resemble about 45% of the five to six 
liters of blood in a human adult. This so-called hematocrit can be coarsely segregated 
into red and white blood cells and platelets. While red blood cells were already 
described in the 17th century, it took until the 1840s until platelets and white blood cells 
(leukocytes) were discovered (Hajdu, 2003). Up until today, well over 20 differentiated 
blood cell types and their precursors have been described. The underlying principles of 
their formation however are still under heavy investigations with implications ranging 
from basic science to translational medicine. 
1.1.1 From hematopoiesis to hematopoieOc stem cells 
While the existence of different blood cell types was already postulated in the 
17th century, their birthplace was only discovered in 1868 by a pathologist, who reported 
for the first time that in mammals, blood cells are produced in the bone marrow (BM) 
and that mature cells exit the marrow via small blood vessels. Up until then, leukemia 
was considered a deficiency disease, so physicians eagerly began to test rather bizarre 
treatments based on these new findings. For example, patients were compelled to 
swallow fresh BM from juvenile cattle at equal parts with fresh orange juice (Forman et 
al., 2015). Obviously, such therapeutic approaches remained without success and it took 
until the 1950s before first allogeneic hematopoietic cell transplantations were reported. 
In 1954, it was noted that irradiated mice recover after infusions from spleen and BM 
cells, followed by experiments in 1956 that showed that transplanted recipient mice 
exhibit the same cytogenetic characteristics of the donor (Ford et al., 1956). In the same 
year, the first successful treatment for leukemia in mice was reported: high-dose full 
body irradiation followed by BM transplantation (Barnes et al., 1956). Although 
hematopoietic precursor cells were already postulated in the 19th century, the first 
experimental evidence for the existence of hematopoietic stem cells (HSCs) –although 
not defined yet – was only given with these transplantation experiments. Directed 
Introduction 
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research on HSCs first began with observations made by Till and McCulloch in the 1960s, 
who reported that the number of colonies in the spleen are related to the number of 
marrow cells transplanted and that colonies contained myeloid and erythroid cells (Till 
and McCulloch, 1961). Later it was reported that cells within individual spleen colonies 
are clonal thus originate from a common precursor (Bortin, 1970; Thomas et al., 1959; 
Thomas et al., 1957; Wu et al., 1967) and that colonies were formed even after 
secondary transplantations (Siminovitch et al., 1963). Right about then, these features – 
multipotency and the capacity to self-renew – were the defining properties of 
hematopoietic stem cells (HSCs), which still hold true today. The isolation or enrichment 
of HSCs, however, was not possible before the development of monoclonal antibodies 
(ABs) against blood cell surface markers and fluorescence-activated cell sorters (FACS) in 
combination with new clonogenic in vivo and in vitro assays for differentiated cells 
(Forman et al., 2015). In the following paragraphs, the prospective isolation of HSCs as 
well as the hematopoietic system with its numerous cell types and hierarchical 
organization is discussed in more detail.  
1.1.2 Immunophenotypic isolaOon of murine and human hematopoieOc 
stem cells 
With the knowledge of the existence of hematopoietic stem cells and the arising 
technological advances such as the development of monoclonal ABs and FACS, 
researchers eagerly sought for surface markers that would help to distinguish HSC from 
other populations. The first striking enrichment for murine HSCs was achieved by 
selecting for cells that would not express any markers that are characteristic for 
differentiated cells (Lineage negative; Lin-), such as B220 (B cells), CD11b and Gr-1 
(granulocytes) or CD4 and CD8 (T cells) (Müller-Sieburg et al., 1988; Müller-Sieburg et al., 
1986). Furthermore, it was noted that mouse Lin- cells were also low for Thy-1 (CD90), a 
marker that in combination with stem cell antigen-1 (Sca-1) positivity enriched HSCs 
even further (Spangrude et al., 1988). Soon after, the stem cell factor receptor c-Kit was 
discovered, which coined the still widely used “LSK” marker combination: 
Lin- Sca-1+ c-Kit+ (Ikuta and Weissman, 1992; Ogawa et al., 1991).In the following years, 
scientist developed growing panels of surface marker combinations to increase the 
purity of the HSC population. For example, LSK cells being additionally negative for CD34 
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and CD135 (Flk2/Flt3) show even higher HSC activity, with CD34 further segregating HSCs 
into cells with short-term (CD34+) and long-term (CD34-) repopulating properties 
(Adolfsson et al., 2001; Christensen and Weissman, 2001; Osawa et al., 1996). LSK 
markers can also be combined with the signaling lymphocytic activation molecule (SLAM) 
markers, CD48 and CD150 with HSCs being positive for CD150 and negative for CD48 
(Kiel et al., 2005). Also, the combination of LSK, CD34, CD135 and SLAM markers yields 
highly purified HSCs (Wilson et al., 2008). Apart from using these markers for the 
prospective enrichment of HSCs, other combinations of the same surface molecules can 
also be used for e.g. more committed progenitors (Figure 1A).  
Compared to murine HSCs, identifying surface markers for human HSCs poses 
much more challenges. All of the above described surface marker combinations were 
discovered and validated through mouse transplantation experiments. Such functional 
experiments measure the engraftment and output of the transplanted cells, with true 
HSCs being capable of replenishing the entire blood system with all lineages over a long 
period of time. Human cells however are rejected by the murine immune system upon 
transplantation, raising the need for immunodeficient mice. To date, many different 
immunodeficient mouse models exist, such as the widely used NOD-Scid Il2γc-/- (NSG) 
mice, which lack B and T and natural killer (NK) cells. Interestingly, the very first marker 
for the enrichment of human HSCs was already discovered before the presence of 
immunodeficient mice. In 1984, Civin and colleagues discovered CD34 as a surface 
marker only present on histologically immature normal and leukemic BM cells (Civin et 
al., 1984). Later, numerous transplantation experiments in mice and patients validated 
CD34 as an HSC-enriching marker, which is still widely used today. Other important 
human HSC markers were discovered only later with the help of transplantation 
experiments, for example the absence of CD45R (Lansdorp et al., 1990), CD38 (Bhatia et 
al., 1997) and low rhodamine 123 retention (Rholow) (McKenzie et al., 2007) or on the 
contrary expression of CD90 (Baum et al., 1992) and CD49f (Notta et al., 2011). Taking all 
of these markers together, CD34+ CD38- CD45RA- CD90+ CD49f+ and Rholow cells would 
resemble the highest possible enrichment of human HSCs to date (Figure 1B). Although 
about 1 in 15 cells within this pool possesses the ability of long-term blood reconstitution 
(Huntsman et al., 2015), one has to consider that some cells outside this definition also 
have the capacity for long-term engraftment, which also holds true for 
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immunophenotypically enriched murine HSCs. For example Weksberg et al. (2008) 
showed, that a CD150- side population also contained long-term HSCs. Moreover, recent 
technological advances like single cell sequencing as well as single cell transplantation 
experiments indicate significant heterogeneity even within highly purified populations, 
raising the question how well phenotype and function are really linked (Lu et al., 2011; 
McKenzie et al., 2006; Velten et al., 2017).  
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Figure 1 | Hierarchical organization of the murine and human hematopoietic system.  
A | Simplified concept of the murine hematopoietic lineage tree showing stem and progenitor cells with 
their most important surface marker combinations on the left and fully differentiated blood cells on the 
right. B | Simplified version of the human hematopoiesis, again with the most relevant surface markers for 
stem and progenitor cells. For both panels, selected intermediate populations are not depicted for clarity. 
HSC, Hematopoietic stem cell; ST-HSC, Short-term hematopoietic stem cell; MPP1-4, Multipotent 
progenitors (1-4); CMP, Common myeloid progenitor; CLP, Common lymphoid progenitor; MEP, 
Megakaryocyte erythroid progenitor; GMP, Granulocyte macrophage progenitor; MLP, multilymphoid 
progenitor; ETP, earliest thymic progenitors; pro B, pro B cells; B/NK, B cell NK cell precursor. Adapted 
from Doulatov et al. (2012) and modified according to Cabezas-Wallscheid et al. (2014), Haas et al. (2015), 
Wilson et al. (2008) and Rieger and Schroeder (2012). 
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1.1.3 The hematopoieOc system – discrete vs. conOnuum-based models 
Classically, the hematopoietic system is regarded as a series of divisions and 
differentiation events originating from a population of homogenous multipotent HSCs 
that reside at the apex of a hierarchically organized branching tree. In this classical 
model, the maturation of a primitive precursor cell towards a fully differentiated effector 
cell is characterized by a compulsory stepwise progression through intermediates 
(Figure 1 and Figure 2A). However, it is important to note that this model has recently 
been challenged by studies showing significant heterogeneity of HSCs in terms of 
self-renewal capacity and lineage biases (Morita et al., 2010; Notta et al., 2016; Velten et 
al., 2017) or even direct maturation of HSCs into megakaryocytes (Haas et al., 2015). As a 
result, new models were proposed such as the early-split model or the continuous 
Waddington-like model. Evidence for early HSC lineage separation (early-split) arose 
from studies showing uni-lineage output of single phenotypic HSCs in transplantation 
experiments or that common-myeloid progenitors (CMPs) are a mixture of committed 
uni-lineage cells that already lost their presumed oligo-potency (Karamitros et al., 2018; 
Rodriguez-Fraticelli et al., 2018) (Figure 2B). Partially in line with this are observations 
from single cell RNA-seq experiments that showed that HSCs gradually acquire lineage 
biases instead of transitioning from one discrete state to another. It was also noted, that 
HSCs directly give rise to uni-lineage restricted cells from a so called continuum of low-
primed undifferentiated hematopoietic stem and progenitor cells (CLOUD-HSPCs) (Haas 
et al., 2018; Velten et al., 2017) (Figure 2C). 
The causes for the HSC heterogeneity are still subject of intensive investigations. 
Until now, several determinants have been suggested, such as the location of the stem 
cell in the BM niche or the genetic and epigenetic heterogeneity. However, also 
transcriptional and metabolic activity, segregation of cell fate determinants or simply 
stochasticity may also serve as distinct sources of HSC heterogeneity (Haas et al., 2018).  
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Figure 2 | Classical and modern models of the hematopoietic tree.  
A | In the classical model, a series of division and differentiation events occur, originating from a 
population of homogenous multipotent HSCs that reside at the apex of a hierarchically organized 
branching tree. B | The early-split model, in which HSCs and MPP are mostly determined in their lineage 
potential. C | The continuous Waddington-like model, in which HSCs undergo a continuous lineage 
commitment. In this model, progenitor populations such as MPPs, CMPs or CLPs do not resemble stable 
cell types but rather transitory states. Reprinted from (Haas et al., 2018), copyright 2018, with permission 
from Elsevier. 
1.1.4 Post-transplant versus unperturbed steady-state hematopoiesis 
Transplantation experiments have greatly advanced our current understanding of 
the hematopoietic system, but their results have always been limited by the fact that it 
might not represent the normal physiological situation. Recently, non-invasive in situ fate 
mapping of HSCs has been successfully employed to study hematopoiesis in mice in an 
unperturbed setting. These new insights have uncovered major differences between 
normal and post-transplant hematopoiesis such as the number of actively contributing 
clones. During unperturbed steady-state hematopoiesis in mice, blood production is 
believed to be maintained by a large number of MPPs, which alternate between 
proliferation and dormancy. HSCs are also actively contributing to hematopoiesis, but to 
a much smaller degree (Busch et al., 2015; Sun et al., 2014). In contrast, post-transplant 
hematopoiesis is driven by a much smaller number of clones which are active over a 
much longer period of time. Also, the contribution of HSCs and progenitors to the blood 
system was found to change at different time points. After HSC or BM transplantation in 
humans and primates, the hematopoietic reconstitution is believed to occur in two 
major waves. A short-term reconstitution phase, lasting about 6-12 months and mostly 
driven by progenitors is followed by a long-term reconstitution phase, starting around 
6-12 months after transplantation, mostly driven by HSCs but also long-term MPPs 
(Biasco et al., 2016; Kim et al., 2014) (Similar observations were made in mice). 
Moreover, due to the long-lasting contribution to the blood production, transplanted 
HSCs are required to have a much higher self-renewal rate compared to HSCs in 
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steady-state. However, the major advantage of transplantation settings is that it 
naturally selects for self-renewing cells that have the ability to repopulate an entire 
organism, hence fulfill all HSC-defining criteria. In contrast, models to study unperturbed 
hematopoiesis again rely on phenotypic definitions of HSCs to use HSC specific loci for 
the transgene expression, leading to biases towards HSC subsets which might not 
represent the whole populations (Busch and Rodewald, 2016). 
 
Figure 3 | Model of clonal dynamics after HSPC transplantation. 
Lentiviral integration sites were used to track individual clones after autogenetic HSPC transplantation 
leading to the proposed model of human hematopoietic reconstitution. GT, gene therapy. Reprinted from 
Biasco et al. (2016), with permission from Elsevier.  
In summary, the endeavor to maintain the cellular composition within the 
hematopoietic system, to respond to intrinsic and extrinsic stimuli and to repopulate an 
entire organism after transplantation through self-renewal, proliferation and 
differentiation resembles an extremely complex task for HSCs. As a consequence, HSC 
behavior needs to be tightly controlled, which in turn is regulated through the 
spatiotemporal activity of genes and their gene-regulatory regions. 
1.2 Gene regulaOon in eukaryotes 
The proportion of protein-coding genes within the genome is almost identical 
across all metazoans regardless of their biological complexity and constitutes only about 
1.5 - 3% of the genome. In contrast, the amount of non-protein-coding DNA (ncDNA) 
positively correlates with the biological complexity of the organism and is nowadays 
appreciated as one basic prerequisite for complex life (Liu et al., 2013). Parts of the 
ncDNA comprise of regulatory elements and non-coding RNAs (ncRNA) required for 
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orchestrating the spatiotemporal expression of genes during development, maintenance 
and homeostasis in all tissues at all times. Consequently, its understanding is 
fundamental to many biological processes, physiological as well as malignant. To this 
date, many different types of gene-regulatory regions are known, which interact with the 
gene promoter trough large protein complexes to modulate gene expression. In the 
following paragraphs, the most important regulatory elements, such as promoters, 
enhancers, insulators and three-dimensional chromatin organization are discussed in 
greater detail. 
1.2.1 Promoters 
The expression of genes can be regulated at various nodes, but always require a 
gene promoter to initiate the transcription process. This stretch of DNA is located close 
to the transcription start site (TSS) and contains multiple DNA consensus sequences, 
such as TATA-binding protein (TBP) binding sites, initiator elements (Inr), transcription 
factor II B (TFIIB) recognition elements, downstream core (DCE) elements or motif ten 
(MTW) elements. The composition of these elements varies between promoters and 
plays a crucial role in the assembly of the transcriptional machinery and thus gene 
regulation (Smale and Kadonaga, 2003). In eukaryotes, these promoter sequences are 
recognized by one of three structurally similar RNA polymerases (RNAP) – RNAPI, RNAPII 
and RNAPIII, which are responsible for the transcription of DNA to RNA. While RNAPI and 
RNAPIII transcribe ribosomal-, transfer-, and other small RNAs, all protein-coding genes, 
miRNAs and some other small RNAs are transcribed by RNAPII, which cooperates with so 
called general transcription factors (GTFs). Among others tasks, these GTFs are required 
for the precise positioning of the RNAPII at the TSS, recognizing DNA sequences such as 
the TATA-box or stabilizing the RNAPII interaction with TBP and TFIIB or recruiting and 
regulating transcription factor II H (TFIIH), which possesses DNA helicase activity to help 
unwinding the DNA and revealing the template strand (Alberts et al., 2008). The complex 
of RNAPII and a minimum of five GTFs are termed the preinitiation complex (PrIC), which 
on its own is not sufficient for the transcription of genes in vivo (Figure 4A). Due to 
complex chromatin structures, RNAPII also requires transcriptional activators, a 
mediator, histone modifying enzymes and chromatin remodeling proteins. The 
transcriptional activators are essential to guide the RNAPII to the desired TSS, which is 
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followed by the interaction of RNAPII with the mediator. The mediator is a large protein 
complex that ensures the communication with the PrIC and activating proteins, histone 
modifying enzymes and chromatin remodeling complexes (Figure 4B). These activating 
proteins are usually TFs, which not only recognize a specific DNA sequence but also 
contain activation domains. Due to the size and multiple subunits of the mediator, 
multiple activation domains of different TFs can interact simultaneously, which facilitates 
enhancer-promoter gene looping (Figure 4B), transcription inhibition mediated by 
insulators or even the organization of DNA into topological domains (Allen and Taatjes, 
2015). Given the essentiality of these three types of interactions, the following 
paragraphs will explain them in more detail. 
 
Figure 4 | Simplified view of the transcription initiation. 
A | General assembly of the RNAPII and GTFs at the promoter region of gene and its gene control region, 
including regulatory sequences or regions which can be occupied by gene regulatory proteins, such as TFs. 
B | Transcription is initiated by interaction with RNAPII, GTFs and the mediator, which links the regulatory 
regions and their activating TFs to form a DNA loop. From: Molecular Biology of the Cell by Alberts (2008), 
Reproduced with permission of Taylor & Francis Group in the format Thesis/Dissertation via Copyright 
Clearance Center.  
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1.2.2 Enhancers 
Enhancers or cis-regulatory modules (CRMs) were first discovered in the SV40 
virus genome more than 30 years ago (Banerji et al., 1981). Since then, enhancers have 
been studied extensively in multiple organisms and their understanding has helped to 
unravel many longstanding questions regarding the complexity of gene regulation. While 
enhancers were readily known for their important roles during organismal development 
by regulating the spatiotemporal expression of many key factors, their importance also 
gained increasing awareness during disease development such as cancer (Sur and 
Taipale, 2016). Enhancers contain short DNA consensus sequences that are recognized 
by sequence-specific TFs. These TFs can be repressive or activating and influence the 
state and activity of RNAPII and the GTFs (Figure 5A). Interestingly, some enhancer locate 
as far as 1Mb or even 1.7Mb away from their target gene, a distance that would never 
be bridged by protein assemblies alone on a linear stretch of DNA. Only the 
three-dimensional structure or DNA-looping of the DNA makes the physical interaction 
between promoters and enhancers possible (Amano et al., 2009; Bahr et al., 2018; 
Shlyueva et al., 2014) (Figure 5B and C). The modular nature of enhancers adds another 
level of complexity and fine-tunes expression through multiple TF-binding sites that can 
act either additively or redundantly. Here, TFs can regulate transcription on different 
levels, e.g. through recruitment of the transcriptional machinery, thereby initiating 
transcription (Figure 4B), or through regulating elongation and termination (Ong and 
Corces, 2011). This, in combination with tissue and/or developmental stage-dependent 
expression of TFs, provides the spatiotemporal regulation of gene expression that is 
essential to complex life. In some cases, enhancers can also actively repress gene 
transcription through binding of repressive TFs, mainly found during development 
(Shlyueva et al., 2014). However, TF-mediated repression of gene expression is classically 
accomplished through silencers – DNA sequences similar to enhancers but primarily 
bound by repressive TFs.  
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Figure 5 | Gene regulation through enhancer mediated transcription. 
A | Genomic locus with consensus sequences for different TF that enhance or repress the transcription of 
gene X. B | Through looping of the DNA, gene X comes into close proximity to Enhancer A that is regulating 
its expression. The DNA-loci are kept in spatial vicinity through the restraining by cohesins. C | Depending 
on the loop size and the location of cohesin, different enhancers can regulate the same gene. In this 
configuration enhancer B associates with gene X while enhancer A is occupied with repressive TFs. 
Adapted by permission from Springer Customer Service Centre GmbH: Springer Nature, Nature Reviews 
Genetics, Shlyueva et al. (2014), copyright 2014. 
1.2.3 Insulators 
To prevent inappropriate binding of TF-bound regulatory regions to non-target 
genes, enhancer and promoter interactions can be controlled with so called insulators. 
These insulators can block the communication between genes and enhancers by e.g. 
maintaining the barrier between euchromatin and heterochromatin. Other mechanisms 
include promoter mimicking (Geyer, 1997) or acting as a physical barrier to interfere with 
RNAPII (Zhao and Dean, 2004). However, these mechanisms have been challenged and 
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may not apply generally. A third mechanism by which insulators block the crosstalk 
between enhancers and non-target genes is the compartmentalization into discrete 
regulatory domains. This is largely mediated by the insulator protein or transcriptional 
repressor CCCTC-binding factor (CTCF) and the protein complex cohesin. DNA-bound 
CTCF proteins can form homodimers and this way cause the DNA to form loops. These 
contact points in the DNA are then reinforced by cohesin ring structures (Figure 5B). Due 
to the essential roles of CTCF and cohesin in mediating chromatin contact loops, their 
function is regarded as both, inhibiting but also facilitating the communication between 
enhancers and promoters (Ali et al., 2016; Hou et al., 2008). Apart from their role of 
forming the anchors of DNA loops, CTCF and cohesin also co-localize at boundaries of 
topologically associated domains (TADs) suggesting that these proteins also convey 
higher order genomic structures at megabase-level (Dixon et al., 2012; Rao et al., 2014). 
In contrast to the cell-type and developmental stage-dependent DNA loops, TADs are 
highly conserved and stable across cell types. The following paragraph describes TADs 
and the technological advances that led to their discovery in more detail.  
1.2.4 Higher order genome structures through topologically associated 
domains 
In 2002, Dekker and colleagues invented a new method called chromatin 
conformation capture (3C) and paved the way for studying the genomic structure in 
eukaryotes in a three-dimensional space (Dekker et al., 2002). In brief, the employed 
method uses formaldehyde cross-linking of the chromatin followed by enzymatic 
digestion to break down the DNA into smaller pieces, which are eventually cross-linked 
through ligation (Dekker, 2006). The resulting stretch of DNA contains two fragments, 
which might have been distant on linear DNA but came into close proximity in the cell 
and therefore were covalently bound during the treatment with formaldehyde. Through 
quantitative PCR (qPCR), the abundance of certain ligation products can be measured, 
which conveys direct information about the frequency with which these two loci 
interact. Soon after, advancements of this methods were developed, with the genome 
wide chromosome conformation capture-on-chip (4C) (Simonis et al., 2006) and 
chromosome conformation capture carbon copy (5C) (Dostie et al., 2006), eventually 
leading to Hi-C (Lieberman-Aiden et al., 2009) a technology that uses massive parallel 
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sequencing to capture all genomic interactions and eventually led to the discovery of 
TADs. In order to further refine the method and to overcome the tremendous complexity 
of such libraries, Mifsud et al. (2015) developed capture Hi-C (CHi-C). This technique is 
based on the original Hi-C technology, but involves a solution hybridization selection step 
that enriches for selected genomic regions and therefore massively increases the 
resolution for sites of special interest e.g. promoters. 
The properties of TADs are diverse and have still not been fully understood, 
however, some fundamental features have been unraveled (Figure 6A-E). In many 
regards, TADs function similar to loops, which are themselves part of TADs and make up 
the so-called sub-TADs. Within TADs, genes can be co-regulated by the same enhancer, 
while genes outside are blocked from that interaction through the insulating TAD 
boundary (Figure 6A and B). In fact, genes with similar functions are often found to 
cluster within TADs, such as olfactory receptor genes (Figure 6E). These boundaries also 
prevent repressive or active chromatin from spreading or even block divergent spread of 
transcription (Figure 6C and D) (Dixon et al., 2016).  
 
Figure 6 | Different modes of action of TADs in genome regulation. 
A | A single enhancer co-regulates multiple target genes within the boundaries of a single TAD. 
B | Enhancers activity is restricted to genes within the same TAD and cannot influence gene expression 
across boundaries. C | TAD boundaries can prevent spreading of repressive or active chromatin to 
neighboring territories. D | TAD boundaries also serve to block divergent spread of transcription. 
E | Exemplary Hi-C data showing the interaction heatmap for an approx. 500kb wide TAD that spans 
around a cluster of olfactory receptor genes. Reprinted from Dixon et al. (2016), copyright 2016, with 
permission from Elsevier.  
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Interestingly, TAD boundaries are not only enriched for CTCF binding sites but 
also for TSS (particularly TSS of housekeeping genes), transfer RNAs and short 
interspersed element (SINE) retrotransposons (Dixon et al., 2012; Gorkin et al., 2014). 
Additionally, computational analysis revealed that TADs are also positively associated 
with H3K36me3 sites, TSS of mRNA and ncRNA genes, RNAPII and other specific TFs, 
indicating that these regions are transcriptionally active, despite being depleted from 
DNase I-hypersensitive sites (Figure 7). 
In summary, higher order genome organization is a highly essential feature of 
complex gene regulation in eukaryotes and recent technological advances such as Hi-C 
have greatly helped to understand its core features. Nonetheless, many questions 
remain and require additional research to complete the picture.  
 
Figure 7 | TAD and TAD boundary properties including enrichment of various genomic features. 
Schematic representation of two adjacent TADs. Due to the nucleosome spacing, chromatin flexibility is 
low at boundaries and highest in TADs, allowing for loop formation in sub-TADs. Insulation is highest at 
boundaries in line with the high occupancy of CTCF binding sites which inhibit e.g. cross-talk between 
enhancers of different TADs. Despite high nucleosome density at boundaries, histone modification that 
mark active gene bodies (H3K36me3) are enriched at these sites, which is in line with enrichment of TSS 
for mRNAs, ncRNAs and most prevalently TSS of housekeeping genes. HK, housekeeping gene. Based on 
Dixon et al. (2016) and (Hong and Kim, 2017) 
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1.3 IdenOﬁcaOon of regulatory regions 
The identification of regulatory regions, such as the aforementioned promoters, 
enhancers and insulators can be challenging. Although gene promoters can be predicted 
using the DNA sequence using e.g. the TATA-box sequence, their activity is cell type 
specific and therefore needs to be addressed in individual cell types through e.g. 
measuring mRNA levels or through reporter constructs. In contrast to promoters, 
enhancers and insulators cannot be identified using the DNA sequence alone but instead 
require the analysis of the epigenome. Similarly to gene promoters, their activity or even 
presence is cell type specific, so again requires a cell type specific analysis to map their 
activity. However, there is also a more general way of identifying active regulatory 
regions – assessing the accessibility of the genome. 
1.3.1 Accessibility of chromaOn 
Mapping active regulatory regions using the chromatin accessibility grounds on 
the notion that condensed or inaccessible chromatin is associated with no transcriptional 
or regulatory activity, while loci that are actively transcribed are “open”. For example, 
DHS-seq is a commonly used technique that uses the DNaseI restriction enzyme, which 
cleaves the DNA only at nucleosome-free regions. In combination with high-throughput 
sequencing (HT-seq) this reveals a genome wide map of accessible or active sites and 
thus putative regulatory regions (Boyle et al., 2008; Thurman et al., 2012). A newer 
technique called assay for transposase-accessible chromatin using sequencing 
(ATAC-seq) uses the hyperactive Tn5 transposase coupled with HT-seq adapters. Tn5 also 
integrates into accessible genomic regions, while compact DNA renders integration less 
probable. Compared to DHS-seq, ATAC-seq is much more sensitive as it requires a 
fraction of the starting material and is thus also applicable to low-input samples such as 
rare primary cell populations (Buenrostro et al., 2013; Buenrostro et al., 2015). 
Nonetheless, both of the above described methods are not capable of distinguishing 
between enhancers, promoters, silencers, insulators, locus control regions or any other 
regulatory regions, but instead only provide a broad overview of regions of open 
chromatin. The specific identification of enhancer can be achieved by other means as 
discussed below. 
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1.3.2 IdenOﬁcaOon of enhancers 
The identification of enhancers involves many challenges and differs substantially 
from the identification of e.g. protein-coding genes. Despite intensive research, to date 
there is no single feature known that is common to all enhancers that would aid the 
prediction from the DNA sequence alone. Although some enhancers have been 
identified through sequence conservation, it cannot be applied invariably to confidently 
predict enhancers due to their rapid evolution or species specificity. Also, the classical 
mutation-phenotype approach that is still used to identify and characterize most genes 
has its limits: On the one hand, there are about 1 million putative enhancers in the 
mammalian genome, 20-fold more compared to the approx. 50,000 gene promoters. On 
the other hand, a lack of phenotype after genetic perturbation cannot preclude any 
functional relevance, as enhancers are often redundant and highly contextual (Coppola 
et al., 2016).  
Recently, deep-sequencing approaches have been developed that exploit 
multiplexed reporter assays to measure transient RNA expression of tens to thousands of 
elements in parallel (Melnikov et al., 2012; Patwardhan et al., 2012). The self-
transcribing active regulatory region sequencing (STARR-seq) method uses a genome 
wide library of randomly sheared genomic DNA fragments. These fragments are cloned 
into reporter plasmids in-between a minimal promoter and a poly-A site and transfected 
into the cells of interest. Fragments that contain transcriptionally active enhancer 
sequences self-transcribe or self-amplify inside the cells, which can be measured by 
extracting poly-A mRNA, reverse transcription and high-throughput paired end 
sequencing. This way, enhancer activity for millions of candidates can be assessed in 
parallel in an unbiased and quantitative way (Arnold et al., 2013). However, most of the 
above-mentioned methods require the manipulation of cells through e.g. 
CRISPR/Cas9-mediated genome editing for mutation-phenotype approaches or transient 
transfection and cultivation of large libraries for reporter-based assays. This largely 
restricts their applicability especially for rare and/or primary cell populations.  
Another commonly used and well-established method is to identify putative 
enhancers through the assessment of TF binding or chromatin state by chromatin 
immunoprecipitation sequencing (ChIP-seq). Using ChIP-seq data, different chromatin 
states can be identified, all of which are characterized by different properties:  
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1.3.2.1 ChromaOn states and histone modiﬁcaOons 
In eukaryotes, DNA is wrapped around nucleosomes – a histone octamer – which 
resembles the basic structural unit of chromatin. Different histone types (H2A, H2B, H3 
and H4) and chemical modifications of histone residues dictate the primary structure of 
chromatin. The development of ABs against distinct histone modifications laid the 
foundation for ChIP-seq experiments, which in turn have led to a tremendous gain in the 
understanding of how histone modifications control the activity of genomic elements like 
enhancers (Zhou et al., 2011). While the presence or absence of single histone 
modifications facilitates the prediction of chromatin states to some degree, predictions 
are made more reliable using combinatorial histone modification signatures. A landmark 
in identifying and allocating different modification combinations was the development of 
a generative machine-learning multivariate hidden Markov model (ChromHMM) (Ernst 
and Kellis, 2017; Ernst et al., 2011), leading to the definition of distinct chromatin states. 
Here, enhancers are categorized into genic, active and weak enhancers, all of which carry 
histone 3 lysine 4 monomethylations (H3K4me1). However, active enhancers additionally 
carry H3K27 acetylation (K3K27ac) marks while genic enhancers carry H3K27ac and 
H3K36 trimethylation (H3K36me3) marks (Figure 8).  
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Figure 8 | Overview of Roadmap Epigenomics 18-state expanded model ChromHMM chromatin states. 
The state emissions describe the quantitative and qualitative combination of histone modifications for all 
18 states. The color intensity corresponds to the probability of observing the mark in the state. The 
genomic annotations describe the fold enrichment of the indicated genomic annotations found in IMR90 
cells with the color intensity being proportional to the fold-enrichment. The TSS neighborhood depicts the 
enrichment of the state in a 2kb window around a set of TSS. Darker colors correspond to a higher 
fold-enrichment. State descriptions for all states with commonly used abbreviations are indicated on the 
very right. Adapted by permission from Springer Customer Service Centre GmbH: Springer Nature, Nature 
Protocols, (Ernst and Kellis, 2017), copyright 2017. 
1.3.3 Medical impact of sequence alteraOons in regulatory regions 
Naturally, defining an alterations in a sequence always implies a reference 
sequence for comparison. In human genomics, this reference sequence is usually the 
average of the human population, measured through thousands of whole genome 
sequencing projects. Although 99.5% of the genome is identical between any two 
humans, the remaining 0.5% can make a huge difference, like hair color, skin tone or 
even medical predispositions. Alterations in a single nucleotide that occur in more than 
1% of the human population are termed single nucleotide polymorphisms (SNPs) and are 
different to classical mutations, which occur at a frequency below 1% (Karki et al., 2015). 
SNPs and mutations in exons of protein-coding genes can change the amino acid 
sequence of a protein and consequently alter its function. The identification of the gene 
that is affected and the resulting change in the amino acid sequence is easy to assess and 
can therefore be simply linked to a disease. However, many mutations or SNPs occur in 
intragenic (intronic) or intergenic regions with unknown impact on gene regulation thus 
pathology. Genome-wide association studies (GWAS) aim to link these mutations or SNPs 
to diseases or traits. The experimental design involves the comparison between subjects 
Introduction 
20 
 
with a given disease or trait and healthy controls. In order to assess the polymorphisms 
of the two groups, either whole genome sequencing data or sequence information from 
genotyping or SNP arrays is used. Next, frequencies of SNPs in both populations are 
statistically compared to assess the linkage disequilibrium (LD), a measure of 
non-random association of alleles at difference loci (Slatkin, 2008). In other words, a 
given SNP or combination of SNPs occur significantly more often in cases than controls, 
which implies a certain risk of developing the trait or disease when carrying the variant. 
As only about 2% of the human genome contains protein-coding genes it comes as no 
surprise that more than 85% of GWAS risk variants are located in inter- and intragenic 
DNA – preferably enhancers. Because of that, it remains a challenge to determine the 
cellular and organismal consequences these SNPs cause. It is thought that SNPs in 
enhancers alter e.g. DNA-protein interaction thus influencing gene expression, however 
the gene or genes, which are directly affected have to be identified experimentally 
(Corradin and Scacheri, 2014). Nonetheless, despite the lack of target gene information, 
enhancers that carry GWAS SNPs can at least be assigned to traits or diseases, making 
GWAS a powerful tool for providing new insights into mechanisms in common diseases.  
1.4 Hematopoiesis and its correcOon in the context of disease 
As described above, hematopoiesis is a fine-tuned process maintained through 
the interplay of HSCs, progenitors and differentiated cells. Mutation in the genome of 
these cells can alter or diminish their function, leading to phenotypes ranging from mild 
symptoms to severe defects or even to death of the affected individual. One example is 
the Wiskott-Aldrich-Syndrome (WAS), a recessively inherited primary immune deficiency. 
Diseases like WAS can be treated by allogenic BM transplantations – BM or 
hematopoietic stem cells, respectively, from another healthy individual. While allogenic 
BM transplantations are unproblematic in inbred mouse colonies, the genetic variation 
between humans can cause the immune system to recognize the transplant as foreign 
and provoke Graft versus Host Disease (GvHD) or complete graft rejection. A disparity 
between recipients is sensed by human leukocyte antigens (HLAs) expressed on T cells 
and NK cells. To prevent GvHD or rejection, donors with matching HLAs are crucial, 
however often hard to find (Nowak, 2008). An alternative path is to provide the patients’ 
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cells with a correct version of the malfunctioning gene – a relatively new treatment 
option called gene therapy (GT).  
1.4.1 Gene therapy for the treatment of WiskoX-Aldrich-Syndrome 
The Wiskott-Aldrich-Syndrome (WAS) is a rare primary immune deficiencie with a 
frequency of about 1-10 males per million and is characterized by low platelet counts 
(thrombocytopenia), skin rashes (eczema) and recurrent severe infections, leading to an 
average life expectancy of less than 10 years. The syndrome was first described in 1954 
by the German physician Alfred Wiskott and the American Robert Anderson Aldrich 
(Aldrich et al., 1954) and later linked to a mutation in the Wiskott-Aldrich-Syndrome 
Protein (WASp) that renders it malfunctional (Derry et al., 1994). Expression of WASp is 
thought to be induced in dendritic cells via T cell receptor signaling in order to form an 
immunological synapse through actin cytoskeletal rearrangements, making it essential 
for proper immune function (Malinova et al., 2016). Apart from that, importance of 
WASp for the regulation of T cells, B cells, NK cells to maturation and function of 
myelomonocytic cells has also been reported (Ochs and Notarangelo, 2005). 
As described above, WAS patients are treated by allogeneic HSC transplantations 
(Albert et al., 2011), given that a HLA-matched donor is available. A relatively new 
treatment strategy for patients without a suitable donor is GT, which describes the 
process of inserting DNA or RNA into body cells as a drug to treat a specific disease. 
While already attempted in the 80s, the first successful trial of inserting human DNA into 
the genome was performed in 1990 (Rosenberg et al., 1990). Following this, a large 
number of GT trials were carried out until today with growing success. In the present 
study, we used data from a GT trial on 10 WAS patients that did not have an HLA-
matching donor. In this trial, a functional wild-type copy of the WASP gene was stably 
inserted into CD34+ cells using γ-retroviruses (γRVs) as vectors for gene delivery. The 
CD34+ cells were extracted from peripheral blood of the patients after mobilization with 
Granulocyte-colony stimulating factor (G-CSF) or G-CSF and the CXCR4 inhibitor 
Plerixafor. After a successful manipulation ex vivo, treated cells were autologously 
transplanted into the patient (Boztug et al., 2010). Because γRVs integrate semi-
randomly into the genome, each transduced cell is characterized by a unique integration 
site (IS). This IS can be traced using highly sensitive Linear Amplification-Mediated 
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Polymerase Chain Reaction (LAM-PCR) (Schmidt et al., 2007) combined with HT-seq 
methodologies. Accordingly, a bulk of cells carrying an identical IS must have originated 
from one transduced stem cell or clone, respectively. 
In order to follow stem cell engraftment and clonality during the WAS GT trial, 
patient blood and BM samples were taken periodically and ISs were amplified using 
LAM-PCR (Also see Figure 12 in the Results 3.1 section). Despite a general success of the 
GT by restoring WASp expression and reversing most WAS-associated symptoms, as of 
2014, seven out of 10 patients showed malignant clonal expansion due to insertional 
mutagenesis of the viral vector (Braun et al., 2014). The following paragraphs are 
discussing the family or Retroviridae in more detail and provide information about the 
specific integration biology of γRVs, insertional mutagenesis and also how γRV 
integration sites can be exploited for the detection of epigenomic features. 
1.5 Biology of retroviruses 
The family of Retroviridae contains a total of seven different virus genera. In the 
context of gene therapy and laboratory use, the two most important subtypes are 
lenti-viruses (LV; e.g. human immunodeficiency viruses; HIV-1) and γRVs (e.g. murine 
leukemia virus; MLV). The retroviral positive sense RNA genome only ranges from 8 to 
11kb in length, yet contains most building blocks required for its entire life cycle. 
Importantly, retroviruses possess the unique ability to reversely transcribe RNA into 
double-stranded DNA, an essential step in order to harness the eukaryotic transcriptional 
machinery and to integrate into the host cell DNA genome. The responsible enzyme – 
the reverse transcriptase – was discovered in 1970 by Baltimore, Temin and his 
co-worker Mizutani, a groundbreaking discovery which laid the foundation for numerous 
laboratory applications and therapeutic approaches (Baltimore, 1970; Temin and 
Mizutani, 1970). Another remarkable property of retroviruses is their ability to integrate 
into the host cell genome and reside as proviral DNA, this way multiplying themselves 
with every doubling of the host cells (Balvay et al., 2007). The proviral DNA can be 
transcribed again, leading to the production of new viral particles that eventually leave 
the cell via “budding” and thus close the life-cycle. The mechanisms behind this are very 
similar between the genera of Retroviridae and start with a small set of proteins 
encoded by four domains: Proteins of the gag domain are required for the viral capsid, 
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env domain proteins provide the components for the viral envelope, proteins encoded 
by the pol domain perform DNA synthesis and integration and pro domain proteases are 
required for the maturation of viral proteins (Balvay et al., 2007). Importantly, the 
understanding of every components role in the life-cycle of the virus has enabled 
researchers to modify the viral genome to produce new entities for safer laboratory and 
gene-therapeutical use. Such research has for example led to the development of 
self-inactivating long-terminal repeats (SIN-LTRs), a modification that reduces the chance 
of undesired activation of genes in the proximity of the provirus (Dull et al., 1998; 
Zufferey et al., 1998).  
While cell entry is very comparable between LVs and γRVs, significant differences 
arise during nuclear entry and integration. LVs do not require the infected cell to divide. 
Instead the viral capsid with the pre-integration complex (PIC) docks to the nuclear core 
complex (NPC) before the capsid disassembles and releases the PIC into the nucleus 
where it integrates into the nuclear laminar-associated DNA (Figure 9A and B). In 
contrast, the capsid enclosed γ-retroviral PIC first associates with the viral p12 protein, 
which is stabilizing the complex. Only during mitosis and concomitant nuclear membrane 
break down, p12 can tether the capsid to the chromosome where it is segregated into 
the daughter cell nucleus, before the PIC is finally released during mitotic exit and the 
viral DNA integrates into the DNA (Figure 9A and C) (Demeulemeester et al., 2015). 
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Figure 9 | Cell and nuclear entry paths of LV and γRV. 
A | The fusion of the virus and the cell membrane delivers viral proteins and RNA into the host cell were it 
is reversely transcribed while shuttled to the nucleus. LV capsids are shuffled towards nuclear pores, while 
γRV capsids associate with the viral p12 protein and await the disintegration of the nuclear membrane 
during mitosis. B | Once the reverse transcription has finished, the LV capsid disassembles and releases the 
PIC core, which traverses through the NPC and integrates the viral DNA into the outer perimeter DNA. 
C | During mitosis, p12 and tethers the capsid enclosed PIC to condensed chromosomes, is transported to 
the nucleus of the daughter cell. Finally, p12 and the capsid are released during mitotic exit and the PIC is 
set free for integration. PIC, pre-integration complex; NPC, nuclear core complex; Adapted with permission 
from (Demeulemeester et al., 2015) 
1.5.1 IntegraOon biology of γ-retroviruses 
In the past decade, γRV integration biology has been studied extensively, not 
alone in the context of gene therapy trials. Early analysis showed that γ-retroviral 
proviruses are often located near TSS of active genes. However these analysis were 
based on either very few ISs or were derived from mutagenesis screens that suffer from 
substantial IS pattern-skewing (Wu et al., 2006). Only a few years later, after profound 
advancements in sequencing technologies and more efficient amplification of viral ISs, 
the understanding of γRV integration became more comprehensive. Many groups 
reported that active gene-regulatory regions such as enhancers were even preferred 
over active TSS. This preference is mediated by the interaction of the viral PIC with BET 
family proteins such as BRD2, 3, and 4 (Cattoglio et al., 2010; De Ravin et al., 2014; 
Deichmann et al., 2011; LaFave et al., 2014). BET proteins are transcriptional 
Introduction 
25 
 
co-regulators and contain two N-terminal bromodomains. The bromodomain modules 
usually target hyper-acetylated tails of histone H3 and H4, while an extraterminal (ET) 
domain takes care of the interaction with other cofactors and the γRV PIC. This stands in 
stark contrast to LVs. Here, the PIC mainly cooperates with Lens Epithelium-Derived 
Growth Factor/p75 (LEDGF/p75), which specifically binds to H3K36me3-modified 
nucleosomes, thus active gene bodies (Demeulemeester et al., 2015). 
In summary, the recent findings of three independent groups (De Rijck et al., 
2013; Gupta et al., 2013; Sharma et al., 2013) soundly establish BET proteins as direct 
mediators of γ-retroviral target site selection, directing them reliably towards strong 
enhancers and active promoters.  
 
Figure 10 | Specific chromatin states are deterministic of the location of viral ISs (Legend continued on 
next page). 
A | The PIC of LVs or γRVs, respectively, hijack intracellular proteins to gain access to specific chromatin 
environments. The LV PIC mainly cooperates with LEDGF/p75 which steers it towards active gene bodies 
mostly displaying H3K36me3 marks. In contrast, PICs from γRVs interact with BET family proteins, which in 
turn read hyper-acetylated histones H3 and H4, thus delegate γRV ISs towards strong enhancers or active 
promoters. Adapted with permission from (Demeulemeester et al., 2015) B | Mean enrichment of γRV ISs 
at indicated ChIP-seq peaks or chromatin states beyond expected by chance. H3K4me3 and H3K27ac but 
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also H3K4me1 marks are highly enriched at γRV IS, which is reflected by the most enriched chromatin 
states – Strong enhancers (4) and active promoters (1). (LaFave et al., 2014), by permission of Oxford 
University Press.  
1.5.2 Retroviral inserOonal mutagenesis 
The notion that retroviruses can cause malignant transformation of cells has 
celebrated its 100th anniversary already some years ago. In 1911, Peyton Rous 
discovered that a cell-free extract from chicken tumors can induce the same type of 
tumor in healthy chicken. As the filters were too fine for bacteria or cells to pass, he 
postulated that the tumor causing reagent had to be a virus – later known as the Rous 
Sarcoma Virus (RSV) (Rous, 1910, 1911). Subsequent research and the development of a 
quantitative in vitro bioassay for RSV in the 1950s led to the identification of oncogenes, 
i.e. genes whose enforced expression induce cancer, such as the src gene in the RSV 
genome. Other examples of oncogenes discovered in viruses long before their discovery 
in humans are myc in the avian myelocytoma virus genome or ras, first discovered in the 
rat sarcoma virus (Weiss and Vogt, 2011).  
Retroviruses, such as the RSV can transform cells not only by expression of 
oncogenes from their own viral genome, but also by altering the expression or structure 
of genes in the host cell genome. This discovery led to the definition of proto-oncogenes, 
normal regulatory genes that act as oncogenes when overly expressed or mutated by the 
viral integrate (Bishop, 1983). The mechanisms by which retroviruses induce insertional 
mutagenesis are manifold and include but are not limited to overexpression of 
proto-oncogenes by viral enhancer elements, structural alteration of proto-oncogenes 
through spliced and un-spliced retroviral/cellular fusion transcripts, premature 
polyadenylation or aberrant splicing of mRNAs or even down-regulation of gene 
expression (Figure 11A-G) (Knight et al., 2013). However, the frequency at which such 
events occur remains speculative. In experimental setups, vector integration usually 
occurs in millions of cells in parallel, making an oncogenic event stochastically very 
probable. Due to the growth advantage of transformed cells, oncogenic events are 
naturally selected for, which in turn generates an impression that these events are very 
common, while the actual rate might be very low.  
Introduction 
27 
 
 
Figure 11 | Overview of retroviral insertional mutagenesis mechanisms. 
A | Classical gene configuration with TSS (arrow), untranslated regions (white boxes), protein-coding 
regions with ATG start codon (grey boxes) and polyadenylated (polyA) tail (indicated by AAAA). gDNA (top) 
and resulting mRNA (bottom) are indicated. B | Retroviral enhancer elements in LTR region upregulate the 
expression of neighboring genes. C | Overexpression of the cellular gene due to mRNA fusion transcript. 
The 5’ LTR is fused via a vector splice site to an exonic splice acceptor. D | Overexpression of the cellular 
gene by fusion after read through of the 3’ LTR. E | Fusion of vector and cellular gene initiated by 3’ LTR 
after deletion of 5’ LTR. F | Generation of premature polyA tail after intronic vector integration. 
G | Aberrant splicing after intronic vector integration can lead to fusion transcripts. (Knight et al., 2013) 
Reproduced with permission of BENTHAM SCIENCE PUBLISHERS LTD. in the format Thesis/Dissertation via 
Copyright Clearance Center. 
1.5.3 Using γRV ISs as molecular tags for acOve regulatory regions. 
Due to the specific target site bias of Retroviridae, it seems plausible to utilize 
vector integrations as molecular tags for certain genomic features. In fact, in a recent 
study Romano and colleagues used retroviral integration signatures to identify 
regulatory regions. The authors integrated Cap Analysis of Gene Expression (CAGE), 
ChIP-seq and Moloney leukemia virus (MLV) integration site mapping in human HSPCs 
and committed erythroid and myeloid progenitors/precursors (EPP and MPP) to profile 
the transcriptional and epigenetic changes associated with HSPC lineage commitment. 
Interestingly, MLV clusters were significantly enriched at super-enhancers (SE) in 
comparison to normal active enhancers, suggesting that MLV integration sites could 
even be specifically used for the detection of SEs (Romano et al., 2016). 
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2 AIMS OF THE THESIS 
Hematopoietic stem cells (HSCs) resemble a small population of cells with a wide 
range of properties. To reconstitute an entire blood system, HSCs need to self-renew, 
proliferate and differentiate, a complex endeavor orchestrated by the genetic and 
epigenetic landscape, which in turn regulates gene expression. Despite the substantial 
progress that has been made in understanding these regulatory circuits, most if not all 
studies on human HSC regulation rely on an immunophenotypic definition of 
hematopoietic stem and progenitor populations. Consequently, transcriptomic or 
epigenetic data are derived from probably impure or heterogeneous populations. In line 
with this, phenotypic HSC definitions might miss cells, which are truly functional but do 
not fulfill surface marker-based selection criteria. To overcome the restriction of 
phenotypic HSC definition, we used a large dataset of γ-retroviral integration sites (γRV 
IS) from a gene therapy trial on 10 Wiskott-Aldrich-Syndrome (WAS) patients. To date, it 
is well established that γRV ISs can be exploited for tracking clonal dynamics and utilized 
as molecular tags for active enhancers and promoters – their preferred integration 
environment (see 1.5.1 and 1.5.3). Consequently, we hypothesized that 1) γRV ISs that 
are detected in the peripheral blood or BM of patients during long-term reconstitution 
have originated from true, functionally defined human HSCs and 2) that we can use γRV 
ISs to identify new regulators of HSCs and hematopoiesis as well as map the regulatory 
landscape that is influencing their spatiotemporal expression. Thereof, the following 
main aims were derived: 
Aim 1: Utilize the WAS patient IS repertoire to identify and select protein-coding 
candidate genes with undescribed roles during hematopoiesis. 
Aim 2: Establish a medium throughput lentiviral overexpression pool to examine the 
influence of the candidate genes on proliferation, self-renewal and differentiation 
of hematopoietic stem and progenitor cells. 
Aim 3: Combine γRV ISs with publicly available datasets to create a genome-wide 
resource for active regulatory regions in functionally defined human long-term 
repopulating HSCs. 
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3 RESULTS 
3.1 IdenOﬁcaOon of novel key hematopoieOc regulators through 
γ-retroviral inserOon sites 
The basis of the present study is laid on a large collection of γ-retroviral (γRV) 
integration sites that were originally acquired (prior to this study) for biosafety reasons 
during a gene therapy trial including 10 patients with Wiskott-Aldrich-Syndrome (WAS) 
(Boztug et al., 2010; Braun et al., 2014). During this trial, CD34+ cells were mobilized 
using either Granulocyte-colony stimulating factor (G-CSF) alone or a combination of 
G-CSF and the CXCR4 inhibitor Plerixafor and extracted from the patients’ blood using 
leukopheresis and magnetic cell separation (CliniMACS system). Next, a functional copy 
of the WASP gene was introduced into the CD34+ cells using γRV vectors, and finally 
CD34+ cells were re-infused as an autologous bone-marrow (BM) transplant. Throughout 
the follow-up of the study, whole blood, sorted blood-cell populations and BM samples 
were collected from the patients, genomic DNA was extracted, and the location of the 
ISs were determined using linear-amplified PCR (LAM-PCR) and high-throughput 
sequencing (HT-seq; Figure 12). Because γRVs stably integrate into the hosts’ cell 
genome, each transduced cell is characterized by a unique integration site (IS). 
Accordingly, a bulk of cells carrying an identical IS must have originated from a common 
ancestor. Moreover, the HT-seq read counts for each IS can to some degree also convey 
information about the clone size. These parameters – the clonality of the sample 
(number of unique ISs) and the approx. clone sizes (% of total read counts) – can be used 
to characterize the patients’ blood reconstitution after transplantation. These 
parameters are particularly crucial for the detection of neoplastic growth of transformed 
clones. However, in the present study we did not focus on single oncogenic integration 
events and their associated genes but instead on the complete picture of γRV ISs in all 
patients collectively, the so called integrome. In the past it has been shown that γRV ISs 
preferentially target active transcription start sites and active enhancer elements (Aker 
et al., 2006; Cattoglio et al., 2010; Deichmann et al., 2011; LaFave et al., 2014) and thus 
are not evenly spread out across the entire genome but almost always occur in clusters, 
so called common integration sites (CIS, also see Figure 12B). These CIS can in turn be 
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used as indicators of genes that are active during the transduction of CD34+ cells and 
hence might play a role during hematopoiesis. 
 
Figure 12 | Genetic correction of diseased hematopoietic stem cells and subsequent monitoring of the 
patients in a clinical gene therapy trial. 
A | After mobilization of the patients’ HSCs, CD34+ cells were isolated and genetically engineered ex vivo 
using γRV vectors. Following gene correction, stem cells were transplanted back and patients were 
monitored for up to six years. Blood and BM samples were collected periodically and were either left 
unsorted or sorted for various cell populations, respectively. Genomic DNA was extracted and 
amplification of the viral integration site was performed (LAM-PCR). B | LAM PCR fragments were 
sequenced and adjacent genomic regions were mapped to the human hg19 reference genome for 
localization of the integration site at 1bp resolution. γRV integration into the genome occurs non-random, 
leading to the local accumulation of clusters of IS, called common integration sites (CIS). Additionally, read 
counts of unique IS provide an indirect measure for the clone size and appearance of the same clone in 
various cell populations at different time points. 
3.1.1 Analysis of common integraOon sites and genes in their vicinity 
To filter for genes that possess a higher likelihood to play a role during 
hematopoiesis we first developed criteria to weight the importance of CIS. Here, we 
hypothesized that a greater number of ISs close to a given transcription start site (TSS) or 
a smaller distance between ISs (higher density) would point towards regions that are 
either more active or regions that are a preferred integration target in a higher 
percentage of cells during the initial rounds of transduction or during engraftment of the 
cells. Thresholds for optimal prediction of CIS were established prior to this study and 
were set to a maximum distance between two ISs of the same CIS of 10kb and a 
maximum distance of the CIS boundary to the nearest TSS of 50kb (Figure 13A). After CIS 
prediction and assignment of TSS, three additional parameters were obtained – the 
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degree (number of ISs around the TSS ±50kb), the CIS order (number of ISs within 
cluster) and the CIS dimension (genomic length of CIS, Figure 12B). 
 
Figure 13 | Schematic overview of genetic loci containing γRV ISs and terminology/parameters used for 
the characterization of clusters and statistic filtering for potential regulatory genes. 
A | ∆IS depicts the distance between two ISs and must not exceed 10kb in order to consider two 
neighboring IS to be present in the same cluster. ∆TSS depicts the distance between CIS and transcription 
start site (TSS) and must not exceed 50kb for the gene to be considered in the proximity of the cluster. The 
degree depicts the number of ISs in a window of ±50kb around a TSS, while the CIS order depicts the 
number of ISs in a given cluster. B | CIS dimension depicts the genomic size in bp a given cluster has. 
3.1.2 Top 100 CIS are highly enriched for hematopoieOc regulators 
After allocation of CIS to their closest TSS, genes were ranked by CIS order. As 
described previously, the three top ranked genes (MECOM, LMO2 and HMGA2) are 
known proto-oncogenes and were previously linked to the development of malignancies 
and clonal expansion in γRV-driven gene therapy trials (Braun et al., 2014; Cavazzana-
Calvo et al., 2010; Hacein-Bey-Abina et al., 2008; Hacein-Bey-Abina et al., 2003a; Hacein-
Bey-Abina et al., 2003b; Ott et al., 2006). However, these genes as well as many other 
hematopoietic malignancy-related genes are also known to play essential roles during 
physiological hematopoiesis (Copley et al., 2013; Kataoka et al., 2011; Yamada et al., 
1998). Strikingly, among the largest 100 CIS about 50% (49 genes) were reported to be 
linked to hematopoiesis, indicating that CIS can indeed be used as genetic marks to 
identify hematopoietic regulators (Figure 14A). 
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3.1.3 SelecOon of protein-coding genes as potenOal novel hematopoieOc 
regulators  
First, genes were ranked according to the order of their associated CIS and 
filtered for protein-coding genes. Next, only genes without a reported role or function in 
the hematopoietic system were selected. Finally, we performed extensive literature 
research to filter for genes with a mouse homolog, a maximum of two major isoforms as 
well as clonability, e.g. maximum length of mRNA of ∼3.5kb. In total, we selected 17 
genes of which three genes had two major isoforms (Lair1, Slx4ip and Xbp1; Figure 14B 
and Table 1).  
 
Figure 14 | Top 100 largest CIS and their associated gene with indicated proportion of every patient. 
A | Top 100 largest clusters ranked for number of unique IS. MDS1 (MECOM) is scaled to an independent 
y-axis. Known hematopoietic regulators are indicated green, selected candidate genes are indicated red. 
B | Candidate genes are listed separately and ranked for number of unique IS. 
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Table 1 | Overview of protein-coding candidate genes in this study 
Location CIS Order Degree hGene Full Name Location of CIS mGene Size  
chr20: 10485470 304 34 SLX4IP SLX4 Interacting Protein Mostly Intron 2, also Intron 1 Slx4ip (long) 1,262 
Slx4ip (short) 1,052 
chr6: 41973175 268 122 CCND3 G1/S-Specific Cyclin D3 Mostly  CIS>TSS or Intron 1 Ccnd3 899 
chr3: 185475315 238 138 IGF2BP2 Insulin-Like Growth Factor 2 MRNA Binding Protein 2 Almost all Intron 1 Igf2bp2 1,799 
chr20: 52251594 232 156 ZNF217 Zinc Finger Protein 217 CIS>TSS Znf217 3,146 
chr20: 9146426 226 121 PLCB4 Phospholipase C, Beta 4 Mostly  CIS>TSS or Intron 1 Plcb4 3,548 
chr22: 29208888 224 144 XBP1 X-box binding protein 1 CIS>TSS Xbp1 824 
Xbp1S 1,136 
chr11: 118104203 200 156 AMICA1 Adhesion Molecule, Interacts With CXADR Antigen 1 Mostly CIS>TSS or Intron 1 Amica1 1,160 
chr11: 9743162 193 138 SWAP70 SWAP switching B-cell complex 70kDa subunit Mostly Intron 2,3, also Intron 1 Swap70 1,778 
chr21: 16611961 179 74 NRIP1 Nuclear Receptor Interacting Protein 1 CIS>TSS (far from TSS) Nrip1 3,506 
chr3: 151935060 173 92 MBNL1 Muscleblind-Like Splicing Regulator 1 CIS>TSS Mbnl1 1,166 
chr7: 5509323 169 103 FBXL18 F-Box And Leucine-Rich Repeat Protein 18 3'UTR>CIS Fbxl18 2,177 
chr12: 727092 164 107 NINJ2 Ninjurin 2 Almost all Intron 1, intronic lncRNA Ninj2 452 
chr14: 100536162 162 109 EVL Enah/Vasp-like Almost all Intron 1 Evl 1,265 
chr16: 23892933 161 57 PRKCB Protein Kinase C, Beta Almost all Intron 1 Prkcb 2,042 
chr19: 54887664 153 95 LAIR1 Leukocyte-Associated Immunoglobulin-Like Receptor 1 Mostly  CIS>TSS 
Lair1 (long) 812 
Lair1 (short) 482 
chr14:77507619 126 94 IRF2BPL Interferon regulatory factor 2 binding protein-like CIS>TSS Irf2bpl 2,345 
chr3: 196353363 106 87 LRRC33 Leucine Rich Repeat Containing 33 CIS>TSS Lrrc33 2,186 
Location, Center of the CIS; CIS Order, Number of ISs in a CIS; Degree, Number of insertion sites within 10 kb in each direction of the transcription start-site of individual 
candidates; hGene, Name of the human Gene, Location of CIS, Describes where most of the ISs site are located in relation to the genes TSS; CIS>TSS, ISs are located 
upstream of the TSS; 3'UTR>CIS, ISs are located downstream of the 3’UTR; mGene, Name of the corresponding mouse gene. “Long” and “short” indicated different splice 
variants. Xpb1S represents a splice variant of Xbp1; Size, Size of the cDNA in bp.  
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3.1.4 Most candidate genes are expressed in the hematopoieOc system 
After selecting the candidate genes, we investigated the expression pattern of 
our candidate genes throughout the human and mouse hematopoietic system by 
screening publicly available RNA-seq expression data (Cabezas-Wallscheid et al., 2014; 
Corces et al., 2016). Importantly, almost all genes showed a slight tendency to be higher 
expressed in stem and progenitor cells compared to more mature blood cells. In 
humans, AMICA1 was the only gene that was not detected across hematopoietic cell 
populations, which was in line with the very low expression detected in mice. In 
contrast, Znf217 was not detected in mice despite its relatively high expression in 
humans. In summary, the majority of the genes showed high to medium expression 
levels in stem and progenitor cells and was similarly expressed across species 
(Figure 15). 
 
Figure 15 | Expression pattern of candidate genes. 
A | Relative expression in the human hematopoietic system. Genes were ranked according to their 
expression in HSCs. B | Relative expression in mouse hematopoietic stem and progenitor cells. Genes are 
ranked according to order in Figure 15A.  
3.2 Establishing a pooled lenOviral based screening pla[orm 
To study gene functions in a specific cellular context, several approaches are 
applicable. Classically, overexpression and knockdown in vivo and in vitro are the most 
commonly used techniques. In this study, we aimed to investigate the gene function in 
murine cells by genetically modifying murine hematopoietic stem and progenitor cells 
through lentiviral transduction. Because of the high number of genes that were intended 
to be investigated, we aimed to design a pooled lentiviral-based overexpression 
approach that will allow us to study the phenotype associated with the candidate genes 
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in a parallel fashion. This step helps to gain functional data for many genes 
simultaneously and to re-evaluate the ranking for further downstream investigations. 
Important considerations for such a screen include the principal study concept, basic 
requirements for the library design as well as essential initial tests to validate 
applicability. The following subchapters of 3.2 address the establishment and testing of 
the screen, while the consecutive subchapters of 3.3 refer to the results generated 
in vitro and in vivo with this library. More information on the functional principle of the 
library-based screen are provided with the subchapters of 3.3. 
3.2.1 Stable overexpression of candidate genes with lenOviral vectors 
The pooled approach is based on lentiviral overexpression constructs that consist 
of an HT-seq compatible 18nt barcode (BC) and an inducible promoter, which initiates 
the transcription of the gene of interest (GOI) and GFP as a marker protein (Figure 16A). 
After synthesis of the candidate cDNAs and cloning into the target vector (see 5.2.1.6 
and 5.2.1.7), we produced GFP only (control) and single candidate gene virus 
supernatants to test GFP stability and mRNA expression in vitro. To this end, we 
transduced human HL60 cells that express the reverse tetracycline-controlled 
transactivator (rtTA) and split the cells after a short recovery period into Doxycycline 
containing (+DOX) or control wells (-DOX). Next, +DOX cells were sorted for GFP to 
increase the purity, using fluorescence-activated cell sorting (FACS). While GFP control 
cells and most other constructs showed stable GFP expression over a period of at least 
one month (data not shown), some constructs showed declining GFP levels over time, 
indicating a greater survival fitness of untransduced cells. Next, mRNA levels of 
candidate genes were measured in GFP enriched candidate- or control GFP 
overexpressing cells, using quantitative PCR (qPCR). Primers specific to the murine codon 
optimized sequence were chosen to exclude unwanted amplification of the human 
endogenous mRNAs. Unfortunately, cells expressing Fbxl18, Mbnl1, Plcb4, Xpb1S and 
Znf217 could not be cultured for an extended period of time without loss of GFP 
positivity, possibly due to greater fitness of non-transduced cells compared to 
transduced cells. Consequently, these mRNA expression levels could not be detected. All 
other constructs however showed stable GFP and detectable mRNA levels, which varied 
between approx. 10% and 100% of the levels of GAPDH (Figure 16B). Moreover, we 
Results 
38 
 
exemplarily measured the protein levels of Igf2bp2 using western blot, which indicated 
sufficient translation of the mRNA into protein (Figure 16C). In summary, the lentiviral 
transduction and expression worked on both, mRNA and protein level in a doxycycline-
dependent manner. Some constructs appeared to compromise the fitness of the cells; 
however, at this point it was not clear whether this resembles a cell type-specific 
biological effect or a general toxicity of the gene product itself. 
 
Figure 16 | Lentiviral-mediated candidate gene overexpression. 
A | Schematic representation of the essential components of the lentiviral overexpression construct in 
active (with DOX, rtTA bound) and inactive (no DOX, rtTA unbound) conformation. ∆LTR, long terminal 
repeat with deletions; Ψ; Retroviral Psi packaging element ;RRE, Rev-responsive element; 18nt, molecular 
BC 18nt sequence that is unique for every gene or construct, respectively (for more detail see section 
3.2.2); pLVX, Tet-inducible promoter; IRES; internal ribosomal entry site; eGFP, enhanced green 
fluorescent protein; B | Relative mRNA expression of candidate gene normalized to GAPDH. C | Igf2bp2 
protein expression in Igf2bp2 overexpressing HL60rtTA cells, segregated in GFP negative and GFP positive 
cells. Housekeeping gene α-tubulin indicates equal loading. 
3.2.2 Custom molecular barcoding and high-throughput sequencing 
casseXe  
To trace the differentiation and proliferation behavior of transduced cells in vitro 
and in vivo, we equipped the lentiviral OE constructs with a ∼250bp barcode cassette, 
harboring primer binding sites for a nested PCR in order to amplify the cassette including 
a 18nt BC from genomic DNA (gDNA) as well as an HT-seq primer binding site. The 
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cassette was adapted from the well-established Cellecta shRNA library, which contains 
more than 27,000 unique 18nt BCs. In total, we randomly selected 96 unique BCs from 
this pool in order to provide two BCs for every GOI and 10 BCs for the controls. The 
remainder of the 96 BCs was used for related projects on miRNA overexpression (Elias 
Eckert, data contained in Wünsche et al. (2018)) or tests for amplification efficiency and 
accuracy (3.2.3).  
Upon detection of BCs in transduced cells, the cassette is amplified by nested PCR 
with the first PCR cycle amplifying the 18nt BC and the P7 sequence (important for 
hybridizing with the chip during sequencing), while eliminating the endogenous P5 
sequence. Because of the anticipated large number of sequencing samples, we re-
designed the reverse primer for the second PCR to harbor one of 96 possible 8nt index 
sequences. This allows for multiplexing the samples and thus for simultaneous 
sequencing of up to 96 samples per Illumina HiSeq lane. Moreover, the reverse primer 
during the second PCR also introduces the binding site for the Illumina index primer as 
well as a new P5 sequence (sequence identical to original P5 sequence, important for 
hybridizing with the chip during sequencing). This way, the generated PCR products are 
ready for sequencing and do not require adapter ligation or library preparation. Finally, 
the sequencing run consists of two steps, the first read provides the barcode sequence 
and thus allows for allocation of the GOI followed by the second read, which provides 
the index and thus allows for the allocation of the sample (Figure 17). 
 
Figure 17 | Detailed representation of the HT-seq barcode cassette with multiplexing PCR step. 
During the 1st PCR the barcode cassette is amplified from gDNA, eliminating the endogenous P5 sequence. 
In a 2nd PCR the barcode is further amplified and reactions can be by one out of 96 8nt indices while also 
introducing a new P5 sequence. Finally, the PCR products are sequenced in a 50bp single read Illumnia 
HiSeq 2000/2500 run in which the 1st read identifies the 18nt barcode (overexpressed gene) and the 2nd 
read the 8nt index (sample)  
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3.2.3 SystemaOc one-by-one ampliﬁcaOon of indices reveals very low 
index-bleeding 
Due to the relatively short sequence of the index (8nt), it is conceivable that 
technically unavoidable sequencing errors could cause the misallocation of samples. To 
minimize this effect, we used the pre-designed NuGene index library, which was 
designed to vary between indices in at least two positions, ensuring accurate indexing. 
To minimize cross-contamination during multiplex primer (Figure 17) synthesis, primers 
were ordered individually and timely spaced. To assure that plasmid stocks were not 
contaminated with other BC containing plasmids, we next transformed bacteria with 
plasmids and picked single colonies for barcode amplification during 1st PCR. The 2nd 
indexing PCR was inoculated using 5µL of PCR product from the 1st PCR. After additional 
quality checks, PCR products were pooled and sequenced using the standard HiSeq 2000 
50bp single read protocol (more detail is provided with Figure 18 and 5.2.1.8).  
 
 
Figure 18 | Matrix experiment to evaluate any potential index bleeding (Legend continued on next 
page). 
After adjusting the concentration of all 96 plasmids, plasmids were aliquoted into a 96 well plate and 
supplemented with competent TOP10 bacteria. After heat shock and incubation, reactions were applied to 
LB-Agar plates to grow single clone colonies. Next, 1st PCR was conducted as a colony PCR amplifying the 
barcode directly from bacterial plasmids to ensure maximum purity of the barcode, followed by the 2nd 
PCR, in which every barcode was amplified with one unique index primer (also see Figure 17). Before 
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pooling, every reaction was loaded on an agarose gel to ensure successful amplification. After pooling of 
all reactions, correctly sized PCR products were enriched using gel purification, followed by concentration 
adjustment, sequencing and data analysis. 
After sequencing, raw data were de-multiplexed and reads were trimmed and 
counted (also see 5.2.1.8). All barcodes showed very low cross-contamination or index-
bleeding with a mean of 734 wrongly allocated BCs per sample at an average of 
1.24 x 106 reads per sample (0.059%), which equals a mere 7.7 incorrectly allocated 
reads per BC per sample (0.0006%, Figure 19). The only exception of relatively high 
cross-contamination levels (approx. 20,000 wrongly allocated reads per sample) were 
found in samples D4 and D10. However, due to the indistinguishable nature of these 
indices compared to other indices, these contaminations might have occurred during the 
preparation rather than the sequencing steps. Taken together, this test experiment 
proofs the feasibility to pool up 96 samples on one HiSeq lane and thus provides the 
basis for all following in vitro and in vivo screening experiments.  
 
Figure 19 | Evaluation of index bleeding. 
A | Heatmap of read counts normalized to 1 x 106 per barcode with color being proportional to number of 
reads. B | Average number of reads per barcode before normalization and quantification of off-targets per 
index and per barcode. BC, barcode; Data jointly produced with Elias S. P. Eckert. 
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3.2.4 Titers can vary between constructs and producOons and do not 
correlate with cDNA length 
Generally, it is believed that bigger plasmids are less efficiently packed during 
virus production or transcribed less abundantly and hence result in lower virus titers 
(Kumar et al., 2001). Because we aimed to produce the virus in a single reaction using 
the pooled plasmid library that contains constructs of varying sizes, we assessed the titer 
for all constructs for comparison. Virus supernatants were produced simultaneously in 
6-well plates to avoid batch effects and titrated on HL60rtTA cells. Interestingly, two 
independent virus productions showed varying results. The 1st production showed a 
relatively tight range of titers varying between approx. 7,000 to 37,000 infectious units 
(IU) per mL, while the 2nd production varied substantially more (100 - 40,000 UI/mL; 
Figure 20A). Although the slope of the linear regression of the 1st production indicated 
that smaller constructs yielded a slightly higher titer, the overall fit was very poor and 
hence suggested that the construct size cannot be the only titer-influencing factor 
(Figure 20B). In summary, all constructs gave rise to functional viruses and titers 
indicated by measurable GFP expression, which were sufficiently comparable for 
following in vitro and in vivo experiments with the pooled lentiviral OE library. 
 
Figure 20 | Relation between construct size and virus titer. 
A | Titer for every construct after two independent virus productions. Productions and their outer 
boundaries of titer variations are indicated by colors and dashed lines. Constructs on x-axis are sorted for 
decreasing construct sizes with the biggest construct on the left and the smallest on the right hand site. 
B | Titers of 1st production plotted against actual size in bp. Fit and slope of the linear regression are 
indicated. Note that the x-axis is reversed. IU, infectious units. 
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3.2.5 Stable GFP expression and barcode representaOon over Ome in vitro 
Next, we investigated the stability of GFP and BC representation in vitro. To this 
end, we used a pool of 25 constructs equal in size (GFP only) but with unique BCs. 
Plasmids were pooled at equal amounts with the exception of two BCs, which were 
spiked in at a 5-fold and 2-fold overrepresentation. After virus production, HL60rtTA cells 
were transduced with two different multiplicities of infection (MOI, 0.13 and 1.3) and 
GFP expression was measured periodically for 41 days. Percentage of GFP positive cells 
was stable across the entire time independent of the MOI (Figure 21A). Additionally, 
genomic DNA (gDNA) was extracted from cell aliquots at day 1, 3, 10, 21 and 28 and 
sequenced after BC amplification. This revealed stable BC representation until day 28. In 
summary, constructs only overexpressing GFP but no cDNA did not encounter positive or 
negative selection in vitro and therefore are suitable for the pooled LV OE library.  
 
Figure 21 | Assessment of GFP and BC stability over time in vitro. 
A | Cells were transduced with a MOI of 0.13 or 1.3, respectively, and GFP was measured at indicated 
days. B | BC representation at indicated time points in comparison to the initial plasmid mix (INPUT). 
Dashed lines indicate the input boundaries for the 5-fold and 2-fold overrepresented BCs.  
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3.3 CharacterizaOon of candidate hematopoieOc regulators 
After establishing the platform required for the simultaneous characterization of 
our candidate genes, we proceeded with in vitro serial colony forming unit (CFU) and cell 
trace assays as well as in vivo transplantation experiments. At this stage of the study, we 
speculated that cells transduced with our candidate genes might have a competitive 
advantage over untransduced or GFP only transduced cells. This hypothesis was based 
on the widely postulated concept that large clusters of ISs near a given gene occur due 
γRV-mediated activation of this gene, which in turn leads to the clonal expansion. Due to 
the expected differences in proliferation changes upon transduction with either only GFP 
or GOI expressing constructs, two independent lentiviral OE pools were produced: 
1) A “GFP pool”, consisting of 10 plasmids only expressing GFP but each harboring a 
unique BC. 
2) A “GOI pool”, consisting of 20 protein-coding genes each represented by two unique 
BCs, resulting in a total of 40 BCs.  
3.3.1 Results of serial CFU re-plaOng assays revealed changes in BC 
representaOon over Ome but were limited by poor library presentaOon 
In order to assess the effect of our candidate genes on proliferation, 
differentiation and self-renewal, we sorted Lineage negative (Lin-), Sca-1+, c-Kit+, CD48- 
and CD150+ (LSK-SLAM) cells from Rosa26 rtTA mouse bone marrow (BM). After 48h 
recovery time, cells were split and either transduced with the GFP pool or the GOI pool. 
Next, DOX was added to the medium in order to induce GFP and/or GOI expression. 72h 
later cells were sorted for GFP followed by seeding into semi-solid medium. For all 
assays, the transduction efficiency was kept below 25%, ensuring a maximum of one 
vector copy per cell. In total, 1,200 cells for both, the control as well as the GOI OE group 
were plated (120-fold / 30-fold barcode representation). Cells were re-sorted for GFP 
after seven days and re-plated again after 15 and 28 days. An aliquot of cells was kept 
for all re-plating time points before and after DOX administration and finally gDNA was 
extracted, barcodes were amplified and sequenced (Figure 22A).  
Besides flow-cytometric analysis of GFP levels at every sort or re-plating time 
point, GFP positivity was also assessed by fluorescence microscopy and revealed bright 
and homogenous GFP levels throughout colonies (Figure 22B). The GOI pool BC analysis 
Results 
45 
 
revealed drastic changes in relative percentages with the majority of BCs declining over 
time in favor of very few BCs, which showed a corresponding increase (Ccnd3, Lair1L, 
Lair1S and Xbp1; Figure 22C). Expectedly, GFP pool BCs appeared much more stable over 
time except for one BC, which also declined over time. However, this BC showed a much 
lower initial representation in the pool compared to other BCs, indicating a technical 
rather than biological effect (Figure 22C, yellow BC, indicated by arrow). In three 
following CFU assays, similar effects were observed with relatively stable GFP pool BCs 
but drastically changing BC proportions in the GOI pool cohort. However, colony 
numbers and transduction efficiencies for all following CFU assays suggested an 
underrepresentation of the GOI pool library, increasing the chance that BC changes 
occur for stochastic rather than biological reasons. Interestingly however, on average 
GOI pool transduced cells did not show increased colony numbers, total cell counts or 
replating efficiencies compared to GFP pool transduced cells, indicating that the 
overexpression of candidate genes did not result in drastic changes in proliferation or 
self-renewal capacity as initially suspected. In summary, the approach appeared to be 
feasible, however, showed limitations due to transduction efficiency and GFP+ colony 
numbers, rendering biological conclusions for individual candidates difficult. 
Nevertheless, the CFU experiments indicated thus far that our candidate genes do not 
massively alter the proliferation or self-renewal capacity of GOI pool transduced cells.  
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Figure 22 | Serial replating of transduced LSK-SLAM cells in semisolid medium (Legend continued on 
next page). 
A | Experimental workflow. LSK-SLAM cells were isolated from Rosa26 rtTA mouse BM, transduced with 
the lentiviral pool and sorted for GFP 72h after DOX induction. Cells were re-sorted for GFP after 1st 
re-plating and subsequently plated two more times. gDNA was extracted from spare cells at every time 
point in order to allow for BC amplification followed by HT-seq. B | Representative fluorescent microscope 
pictures of colonies at 40x magnification with bright field (left columns) and GFP channel pictures (right 
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columns). C | Log2 of BC counts normalized to initial LSK-SLAM representation before DOX administration 
(±SEM). The BC with very low initial representation (yellow points) in GFP-control group is indicated by an 
arrow.  
3.3.2 Cell trace experiment indicated varying proliferaOve potenOal 
between cells transduced with diﬀerent lenOviral OE constructs 
Due to the limitations encountered in the CFU assay, we developed another 
assay that is scalable to larger numbers of cells. To this end, approx. 4 x 105 LSK cells 
from donor Rosa26 rtTA mice were split into 1/3 GFP pool and 2/3 GOI pool cells and 
transduced as described above (3.3.1). Next, transgene expression was initiated using 
DOX and cells were stained with CellTrace™ violet, a FACS compatible membrane bound 
dye which signal intensity is approx. halved with every cell division. Stained cells were 
cultured for 3 or 5 days, respectively, and finally sorted into fast (weakest signal 
intensity), intermediate fast, intermediate slow and slow (highest signal intensity) cycling 
cells. Lastly, gDNA was extracted and BCs were amplified and sequenced (Figure 24A and 
B). In general, most of the genes appeared to have only little effect on the proliferation 
of LSK cells in vitro, which was reproducible in both independent experiments. The only 
two genes which showed a mild effect on proliferation were Irf2bp2, which was enriched 
in the fast cycling fraction and the long splicing form of Lair1 (Lair1L), which was 
enriched in the slow cycling fraction. Taken together, the two experiments showed 
comparable results, indicating that the approach is feasible and less prone to stochastic 
effects due to the higher initial number of cells. However, the relatively short culture 
time of 3 to 5 days requires profound changes in proliferation to become apparent in 
this assay. Our candidate genes however, appeared to only mildly affect proliferation 
in vitro, which is partially in line with the observations made in the CFU assay.  
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Figure 23 | CellTrace assay for the detection of changes in proliferation upon GOI OE (Legend continued 
on next page). 
A | Experimental workflow. LSK cells were isolated from Rosa26 rtTA mouse BM and transduced with 
either the GFP or GOI pool. Transgene expression was induced using DOX, cells were stained with 
CellTraceTM and cultured for 3 or 5 days, respectively, before sorting fast, intermediate fast, intermediate 
slow and slow cycling cells. Finally, gDNA was extracted from sorted fractions, followed by BC amplification 
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and HT-seq. B | Exemplary FACS plots showing the gating strategy and generational peaks. C | Log2 of the 
mean counts of two BCs per gene normalized to initial LSK representation (grey dashed line) before DOX 
administration (±SEM). Results of two independent experiments are plotted in one plot (orange and green 
dots and lines), while GFP control experiments are plotted individually. F, fast; IF, intermediate fast; IS, 
intermediate slow; S, slow; FSC, forward scatter; SSC, side scatter.  
3.3.3 In vivo lenOviral overexpression screen reveals potenOal 
hematopoieOc regulators but is again limited by engra_ment and library 
representaOon 
After gathering initial results through in vitro assays we continued characterizing 
the candidate genes through mouse transplantation experiments. To this end, 
LSKRosa26 rtTA cells were harvested and transduced as described before (3.3.1). After 
transduction, cells were kept in culture for 48h-72h and finally transplanted into lethally 
irradiated recipient mice. For all experiments, peripheral blood (PB) was harvested for 
the first time four weeks after transplantation, followed by addition of DOX to the 
drinking water to induce expression of GFP or GFP and GOI, respectively. Next, PB was 
harvested every four weeks until week 20. At all bleeding time points, barcodes were 
amplified from whole blood samples as well as sorted fractions of myeloid cells, B cells 
or T cells (myeloid cells: Ly-6G+ CD11b+, T cells: CD3+, B cells: CD45R+; lineage data not 
shown). Collectively, out of 156 transplanted mice, 11 mice from the GFP pool group 
(approx. 25-28% GFP+ cells and 37-51% engraftment) and 11 mice from the GOI pool 
group (approx. 20% GFP+ cells and 75% engraftment) exhibited sufficient GFP positive 
cells and engraftment for BC analysis (for an overview of conducted experiments see 
Table 2). All mice revealed significant proportional changes over time in both groups, 
with control mice appearing more stable, compared to mice transduced with the GOI 
pool (Figure 24B and Figure 25). Comparable to the results from the CFU assay, many 
BCs showed a decline over time with Nrip1 declining most significantly. Importantly 
however, Nrip1 also showed the lowest initial BC representation, indicating a 
comparably low titer and consequently an initial lower number of transduced cells. 
Interestingly, all genes that showed a significant change in BC representation 
(Friedman-Test) showed declining BCs, while no gene showed a consistent and 
significant increase in BC representation. Unexpectedly, control mice transplanted with 
GFP pool transduced LSKRosa26 rtTA cells also showed significant changes in relative BC 
proportion (both, increasing and decreasing BC representation; Figure 25). However, 
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here every BC was tracked on its own, while the two BCs for every gene in the GOI pool 
were averaged first before statistical evaluation, making a direct comparison difficult. To 
account for the differences in the number of BCs, we performed an independent 
statistical comparison between GFP and GOI pool, which is explained in more detail 
below (see 3.3.4).  
Although the interpretation of the in vivo data is again challenging due to a 
relatively low library representation and possibly small number of engrafted and 
transduced clones, we strikingly never observed clonal expansion or signs of leukemia or 
neoplastic growth in any of the 156 transplanted mice. This again shows that the effect 
on proliferation or self-renewal of transduced cells is much smaller than initially 
anticipated, questioning whether the clusters of γRV ISs that were originally used for the 
selection of candidate genes appeared due to enhanced expansion or self-renewal or 
rather marked large regulatory sites in the genome of transduced cells.  
Table 2 | Overview of performed transplantation experiments 
Exp. # LSK cells per mouse 
Mean % GFP  
GFPp | GOIp 
# Mice  
GFPp | GOIp 
# Mice survived  
(4w) GFPp | GOIp 
Mean 
% engraftment 
(4w) GFPp | GOIp 
TX V01 5,000 0% | 0% 6 | 12 6 | 12 69% | 46% 
TX V02 15,000 45% | 20% 6 | 12 0 | 12 0% | 75% 
TX V03 15,000 25% | 17% 6 | 12 5 | 10 51% | 53% 
TX V04 15,000 28% | - 6 | 12 6 | 2 37% | 52% 
TX V05 5,000 0% | 22% 6 | 12 6 | 8 0% | 0% 
TX V06 15,000 - | - 6 | 12 5 | 9 0-35% 
TX V07 40,000 0-1% 24 (Mix) 9 60-70% 
TX V08 20,000 0-1% 24 (Mix) 18 70-80% 
Exp., name of experiment; #, number of; GFPp, mice transduced with GFP pool; GOIp, mice transduced 
with GOI pool; Mix, mice transduced with lentiviral pool containing both GFP control and GOI constructs; 
4w, four weeks after transplantation. 
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Figure 24 | Relative proportions of read counts for each gene (mean of two BCs) per mouse over time. 
A | Experimental workflow. LSK cells were isolated from Rosa26 rtTA mouse BM and transduced with 
either the GFP or GOI pool. Transgene expression was induced using DOX 4 weeks after transplantation 
and mice were bled every four weeks. After lysis of erythrocytes, gDNA was extracted from peripheral 
blood samples fractions, followed by BC amplification and HT-seq. B | Relative % of BC counts over time 
(mean of 2 BCs that depict the same gene). Data was not normalized to 4 weeks after transplantation to 
indicate initial BC representation. TX V02, Transplantation cohort No. 2 (Table 2). Gray dashed lines 
indicate the theoretical mean proportion for each barcode (2.5%). Friedman Test: * = p ≤ .05, ** = p ≤ .01, 
*** = p ≤ .001, **** = p ≤ .0001, ns = not significant.  
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Figure 25 | Relative proportions of GFP control BCs per mouse over time, related to Figure 24. 
Relative % of BC counts over time Data was not normalized to 4 weeks after transplantation to indicate 
initial BC representation. TX V03, TX V04, Transplantation cohort No. 3 + 4, respectively (Table 2). Gray 
dashed lines indicate theoretical mean proportion for each barcode (2.5%). Friedman Test: * = p ≤ .05, ** 
= p ≤ .01, *** = p ≤ .001, **** = p ≤ .0001, ns = not significant.  
3.3.4 StaOsOcal evaluaOon of BC combinaOons indicates that changes in BC 
proporOons are parOally driven by a biological eﬀect 
Due to the experimental design with 10 BCs representing empty GFP OE 
constructs and only 2 BCs representing one GOI, a direct comparison using the average 
of BCs depicting the same gene would be biased. On the one hand, averaging over all 10 
BCs in the GFP pool would result in an artificially stable BC representation, as effects 
would cancel each other out. On the other hand, creating the average of pairs of two 
GFP pool BCs can be biased, depending on which pairs are created. To circumvent this 
problem, we calculated the p-values using a Wilcoxon-test for all 45 possible BC 
combinations of the GFP pool comparing 4 weeks with 8-20 weeks after transplantation 
and determined the percentage of significant BC combinations (Figure 26A and B). For 
comparison, we also calculated the p-values for all 780 possible BC combinations from 
the GOI pool as well as the p-values for the true BC combinations. We hypothesized that 
BC combinations that depict the same gene should behave similarly, while BC 
combination of different genes would only behave similarly by chance. In fact, only 
approx. 5% of all BC combinations from the GFP pool exhibit a p<0.05, which 
corresponds to the 5% false discovery rate (FDR), hence the amount of significant 
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combinations one would expect by chance. In contrast, about 15% of BC combinations 
are significant when combining GOI pool BCs. This indicated that most genes or BCs, 
respectively, behave similarly (most of BCs decline over time) and thus result in more 
significant combinations than expected. However, the percentage of significant 
combinations is highest (approx. 25%) when comparing true BC combinations, indicating 
that BCs behave most similarly when allocated to the same gene (Figure 26B). In 
summary, this analysis demonstrates that the over expression of our GOIs might indeed 
show a biological effect. Nonetheless, given the large differences and BC deviations 
between individual mice, higher transduction efficiencies and better engraftment or 
combined GFP and GOI pools are needed draw definite conclusions. 
 
Figure 26 | Wilcoxon-test for all possible barcode combinations. 
A | p-values of Wilcoxon-test comparing all possible combinations of the mean of 2 BCs at 4 and 20 weeks 
after transplantation. p-values are sorted for decreasing significance along the x-axis except for true GOI 
combinations. Here p-values are sorted according to gene name (alphabetically). Grey dashed line 
indicates p-value of 0.05. Black diagonal represents the theoretical distributions of p-values of infinite 
tests of random data-pairs. B | Percent significant combinations for 4 vs. 8, 12, 16 and 20 weeks. 
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The following paragraphs of the results contain text sections that have been taken from 
Wünsche et al., (2018) and have been originally written by myself. All literal quotes are 
indicated by quotation marks (” … “), following the guidelines of good scientific practice 
of the Ruperto-Carola University of Heidelberg. 
Reprinted or adapted figures and tables from Wünsche et al., (2018) are indicated as 
such either in the figure legend or table header. 
 
 
3.4 Mapping acOve gene-regulatory regions using γ−retroviral 
integraOon sites 
During the last decade, intensive investigations and technological advances have 
reshaped the understanding of insertional preference of viruses. Instead of being 
scattered randomly across the genome, γ-retroviral integration sites (γRV ISs) have been 
found to almost exclusively accumulate in so called common integration sites (CIS), a 
phenomenon that primarily occurs due to insertional preference for active transcription 
start sites (TSS) and active strong enhancers (Cattoglio et al., 2007; Cattoglio et al., 2010; 
De Ravin et al., 2014; Deichmann et al., 2011; LaFave et al., 2014; Sharma et al., 2013; 
Sultana et al., 2017; Suzuki et al., 2002; Wu et al., 2003). As a consequence, γRV ISs can 
be used as molecular tags to map the aforementioned active regulatory regions in the 
genome of transduced cells (Romano et al., 2016). Due to the stable integration into the 
genome, transduced cells inherit the ISs to all offspring, which enables to derive 
information about the regulatory landscape of the cell of origin through sequencing and 
mapping of ISs in their descendants. Thus, we hypothesized that γRV ISs sequenced 
during steady-state hematopoiesis in differentiated blood and BM cells from patients 
that were transplanted with transduced HSPCs would point towards regulatory regions 
in long-term reconstituting HSCs. To this end, we re-analyzed the complete repertoire of 
181,055 ISs or 130,637 unique ISs, respectively, and combined these data with an array 
of publicly available datasets (Table 3) for meta-analysis and validation purposes.  
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Table 3 | Overview of γRV ISs and complementary datasets used in this study. Taken from Wünsche et 
al. (2018) 
Cell Type Type of Data Quantity / Type  Source Build 
CD34+ cells post-
transpl. 
γRV ISs 130,637 IS This study 
GRCh37/hg19 
CD34+ cells pre-transpl. γRV ISs 1,014,151 IS De Ravin et al., 2014 
CD34+ cells xenotranspl. γRV ISs 16,288 IS De Ravin et al., 2014 
CD34+ cells pre-transpl. γRV ISs 209 IS Aiuti et al., 2007 
CD34+ cells post-
transpl. 
γRV ISs 484 IS Aiuti et al., 2007 
HepG2 cells γRV ISs 2,620, 137 IS LaFave et al., 2014 
K562 cells γRV ISs 230,950 IS LaFave et al., 2014 
13 primary  
blood cell types 
Fast ATAC-seq 5,000 cells Corces et al., 2016 
13 primary  
blood cell types 
RNA-seq 1,000-100,000 cells Corces et al., 2016 
CD34+ cells Capture Hi-C 418,037 interactions Mifsud et al., 2015 
CD34+ cells ChIP-seq 
(H3) K4me1, K36me3, 
K27ac, K9me3, K27me3, 
K4me3 
Bernstein et al., 2010 
CD34+ cells ChIP-seq CTCF binding sites Jeong et al., 2017 
CD34+ cells Hi-C TAD boundaries Rao et al., 2014 
GWAS SNPs Medical impact 24,435 GWAS SNPs NHGRI-EBI Catalog 
SNPs 
No known 
impact 
38,128,476 SNPs NCBI human variants 
xenotranspl, human CD34+ cells transplanted into NSG mice; GWAS, genome wide association study; SNP, 
single nucleotide polymorphism.  
3.4.1 The majority of γRV ISs are located in enhancer regions 
Because we aimed to use γRV ISs as molecular tags to mark active genes and 
gene-regulatory regions, we first sought to confirm the reported integration preference 
in our patient cohort. Indeed, we found that ISs sharply peak around TSS as reported in 
the earliest studies that investigated γRV insertion biology. However, in line with more 
recent studies, we found that 70% of ISs locate further away from TSS than ±5kb, 
indicating that ISs predominantly mark non-promoter regulatory regions (Figure 27A). 
ISs that locate in a 10kb window around TSS can be further segregated into gene classes, 
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showing that protein-coding genes are by far the most common class, followed to a 
much lesser extend by lincRNAs and lastly miRNAs (Figure 27B). However, one has to 
note that this is not corrected for the abundance of the different gene classes. The 
notion that ISs preferentially target active regions was also further supported by a 
20-fold enrichment of active histone marks (H3K4me1, H3K27ac, H3K4me3) compared 
to repressive marks (H3K9me3, H3K27me3, H3K36me3). Particularly co-occurrence of 
H3K4me1 and H3K27ac modifications are a surrogate for strong active enhancers, while 
H3K4me1 are usually absent from promoters (Zhou et al., 2011) (Figure 8 and 
Figure 27C).  
 
Figure 27 | ISs mainly cluster around protein-coding gene TSS and histone marks associated with active 
promoters or enhancers 
A | Distance of ISs to closest TSS. Red areas with percentages depict ISs further away than ±5kb. 
B | Percent of all genes that are marked by ISs closer than ±5kb segregated by gene classes. 
C | Association of ISs positions and ChIP-seq signal for major active (red shades) and repressive (violet 
shades) marks. Subpanel A and C are adapted from Wünsche et al. (2018) 
3.4.2 Switch from short-term to long-term hematopoiesis a_er 
transplantaOon occurs a_er 6-12 months 
In order to map regulatory regions in long-term contributing HSCs, we sought to 
determine the transition of short-term (transient) to long-term hematopoiesis for all 
patients. After BM transplantation an early transient reconstitution phase mostly driven 
by highly proliferative progenitor cells occurs, quickly supplying the organism with new 
blood cells followed by a long-term hematopoiesis phase, driven by HSCs (Busch and 
Rodewald, 2016). While studied extensively in mice, the dynamics of this process have 
only recently been revealed for non-human primates and humans (Biasco et al., 2016; 
Kim et al., 2014). The switch between these two phases of reconstitution is 
characterized by a change in clonal association between time points, with low 
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association during the early phase and higher association during the stable long-term 
phase. To estimate the switch in our patient cohort, we calculated the pairwise positive 
association (odds ratio) between all samples and time points for all patients with 
sufficient sequencing depth and time points (Figure 28). Moreover, we developed a 
mathematical model-fit that describes the increase in association for patients objectively 
based on the mean log2 odds ratio for all sequencing time points. After modeling the 
data, the switch was defined as 30% of the functions maximum (Figure 28, horizontal 
dashed lines). In line with the study from Biasco et al., (2016), we detected a noticeable 
change in association (onset of long-term hematopoiesis) between 6-20 months after 
transplantation. Unfortunately, patients 3, 6, 7, and 10 had insufficient data for a robust 
determination of the switch, so instead we used the median of 404 days as a stringent 
cut off – calculated from the remaining patients. These results illustrate not only the 
transient phase of hematopoiesis, but also the stable long-term commitment of HSCs, 
indicated by a continuous positive association starting from 6 months up to more than 6 
years post transplantation. These findings are also in line with blood reconstitution 
experiments after irradiation in non-human primates, where clones appeared transiently 
for 6-12 months after transplantation, which eventually were replaced by long-term 
repopulation HSC whose progeny were still detectable after 12 years (Kim et al., 2014). 
Based on the patient specific cut off, we excluded ISs sequenced before the switch in 
order to prevent contamination with progenitor-derived IS positions, yielding 79,424 
unique IS. A detailed overview of ISs per patient, separated into total, early and late 
sequenced ISs according to the patient-specific switch is provided with Table 4. 
Hereinafter, only ISs sequenced after the switch to long-term hematopoiesis (79,424 IS) 
were used for analysis, unless stated otherwise. 
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Figure 28 | Positive association matrices from patient 1, 2, 4, 5, 8, and 9 indicate a switch from 
short-term to long-term hematopoiesis after 6-20 months. 
Positive association was plotted with the color intensity being proportional to the log2 odds ratios (OR). 
Samples are ranked for time-point of sequencing and color coded. Sequencing time points are categorized 
into < 6 months, 6-12 months, 12-24 months and > 24 months and color coded. For every patient, a log-
logistic model is used to fit the mean log2 odds ratio of the pairwise positive association (red curve). The 
switch from early to stable (late) hematopoiesis was defined as 30 % of the functions maximum. Adapted 
from Wünsche et al. (2018). 
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Table 4 | Overview of ISs per patient, separated into total, early and late sequenced ISs according to 
indicated switch. Taken from Wünsche et al. (2018) 
Patient #samples #total ISs #early ISs #late ISs %early ISs %late ISs Switch [d] 
1 60 8,137  866  7,271  10.64  89.36  153 
2 55 19,124  1,348  17,776  7.05  92.95  192 
3 6 928  928  - 100.00  - 404* 
4 18 17,951  9,439  8,512  52.58  47.42  440 
5 30 23,897  9,334  14,563  39.06  60.94  367 
6 24 10,229  8,194  2,035  80.11  19.89  404* 
7 22 12,212  2,368  9,844  19.39  80.61  404* 
8 24 16,294  10,937  5,357  67.12  32.88  627 
9 18 15,886  9,551  6,335  60.12  39.88  635 
10 13 11,032  3,302  7,730  29.93  70.07  404* 
#, number of; d, days. 
3.4.3 IntegraOon site paXern of γRVs mark cell-type speciﬁc regulatory 
elements     
Because the activity of enhancers and promoters is highly cell type specific (Heinz 
et al., 2015), we investigated the IS pattern across all 10 patients including four 
additional public datasets, which contain γRV ISs from human CD34+ (pre and post-
transplantation in NSG mice), myelogenous leukemia K562, and hepatocellular cancer 
HepG2 cells. We expected that the IS pattern are similar between patients, as both, the 
initial population of CD34+ cells before transplantation as well as the resulting 
population of HSCs after engraftment should be comparable. To this end, we performed 
Pearson correlation as well as Principle Component Analysis (PCA) using the relative 
percentage of all ISs in genome-wide 10kb bins and adjusted for differently sized 
datasets by random sampling (Figure 29A and B). Pearson correlation showed a high 
similarity between all patients except patient 3, who suffered from engraftment failure, 
which was also reflected by PCA. Interestingly, while ISs from CD34+ cells showed a high 
Pearson correlation with patient IS, PCA revealed a distinct difference in the 2nd 
component. This difference decreased two months after transplantation of CD34+ cells 
into NSG mice (xenotransplant), indicating a converging of the IS patterns from patients 
and CD34+ cells during engraftment. Expectedly, ISs from K562 or HepG2 cells showed a 
poor Pearson correlation with patient ISs and located far outside the patient cluster in 
the PCA (Figure 29A and B). These results underline the non-random and cell type 
specific integration nature of γRV and indicate that transplantation and engraftment 
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renders the regulatory landscape highly similar among patients and most importantly 
different from the initial state in CD34+ cells. 
 
Figure 29 | Similarity between IS pattern is highest among patients 
A | Pearson correlation matrix of all patient ISs and in vitro IS data sets ranked according to principle 
component 1 in PCA. Color intensity is proportional to correlation coefficient, which are depicted in the 
squares. B | PCA on the same datasets as used for the Pearson correlation matrix. Percentages in brackets 
represent the proportion of variance explained by this component. all WAS ISs, IsS pooled from all 
patients; early/late WAS ISs, ISs occurring either during short-term (early) or long-term (late) 
hematopoiesis; using the patient specific cut off; CD34+ ISs, ISs from CD34+ cells before transplantation; 
CD34+ xeno ISs, after transplantation of human CD34+ cells into NSG mice; K562 ISs/HepG2 ISs, ISs from 
K562 or HepG2 cells, respectively. Subpanel B is adapted from Wünsche et al. (2018) 
3.4.4 Rainfall plots visualize commonaliOes and diﬀerences between 
paOent ISs and ISs from CD34+ cells 
Next, we visualized the differences between patients IS and a number matched 
representative sampling of ISs from CD34+ cells in greater detail by plotting the genomic 
distances from one IS to its consecutive IS (inter-IS distance, Figure 30). Interestingly, the 
fundamental properties of both datasets did not appear substantially different, as both 
datasets showed the same characteristic gap of inter-IS distance at approx. 10 kb. This 
indicates that most ISs are contained within clusters and only the minority has a greater 
distance to the neighboring IS of more than 10 kb (Figure 30). Moreover, the distribution 
of ISs along the genomic scale is also similar between the two datasets, again indicating 
an absence of major clonal skewing events, which would have led to the appearance of 
very few large clusters instead of thousands of small ones. Nonetheless, there are 
noticeable differences in the distribution of the top 100 biggest clusters. For example, 
Results 
61 
 
WAS patients exhibit few very large clusters (e.g. Chr3 – MECOM, Chr11 - LMO2), which 
have indeed occurred due to insertional mutagenesis, as reported previously (Boztug et 
al., 2010; Braun et al., 2014). However, most of the remaining clusters appear at a 
similar size compared to those observed for CD34+ cells (Figure 30). This indicates an 
overall unchanged clonality again arguing against a frequent outgrowth of clones due to 
insertional mutagenesis (with the exception of the aforementioned oncogenic 
examples). Yet, the positions of the top 100 clusters are considerably different, 
suggesting an underlying dissimilarity between cells in patients and CD34+ cells. As the 
initial population of cells in the gene therapy study was also CD34+, it is conceivable that 
the observed differences have occurred post transplantation. 
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Figure 30 | Rainfall plots of ISs from WAS patients and CD34+ cells visualize commonalities and 
difference between the two datasets (Legend continued on next page). 
IS are shown as grey or red dots and are numbered and ordered on the x-axis according to their position in 
the genome, segregated by chromosome. The position on the log10 y-axis corresponds to the distance in 
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bp to the subsequent IS, calculated using the imd function from the ClusteredMutations package for R. ISs 
contained within the top 100 clusters (according to number of ISs per cluster) are marked red. 
3.4.5 Clonal skewing of ISs paXern is restricted to few known leukemogenic 
loci 
It has been known for over a century that γRV insertions have a mutagenic or 
transforming potential via activation of proto-oncogenes (Ellermann and Bang, 1908; 
Rous, 1911). In fact, for many years γRVs were used to screen for oncogenes in a variety 
of mouse tissues (Kool and Berns, 2009). Here γRV ISs were used as genetic molecular 
tags pointing towards proto-oncogenes due to the outgrowth of malignant clones, 
resulting in a shift from a polyclonal to an oligo- or monoclonal pattern within the 
studied system – an unfavorable side effect when highly complex clonality is desired. 
Consequently, we sought to estimate the impact of clonal skewing in the patients on the 
complexity of our dataset. As of 2014, seven out of ten patients within the WAS gene 
therapy cohort developed either AML or T-ALL. However, ISs in dominant clones or blast 
cells detected in patients were found almost exclusively in the vicinity of MDS1/EVI1 
(MECOM) or LMO2, followed to a lesser extent by MN1 (secondary AML), SETBP1, 
PRDM16 and CCND2, all of which were observed previously during benign or malignant 
expansion of clones in other γRV gene therapy trials (Braun et al., 2014; Hacein-Bey-
Abina et al., 2003a; Hacein-Bey-Abina et al., 2003b; Howe et al., 2008; Ott et al., 2006; 
Stein et al., 2010). However, only clones carrying ISs in the proximity of MECOM and 
LMO2 were commonly found across all patients, suggesting a driver role of these genes 
only. To address whether other unexplored oncogenic events led to clonal skewing of 
our dataset, we compared the quantity of ISs per cluster as well as the cluster sizes 
found in patients with three in vitro IS datasets (Figure 31A). Importantly, clonal skewing 
of the in vitro datasets can be excluded as all three in vitro IS datasets were sequenced 
2-4 days after transduction. Although there was a statistical significant difference 
detected in cluster dimension and size between patient ISs and most of the in vitro 
datasets, the magnitude was neglectable and comparable to those between the 
individual in vitro datasets themselves (Figure 31A). As neoplastic cell growth after 
transformation usually occurs with some latency, we also compared early and late 
occurring cluster dimensions and sizes in patients (Figure 31B). Strikingly, we did not 
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observe any significant differences, again indicating that clonal skewing only occurred 
for very few and already reported loci and does not resemble a general phenomenon 
applicable to all IS. 
 
Figure 31 | Mean cluster dimensions [bp] and sizes of patient and in vitro IS datasets as well as early and 
late patient ISs are highly similar. 
A | Comparison of cluster dimensions [bp] and size [number of ISs per cluster] of patient ISs and three in 
vitro IS datasets. Plots show one representative sampling of 1,000 samplings of the in vitro IS datasets to 
match the number of patient IS. Genes closest to clusters, which exceed the mean (red dashed line) of the 
maximum cluster size or dimensions of 1,000 samplings from all in vitro datasets are labeled. 
B | Comparison of cluster dimensions [bp] and size [number of ISs per cluster] of early and late occurring 
ISs as described above. Genes closest to clusters, which exceed the maximum cluster size or dimensions of 
early WAS ISs are labeled. NS, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
Reprinted from Wünsche et al. (2018). 
To further expand on this, we measured the cumulative number of ISs that mark 
the same gene over time as a surrogate for proliferation and calculated the area under 
the curve (AUC, Figure 32A). We hypothesized that clones marked by unique ISs which 
show accelerated proliferation should be detected at a higher rate as compared to 
normally behaving clones. Confirmatively, only 13 genes, most of which are established 
drivers of clonal expansion, were detected to exhibit an AUC greater than the 95% 
confidence interval (CI, Figure 32B) and were thus statistically suspicious. The vast 
majority (96.8%) however shows an accumulation of ISs over time at a slow but constant 
rate, again leading to the conclusion, that the majority of ISs are of inert behavior and do 
not lead to clonal expansion. 
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Figure 32 | Statistical analysis of occurrence of ISs over time highlights known leukemogenic drivers.  
A | Cumulative number of unique ISs per gene with time point of sequencing. Genes with a greater 
loge(AUC) than the 95% CI are labeled red. B | Frequencies of the loge area under the curve (AUC) for all 
genes calculated from the cumulative amount of ISs depicted in Figure 32A. The grey dashed line indicates 
the mean, the red dashed line indicates the 95% CI. Genes that show a higher loge(AUC) than the 95% CI 
are labeled red. CI, confidence interval. Adapted from Wünsche et al. (2018). 
3.4.6 HSC speciﬁc ATAC-seq signal intensity but not gene expression 
correlates with IS paXern 
Because we hypothesized that γRV ISs from patients sequenced during long-term 
hematopoiesis originate from long-term HSCs, we matched RNA-seq and ATAC-seq data 
from 13 primary human blood cell types with our IS data. As both, ATAC-seq signal – a 
measure for accessible chromatin – as well as gene expression signatures are cell type 
dependent, we aimed to identify the cell population that resembles the CIS positions 
best. To this end, we correlated either the expression level of genes with the number of 
ISs in their vicinity or the ATAC-seq signal intensity at CIS, respectively (Figure 33).  
 
Figure 33 | Conceptual outline. 
Correlation of the cell type specific gene expression with the number of ISs in their vicinity and intensity of 
ATAC-seq signals at sites of IS. Related to Figure 34, Figure 35 and Figure 36. Adapted from Wünsche et al. 
(2018). 
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In contrast to the findings of De Ravin et al. (2014), the expression of genes in 
HSCs but also in any other cell type did not correlate with the number of ISs when 
considering all ISs to its closest gene regardless of the distance (Figure 34A). 
“Accordingly, the median expression of IS-tagged genes in HSCs, although ranked highest 
of all blood cell populations, was not significantly different compared to their expression 
in most progenitor populations (Figure 34B).” Even testing various genomic windows 
around TSS did not improve correlation (data not shown). Importantly however, De 
Ravin et al. only considered ISs in a narrow 2 kb window around TSS and averaged the 
expression levels for a limited number of bins separated by relative activity. This stands 
in contrast to our approach, which compares all ISs per gene regardless of the distance 
with their individual expression level. Therefore, our analysis demonstrates that e.g. the 
number of ISs which can be used as a surrogate for enhancers and their accessibility may 
not necessarily correlate with gene expression. On the other hand, enhancers can 
regulate distal genes while skipping genes in their vicinity, rendering proximity-based 
approaches very difficult. In summary, correlation of patient IS data and gene expression 
did not show striking differences between all 13 primary cell types. In contrast, the 
median ATAC-seq signal intensity at ISs was significantly higher for HSCs compared to all 
downstream progenitors except for closely related multipotent progenitors (MPPs, 
Figure 35A), indicating that the WAS ISs positions recapitulate the chromatin 
configuration of HSCs best. As a control, we also performed the same analysis using ISs 
derived from untransplanted CD34+ cells, which resemble the IS pattern before 
transplantation. Unfortunately, we do not have IS data from pre-infusion CD34+ cells 
that were used in this WAS GT trial. Instead, we used ISs from CD34+ cells from De Ravin 
et al. (2014), which were mobilized, culture and transduced in a very comparable fashion 
(Table 5). “Interestingly, ISs from CD34+ cells resembled best the ATAC-seq peaks from 
common myeloid progenitors (CMPs) followed by MPPs and megakaryocyte-erythroid 
progenitors (MEP, Figure 35B).”  
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Table 5 | Comparison of purification, cultivation and transduction between different studies 
 
This study - Boztug et al. 
(2010), Braun et al. (2014) 
De Ravin et al., (2014) Aiuti et al. (2002), Aiuti 
et al. (2007) 
Mobilization G-CSF or G-CSF and CXCR4 inhibitor plerixafor G-CSF Not mobilized 
Purification Leukopheresis and CliniMACS system Apheresis and MACS 
collected from bone 
marrow 
Culture 
conditions, 
Cytokines 
X-VIVO 10 medium with 2mM 
L-glutamine, 60ng/ml IL-3, 
300ng/ml SCF, 300ng/ml 
FLT3L, and 100ng/ml TPO 
X-VIVO 10 medium with 1% 
HAS, 10ng/ml IL-3, 50ng/ml 
SCF, 50ng/ml FLT3L, and 
50ng/ml TPO 
IL-3, SCF, FLT3L, TPO 
Vector  CMMP-WASP gRV vector MFGS-gp91 MLV gRV vector GIADAl MLV gRV vector 
MOI approx. 5 ND ND 
Rounds of 
transduction 2 x transduction every 24h  
Spinoculation, 3 x 
transduction every 24h 
3 x transduction every 
24h 
Flask 
treatment retronectin coated retronectin coated ND 
G-CSF, granulocyte-colony stimulation factor; CliniMACS/MACS, Magnetic Cell Separation; IL-3, 
Interleukin-3; SCF, Stem Cell Factor; FLT3L, FLT3-ligand; TPO, Thrombopoietin; ND, not disclosed 
Due to the lack of own ISs data from pre-infusion CD34+ cells, we next 
investigated whether we observe the same change in ATAC-seq signal intensity after 
transplantation using ISs “[…] from an independent dataset from a γRV ADA-SCID gene 
therapy study (Aiuti et al., 2007)” and ISs from CD34+ cells that were transplanted in 
immunodeficient mice (De Ravin et al., 2014). “Importantly, all 5 patients in the 
ADA-SCID study lacked any sign of clonal expansion up to 47 months after 
transplantation. Despite the small number of ISs available (209 ISs pre-transplantation 
and 484 ISs post-transplantation), we observed a similar change in ATAC-seq signal 
intensity, comparing pre and post-transplantational IS, thus validating our findings in an 
independent cohort (Figure 36A and B). Strikingly, ISs from CD34+ cells that were 
transplanted into NSG mice also showed significant enrichment of ISs at HSC specific 
ATAC-seq peaks (Figure 36C and D).” Alongside with the differences between WAS ISs 
and CD34+ ISs observed in the PCA (Figure 29B) and the rainfall plots (Figure 30), these 
results strongly suggest a post-transplant effect that has led to the enrichment of HSC 
specific IS.  
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Figure 34 | Correlation between WAS ISs and gene expression in 13 primary cell types. 
A | Correlation analysis of expression of IS-tagged genes in 13 primary cell types and their corresponding 
cluster size (number of IS) in patients. Genes that are tagged by a cluster greater than 120 ISs but with an 
expression below the 90% quantile (grey dashed lines) are labeled. B | Violin plot of expression of all 
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IS-tagged genes in transcripts per million (TPM) ranked for median expression from left to right. Subpanel 
A “HSC” is adapted from Wünsche et al. (2018). 
 
 
Figure 35 | Signature ATAC-seq signal intensity at ISs from patients is highest in HSCs, while ISs from 
CD34+ cells mostly enrich for CMP specific ATAC-seq peaks. 
A | Signal intensity of ATAC-seq signature peaks at sites of WAS ISs ranked for median signal intensity. 
B | For comparison, signal intensity of ATAC-seq peaks was also measured at ISs in CD34+ cells and ranked 
for median signal intensity. For abbreviation of cell type see 9.1. NS, not significant; *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001. Reprinted from Wünsche et al. (2018). 
Results 
70 
 
 
Figure 36 | ATAC-seq signal intensity at ISs from two independent studies is also highest in HSCs after 
transplantation. (Legend continued on next page) 
A | Signal intensity of ATAC-seq peaks at sites of 209 pre-transplant ISs from Aiuti et al. (2007) ranked for 
median signal intensity. B | Signal intensity of ATAC-seq peaks at sites of 484 post-transplant ISs from Aiuti 
et al. (2007) ranked for median signal intensity. C | Signal intensity of ATAC-seq peaks at sites of 22020 
pre-transplant ISs from De Ravin et al. (2014) ranked for median signal intensity. D | Signal intensity of 
ATAC-seq peaks at sites of 22868 post-transplant ISs from De Ravin et al. (2014) ranked for median signal 
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intensity. For abbreviation of cell type see 9.1. NS, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001. Subpanel A, B and D have been reprinted from Wünsche et al. (2018). 
3.4.7 Reported key hematopoieOc transcripOon factors are eﬃciently 
marked by WAS IS 
To further expand on the enrichment of HSC specific ISs after transplantation, we 
next analyzed the genetic loci of ten previously described key hematopoietic stem and 
progenitor cell (HSPC) transcription factors (TFs) (Wilson et al., 2010) for their presence 
of patient ISs (Figure 37A). Moreover, we also included promoter capture Hi-C (CHi-C) 
data from CD34+ cells (Mifsud et al., 2015), in order to detect interactions of IS-tagged 
regions with the gene promoters of the TFs. Although derived from CD34+ cells, 
incorporating the chromatin conformation information through CHI-C data allows to 
predict putative regulatory regions of GOI. Reassuringly, all ten loci showed intronic ISs 
or ISs in close vicinity, many of which located in regions that were found to physically 
interact with the promoter of interest in CD34+ cells. Particularly, the intronic eR1 
sub-module of the RUNX1 super-enhancer was efficiently tagged, which has been 
reported to be specifically active in HSCs and MPPs (Ng et al., 2010). Interestingly, this 
enhancer module showed a balanced occurrence of early and late IS, probably 
suggesting equal activity in HSCs and MPPs (Figure 37B).  
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Figure 37 | “Circular plots showing loci of reported HSPC regulators with CHi-C interaction and WAS IS.” 
“A | Circular plots of known HSC regulators (Wilson et al., 2010). Shown are significant interactions of 
promoter regions of selected genes (light green). Patient ISs are depicted as green dots. For clarity 
reasons, some genes are not shown. B | WashU Epigenome Browser view of the RUNX1 locus with 
ATAC-seq and ChIP-seq signal intensities as well as patient IS cluster. eR1 super enhancer sub module is 
indicated by the grey dashed line.” Reprinted from Wünsche et al. (2018). 
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3.4.8 Diﬀerences between paOent and CD34+ ISs highlight long-term HSC 
speciﬁc genes 
As many of the reported hematopoietic key TFs are active in both, HSCs and 
downstream progenitor cells, we next aimed to further enrich for HSC specific IS, by 
subtracting the IS signal before transplantation from the signal found during stable long-
term hematopoiesis after transplantation. To this end, we down-sampled ISs from CD34+ 
cells (De Ravin et al., 2014) 1,000 times to match the number of late WAS ISs and 
subtracted the average number of ISs per gene in CD34+ cells from the number of WAS 
ISs for the same gene (Figure 38A). Because CD34+ cells mostly consist of progenitors, 
genes with more ISs in CD34+ cells vs. patients (∆IS < 0) should highlight progenitor 
specific regions, whereas regions with more ISs in patients vs. CD34+ cells (∆IS > 0) 
highlight HSC specific regions. To test our hypothesis, we performed pairwise 
comparisons for all IS-tagged genes (Figure 38B) and performed gene set enrichment 
analysis (GSEA) “[…] on 4,731 curated gene sets (C2) from the MSigDB Collections 
complemented with 20 custom gene sets from Cabezas-Wallscheid et al. (2014) that 
specifically compare murine long-term HSCs (LT-HSCs) with short-term HSCs (MPP1) and 
three other multipotent progenitor types (MPP2-4). Strikingly, 7 out of 9 significantly 
enriched gene sets (FDR < 0.1) were HSC related along with another HSC gene set, 
ranking 11th, while only one gene set showed significant enrichment (FDR < 0.1) of genes 
that have more ISs in CD34+ cells. Interestingly, mouse gene sets containing genes that 
are significantly higher in LT-HSCs compared to ST-HSCs and other MPP populations 
showed the highest adjusted p-values (Figure 38C). Furthermore, we analyzed the 
overlap between HSC relevant gene sets to address similarity and robustness of the 
different sets (Figure 38D and E). In summary, differential analysis of CD34+ ISs vs. 
patient ISs demonstrated that the IS pattern after transplantation changes towards HSC 
specific genes in line with the enrichment of HSC-specific ATAC-seq peaks after 
transplantation.” 
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Figure 38 | “Gene set enrichment of differentially tagged genes in WAS patients vs. un-selected ISs from 
CD34+ cells highlight long-term HSC specific genes (Legend continued on next page).” 
“A | Conceptual outline. Difference was measured by subtracting number matched samplings of CD34+ ISs 
from late WAS ISs that are associated with the same gene. B | Histogram showing the differences in 
number of late ISs from WAS patients compared to CD34+ cells for each gene. Differences were calculated 
as the sum of WAS ISs per gene subtracted by the mean sum of CD34+ ISs for the same gene from 1,000 
random down-samplings to match the WAS data set. Genes that scored in any of the 9 HSC related gene 
sets listed under C are marked red. C | Barplot of gene sets enriched for genes with positive fold-change in 
red (FDR < 0.2) and genes with negative fold-change (FDR < 0.2) are displayed. Grey dashed line indicates 
FDR –log10 (0.1). In total, 4,751 gene sets were analyzed. Murine gene sets are italicized. D | Network plot 
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illustrates overlap between HSC relevant gene sets. Circles are numbered according to gene set. Node size 
is proportional to number of genes within gene set while edge width corresponds to number of shared 
genes. E | Heatmap of scoring genes from HSC relevant gene sets. Number on x-axis correspond to 
number in Figure 38D. Gene sets are sorted from left to right according to p-value, genes are sorted for 
increasing fold-change. Color intensity reflects log2 fold change; grey = gene not present in gene set. FDR, 
false discovery rate.” Reprinted from Wünsche et al. (2018). 
3.4.9 The Ome point of ISs detecOon indicates acOvity of enhancer modules 
in HSCs and progenitor populaOons 
So far we have established that ISs from WAS GT patients detected after the 
switch from short to long-term hematopoiesis originate from bona fide long-term HSCs. 
Moreover, we showed that ISs locate in chromatin regions most accessible in HSCs 
compared to other hematopoietic cell populations and that genes nearby clusters of 
WAS ISs have been previously linked to HSC functions. However, as observed for the eR1 
RUNX1 enhancer sub-module (Figure 37B), the time point of sequencing of WAS ISs 
harbors additional information, as WAS ISs sequenced early are more likely to be derived 
from progenitors, while WAS ISs sequenced later are increasingly more HSC-specific. 
Along with the 10 key TFs described above, MYC also displays another key 
hematopoietic TF with well-established roles in HSC biology. Although the gene 
promoter itself harbors only very few IS, “[…] the recently reported blood enhancer 
cluster (BENC) that has been shown to physically interact in CD34+ cells with the 1.7 
megabases downstream located MYC gene shows well defined clusters of ISs 
(Figure 39A) (Bahr et al., 2018). The human BENC consists of at least 8 enhancer modules 
with selective activity in different blood cell populations, this way regulating MYC 
expression throughout the hematopoietic hierarchy. By assessing early and late 
occurring ISs as well as the last time point of clone detection within BENC modules, we 
were able to recapitulate the reported results (Figure 4B). The median time point 
correlated well with their suggested activity, with persistent ISs in the HSC specific 
modules C/D and more transient or short-lived clones detected in the progenitor like 
modules G/I. In line, module A/B, which is equally active in HSCs and progenitors showed 
both, transient and long-lived clones (Figure 39C). Strikingly, we also identified three 
additional modules (X1, X2 and X3) that are located outside of the reported module 
boundaries and therefore were not experimentally addressed before, all of which 
showed equal or even higher HSC specificity than modules C/D (Figure 39C). Collectively, 
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these data demonstrate the power of γRV ISs mapping in long-term engrafted CD34+ 
cells to identify HSC regulatory regions.” 
 
Figure 39 | “Differential IS patterning at MYC enhancer correlates with selective activity of enhancer 
modules in HSCs and progenitor populations.” 
“A | Circular plot of the MYC locus including the BENC region. Shown are significant interactions (color of 
arcs represents interaction score) with the MYC gene (light green). Patient ISs are depicted as green dots. 
The BENC module region is highlighted by a dashed box. B | WashU Epigenome Browser view of the BENC 
region with ATAC-seq signal intensities, GWAS SNPs as well as early and late patient IS clusters. BENC 
enhancer sub module are indicated by the colored dashed boxes. C | Representation of the sequencing 
time points of ISs at known (A, B, C, D, G, I) and novel sub modules (X1, X2 and X3). BENC, blood enhancer 
cluster.” Reprinted from Wünsche et al. (2018). 
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3.4.10 Tagged enhancers and disease variants can be linked to their 
putaOve target gene by integraOon with long-range interacOon data 
“A major challenge for the investigation of regulatory non-coding elements 
remains the prediction of their target promoters as not all genes are controlled by 
regulatory elements located in close proximity to their TSS. As described above, we used 
promoter capture Hi-C (CHi-C) data from primary CD34+ cells to assign non-coding 
regions of interest to their prospective gene or promoter (Mifsud et al., 2015). One of 
the most heavily IS-tagged genes in our dataset was Nuclear receptor interacting protein 
1 (NRIP1), which shows interaction with an array of IS-tagged enhancers spanning over 
more than 500kb (Figure 40A). Interestingly, despite the global lack of correlation of 
gene expression and number of IS, NRIP1 is expressed highest in HSCs with a gradual 
decline towards more committed progenitors (Figure 34B and C, Figure 40B), indicating 
that for some genes a high expression is indeed associated with a high number of IS. As 
many IS clusters are generally associated with interactions (Figure 37A and Figure 40A), 
we next examined if this enrichment was significantly higher than expected by chance. 
Interestingly, patient ISs showed a striking enrichment, which was highest for promoter 
interactions (approx. 6.4-fold, p≈0), followed by all interactions (approx. 2-fold, p≈0) 
and non-promoter interactions (approx. 1.6-fold, p≈0) (Figure 40C). ISs from CD34+ cells 
were slightly more enriched, which was also reflected by the higher Chi-Square value 
(39,084 vs. 17,340). However, as the enrichment was not overly different between WAS 
ISs and ISs from CD34+ cells, it seems conceivable that HSCs and CD34+ cells share the 
majority of interactions, increasing the likelihood that interactions at clusters of WAS ISs 
indeed point towards their putative target gene.” 
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Figure 40 | ”Integration of long-range interaction data links ISs to enhancers and disease variants of 
their putative target gene.” 
“A | ATAC-seq and ChIP-seq signal intensities, early and late WAS ISs and capture Hi-C (Chi-C) interactions 
from CD34+ cells at the NRIP1 locus. GWAS SNPs are indicated according to position and subclass. 
B | RNA-seq TPM expression data of NRIP1 in HSCs and progenitor populations. C | Chi-square test with 
Yates’s correction for continuity to compare interaction fragments either containing or not containing ISs 
(WAS or CD34+). Genomic HindIII restriction sites coordinates are equivalent to those of interaction 
fragments. TPM, transcripts per million.” Reprinted from Wünsche et al. (2018).  
3.4.11 Clusters of ISs co-localize with hematological GWAS SNPs 
“We next asked whether IS-tagged regions possess functional properties across 
tissues and if these regions are particularly important in the human blood system. To 
address this question, we utilized a collection of 24,495 genome wide association study 
single nucleotide polymorphisms (GWAS SNPs) along with number-matched random 
samplings of approx. 3.8 x 109 common SNPs with no known medical impact. As 
enhancers are generally more prone to carry disease variants compared to other non-
coding regions (Corradin and Scacheri, 2014; Ernst et al., 2011), we expected γRV ISs to 
be enriched in the vicinity of GWAS SNPs. Indeed, WAS ISs were highly enriched near 
GWAS SNPs compared to common SNPs (p = 8.35 x 10-64), which was also observed to a 
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similar degree for all other in vitro IS datasets (Figure 41A). Next, we classified all traits 
and diseases into 17 categories (adapted from Mifsud et al., 2015; Maurano et al., 2012, 
Figure 41B) and calculated their relative enrichment or depletion. GWAS SNPs 
categorized into hematological parameters were the most significant and highest 
enriched sub-class (Figure 41C). A similar pattern was observed for CD34+ and K562 
derived IS, while the hepatocellular carcinoma cell line HepG2 showed strongest 
enrichment for serum metabolites SNPs (Figure 41D-F). Collectively, these findings 
suggest that clusters of γRV ISs do not only mark regulatory regions but also seem to 
favor elements with functional roles in a cell type-specific manner.”  
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Figure 41 | “p-values of GWAS SNP enrichment at sites of ISs along with categorical enrichment across IS 
datasets.” 
“A | Significance of GWAS SNPs co-occurring with ISs compared to common SNPs. Black dashed line 
indicates –log10 p value of 0.05. B | Number of GWAS SNPs for each category. C-F | Percentage of GWAS 
SNPs that overlap with a window of 5 kb around IS-derived from indicated cells segregated by subclasses. 
Bar plot shows relative enrichment or depletion over mean association. Bars with no asterisks were not 
significantly altered from mean. No asterisk, not significance; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 
0.0001.” Adapted from Wünsche et al. (2018). 
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3.4.12 IntegraOon sites show elevated sequence conservaOon 
Since we detected a significant enrichment of GWAS SNPs at sites of viral 
integration, we investigated the sequence conservation around ISs across 46 primates. 
First, we checked whether cluster positions coincided with particularly conserved 
regions by visual inspection of some of the most prominent clusters. Interestingly, 
conservation appeared to peak to a greater extent in close vicinity to clusters than at 
clusters itself (Figure 42A and B). To expand on this, we measured the phyloP and 
phastCons conservation scores in a 500bp window around ISs as well as around GWAS 
SNPs, and common SNPs, and used the genomic mean for comparison (Figure 42C and 
D). PhastCons score describe the likelihood for each nucleotide to belong to a conserved 
element based on the multiple alignment of n given species, such as the 46 primates 
used here. Moreover, phastCons score also considers the flanking elements, making the 
score more sensitive to consecutive stretches of conserved elements. By contrast, 
phyloP scores ignore the context of neighboring elements, rendering it more appropriate 
for estimating the evolutionary selection at particular nucleotides or classes of 
nucleotides. While phyloP score can measure evolutionary acceleration, indicated by a 
negative score (-log p-values under a null hypothesis of neutral evolution), phastCons 
score only represent probabilities of negative selection and range between 0 and 1 
(Hubisz et al., 2011; Pollard et al., 2010; Siepel et al., 2005). As described before, both 
phastCons and phyloP scores sharply decline at sites of common SNPs (Castle, 2011). 
Likewise, GWAS SNPs showed a similar pattern, although the overall scores are higher 
compared to common SNPs and averaged above the genomic mean (Figure 42C and D). 
This is in line with the results from Ma et al. (2015), who showed that GWAS SNPs 
categorized into complex disease variants (the majority of GWAS catalog SNPs are 
complex disease variants) show no conservation, indicated by another conservation 
score – the GERP score. Interestingly, phastCons scores also decline at sites of IS, yet to a 
much lesser extent than GWAS SNPs and common SNPs (p = 5 x 10-7 and 2.9 x 10-9, 
respectively). In contrast, phyloP scores for ISs did not show any decline, but instead 
appeared relatively stable across the entire genomic window (p = 4.9 x 10-12 - 2.5 x 10-81). 
Collectively, the conservation at sites of γRV insertions was significantly higher as 
compared to the genomic mean or SNPs and GWAS SNPs, pointing towards a functional 
role of the IS-tagged regulatory regions.  
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Figure 42 | “Global phastCons and phyloP conservation scores at ISs […]” point towards functional roles 
of IS-tagged regulatory regions. 
“A | Complete IGF2BP2 locus with CHi-C interactions and WAS IS. B |  Zoom of above panel as indicated by 
grey box with tracks for phyloP and phastCons scores as well as ChIP-seq signal for active promoter and 
enhancer marks in CD34+ cells. C | Mean phastCons scores from 46 primates in a 500 nucleotide window 
centered on 130,000 random SNPs, 24,434GWAS SNPs, or 130,637 IS, respectively. D |  Mean phyloP 
scores from 46 primates displayed as described in C.” Reprinted from Wünsche et al. (2018). 
3.4.13 Boundaries of topological associated domains but not CTCF 
sites show signiﬁcantly more ISs than expected by chance 
“As boundaries of topologically associated domains (TAD) also show higher 
conservation (Harmston et al., 2017), we checked for enrichment of ISs at these sites. 
Moreover, we also assessed the relative enrichment of ISs at CTCF sites, as both, TAD 
boundaries as well as CTCF sites are relevant for chromatin integrity that could 
potentially be disrupted by IS. As TAD boundaries are known to be transcriptionally 
active (Dixon et al., 2012), we expectedly observed significantly more ISs within TAD 
boundaries mapped in K562 cells (Rao et al., 2014) than expected by chance (expected: 
2.21%-2.26%; observed: 2.60%-3.19%; Percent ISs within TAD boundaries). However, ISs 
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from CD34+ cells before and after transplantation showed a very comparable 
percentages of IS, […]” thus were neither further enriched nor depleted, “[…] indicating 
that ISs at boundaries do not grossly disrupt or enhance cell function (Figure 43A). In 
contrast, we neither observed significant enrichment nor depletion of ISs in CTCF sites 
mapped in CD34+ cells (expected: 0.12%-0.13%; observed: 0.08%-0.15%; Percent ISs 
within CTCF sites) (Jeong et al., 2017) (Figure 43B).” Collectively, these results further 
promote the notion of directed integration at active sites, however also suggest that the 
integration per se did not grossly disrupt the function of such loci.  
 
Figure 43 | TAD boundaries but not CTCF sites show significantly more ISs than expected by chance 
“A | Comparison of the percentage of overlap between indicated IS datasets, with observed and 
randomized K562 TAD boundaries (±2.5 kb) (Rao et al., 2014). For statistical testing, TAD domains were 
shuffled 10,000 times while maintaining the original characteristics (size, distance, genome gap exclusion). 
IS data sets were down-sampled 10,000 times to match the smallest data set (xeno CD34+ IS). Expected 
(grey) and observed (red) observations are indicated by dashed lines. B | Comparison of the percentage of 
overlap indicated IS datasets, with observed and randomized CTCF sites from CD34+ cells (±50 bp) (Jeong 
et al., 2017). For statistical testing, CTCF domains were shuffled 10,000 times. IS data sets were down-
sampled 10,000 times to match the smallest data set (xeno CD34+ IS). Expected (grey) and observed (red) 
observations are indicated by dashed lines. Obs, observed; Exp, expected; P, p-value.” Adapted from 
Wünsche et al. (2018). 
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3.4.14 γRV provide a catalogue of >3,000 regulatory regions in 
funcOonally deﬁne human long-term HSCs 
“In summary, we show that γRV ISs can be used as molecular tags not only for 
clonal tracking, but also to mark regulatory regions in functionally defined cell 
populations. Unlike sequencing approaches of phenotypically defined cell populations, 
our method exploits the natural selection process enriching for long-term repopulating 
HSCs after transplantation.” Through extensive analysis of our own data in conjunction 
with publicly available datasets, “[…] we were able to detect >79,000 genomic tags from 
10 patients,” creating a rich resource of >3,000 active gene-regulatory regions in human 
repopulating long-term HSCs (Figure 44). “These data provide new insights into active 
regions and regulatory mechanisms of repopulating HSCs and represent a solid basis and 
comprehensive resource for functional studies investigating stem cell self-renewal and 
differentiation.” 
 
 
Figure 44 | Schematic representation showing the concept and strategy of mapping the gene-regulatory 
regions in human repopulating long-term HSCs.  
After transduction of heterogeneous CD34+ cells from WAS patients, γRV pre-integration complexes mark 
active enhancers and promoters. Next, cells are re-infused into the patients and engraft which naturally 
selects LT-HSCs over time. Through LAM-PCR and HT-seq methods, γRV positions are mapped to the 
genome. Integration of additional data-sets such as CHI-C, GWAS SNPS, ChIP-seq and ATAC-seq data 
provide further information on IS-enriched regions and validate our approach, eventually leading to the 
resource of more than 3,000 active gene-regulatory region in human repopulating LT-HSCs. Adapted from 
Wünsche et al. (2018). 
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4 DISCUSSION 
In the present study, we used a large collection of γ-retroviral integration sites 
(γRV ISs) that were collected prior to this thesis over a period of 6 years from 10 
Wiskott-Aldrich-Syndrome (WAS) patients. In total, we used 181,055 ISs, which map to 
130,637 unique sites for the purpose of identifying, selecting and finally validating novel 
hematopoietic regulatory genes as well as creating a genome-wide resource of active 
gene-regulatory regions in human repopulation long-term HSCs. 
4.1 The lenOviral overexpression-library approach is largely 
limited by transducOon eﬃciencies and cell numbers  
After the selection of candidate genes based on IS cluster size and proximity to 
the TSS, we first aimed to collect in vitro and in vivo data for all genes to re-evaluate the 
list of candidates and to eventually focus on one or two candidates for functional and 
mechanistic experiments. We hypothesized that transduction of LSK or LSK-SLAM cells 
with a pool containing all candidate gene constructs would allow to study their influence 
on hematopoietic dynamics simultaneously. Through unique barcodes (BCs) for every 
candidate within a small cassette that is suitable for genomic amplification and HT-seq, 
we aimed to track changes in relative proportion throughout the experimental timeline, 
caused by alterations in proliferation or differentiation upon candidate over expression.  
4.1.1 Tracking clonal dynamics in vitro and in vivo through geneOc barcodes 
and mulOplexed HT-seq is technically feasible  
In order to trace and distinguish transduced cells throughout the experiment, we 
first established the lentiviral overexpression pool. During the first step of the nested 
PCR, the BC-containing cassette is amplified from genomic DNA. During the second step, 
different samples can be indexed, using one of 96 different multiplex reverse primers 
(Figure 17). Finally, up to 96 indexed samples can be mixed to be sequenced on a single 
Illumina HiSeq 2000, which can eventually be de-multiplexed using the index-read. To 
ensure that BCs (18nt) and indices (8nt) were sufficiently different in their sequence to 
prevent cross-contamination (“bleeding”) of BCs or indices caused by sequencing errors, 
we ran a defined series of PCR reactions. Here, each of the 96 BCs was amplified with 
one of the 96 indices and subsequently pooled and sequenced (3.2.3, Figure 18). The 
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results demonstrated that BC or index-bleeding, respectively, occurred to a negligible 
degree (0.059% off-target reads per index or 0.0006% off-target reads per index and BC; 
Figure 19B). This indicated that 1) it is feasible to distinguish all BCs in our small library 
and 2) multiplex (index) up to 96 samples without considerable BC or index-bleeding. 
These results were expected due to the relatively high BC/index diversity (minimum 
distance of  two nucleotides between BCs and indices) and low error rate of Illumina 
HiSeq platforms (∼0.1% or 1 in 1,000) (Manley et al., 2016). Thus, the chance that the 
two nucleotides that distinguish indices/BCs from one another are both sequenced 
wrongly is only 1,000 x 1,000 hence 1 in 1 million (0.0001%). In case that any base 
substitution at two positions would generate another BC/index sequence also present in 
the library (worst case scenario), the chance would increase to 95 in 1 million, thus 
approx. 1 in 10,000 or 0.01%. However, as many BCs/indices are different in more than 
two positions, this chance is likely too high. Note, that a difference in three positions 
between BCs/indices would decrease the chance to 1 in 1 billion. Taken together, the 
observed rate of wrongly annotated read per single index was slightly higher than 
expected by chance (exp.: 0.0001%; obs.: 0.0006%). This could be explained by minor 
spillover or aerosol contaminations between wells during sample preparation, which is 
also possible during sample preparation of actual experiments. However, overall these 
miss-allocations of BCs/indices occurred at a very low rate, thus should not have grossly 
effected the results of the following experiments.  
4.1.2 Titer variaOons in cDNA overexpression library screens  
Most in vitro screens are performed using knock-down of cellular transcripts or 
knock-out of genes using RNA interference or more recently CRISPR/Cas9 libraries. Such 
libraries have the great advantage of uniformly sized shRNAs, siRNAs or sgRNA inserts, 
resulting in comparable virus titers for all constructs within the library (Miles et al., 2016; 
Mohr et al., 2010). Unlike gene knock-down or knock-out screens, overexpression 
screens usually work through continuous high expression levels of wild-type genes. 
Although the first overexpression screen was already performed in 1982 in yeast cells 
using a library of random genomic fragments, they are more complex than RNAi or 
CRISPR screens, due to varying fragment sizes (Carlson and Botstein, 1982). Today, also 
more sophisticated libraries have been developed for additional organisms including 
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Homo sapiens covering ∼15,000 full-length human cDNAs driven by a cytomegalovirus 
(CMV) promoter (Liu et al., 2007). While relatively easy in yeast due to transient 
transfection with 2μ vector-based plasmid libraries, stable overexpression of cDNAs in 
mammals usually requires γRV or LV packaging and stable transduction (Ludwig and 
Bruschi, 1991; Prelich, 2012). However, systematic investigation of the packaging limit of 
HIV-based vectors (LV) has shown that virus titers decreased semi-logarithmical with 
increasing construct size. Although we did not observe such a striking correlation 
between size and titer, we still observed some significant variations (3.2.4, Figure 20A). 
As a consequence, the initial representation of cDNAs or BCs, respectively, might be 
imbalanced, possibly leading to the over or underrepresentation. To compensate for 
this, we used an inducible vector system in order to measure the relative proportion of 
all BCs before cDNA expression for normalization. However, gross variation in titers 
could lead to biases regarding transduced cell types or bottleneck effects e.g. during 
passaging or engraftment. In fact, even for uniformly-sized pooled libraries, usually a 
500x coverage is aimed for, meaning that the number of infected cells should be at least 
500 times higher than the number of genes or BCs present in the library (Doench, 2017). 
Naturally, with increasing titer variations, this number has to be even higher. 
Additionally, one has to consider that transduction efficiencies should be kept in the 
5-20% range, as higher rates will massively increase the likelihood of double or even 
multiple integration sites per cell (Doench, 2017). Thus, at a transduction efficiency of 
20% the number of starting cells has to be at least 2500 times the number of BCs, 
making genetic screens with limited primary material extremely challenging. 
4.1.3 TransducOon with pooled overexpression library in CFU assays is 
limited by colony number and transducOon eﬃciency 
After having established the technical requirement for the overexpression pool, 
we aimed to assess the influence of our candidate genes on proliferation, differentiation 
and self-renewal. First, we tested our library in a colony-forming unit (CFU) assay using 
LSK-SLAMRosa26 rtTA cells. As discussed in 4.1.2, it is very important to establish and 
maintain a sufficient library representation throughout the experiment. However, this 
can be very challenging when working with limited primary material. Due to the 
experimental setup, we did not achieve a higher BC representation than 120-fold for the 
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GFP pool or 30-fold for the gene of interest (GOI) pool, respectively. The fold coverage 
for individual BCs in the GOI pool might be even higher or lower, depending on the 
individual titers. This makes interpretation of the results very challenging, as it increases 
the chance of observing significant chances in BC representation by chance (Figure 45).  
 
Figure 45 | Effects of insufficient library representation during several rounds of passaging.  
A | Simulation of the library distribution across passages. At a low 50-fold (50x) representation, the library 
spreads out, leading to a relatively high amount of perturbations falling outside of the 2 standard 
deviations (SD). This effect is observed without any selective pressure but is only due to random chance. In 
contrast, a simulation of a 500-fold (500x) library representation does not show spreading. B | Fractions of 
perturbations greater than 2 SD after 6 passages for different library representations. Adapted by 
permission from Springer Customer Service Centre GmbH: Springer Nature, Nature Reviews Genetics, 
Doench (2017), copyright 2017. 
One way to control for random enrichment or depletion can be partially achieved 
through redundancies. This can either be a large number of repetitions of the same 
experiment or through the usage of different BCs for the same gene. For the latter, we 
hypothesized that a similar behavior of 2 independent BCs that depict the same gene 
indicate a biological effect, while opposing behavior of 2 independent BCs that depict 
the same gene indicate a non-biological effect. However, the relative change of BC 
representation can generally only attain three different states: Increasing, static or 
declining. Accordingly, the assessment whether a change in representation occurs as a 
consequence of a biological effect should also take the magnitude of change into 
consideration. Applying the above-mentioned criteria, only a few genes showed a 
consistent phenotype through all passages in the CFU assay. For example, both BCs for 
Plcb4 showed a very consistent decline over time, similar to Irf2bp2, Xbp1S and Znf217. 
None of the genes showed a comparably consistent increase over time.  
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Conclusively, due to the poor library representation in the CFU assay we did not 
derive interpretable results. Although we tried to increase the coverage in follow-up 
experiments, the limited number of cells, the relatively low virus titers as well as the 
limited number of colonies that can be grown on a plate and the costly reagents did not 
allow for significant improvements. 
4.1.4 Cell trace experiments showed improved library representaOon but 
insuﬃcient Omeframe  
In order to improve upon the low number of cells possible in CFU assays, we 
aimed to address changes in proliferation using the CellTraceTM dye. To this end, we 
transduced approx. 1 x 105 LSKRosa26 rtTA cells with the GFP pool (10 BCs) and approx. 
3 x 105 LSKRosa26 rtTA cells with the GOI pool (40 BCs). At a transduction efficiency of 
20-25%, this equals a ∼2,000-fold BC representation in the GFP pool transduced cells and 
a ∼1500-fold representation in the GOI pool. In fact, the results of the individual 
experiments showed substantially less deviation between BCs of the same genes 
compared to the CFU assay. Moreover, most genes behaved similarly in both 
independent experiments, indicating that the approach was technically more feasible 
compared to the CFU assay. However, the effect on proliferation was very moderate for 
most genes. This could be either explained by little or no effect of our candidate genes 
on proliferation of LSK cells in vitro or by the relatively short cultivation time of 3 or 5 
days, respectively. The cultivation time however is largely limited by the detection of the 
dye, which loses approx. half its signal intensity with every cell division (Filby et al., 
2015). Usually, the maximum number of divisions that can be traced with this dye is 
around 7-8, which roughly equals 5-8 days of fast cycling LSK cell in vitro. Collectively, 
this approach seems to overcome the problems with the library representation, 
however, is not suitable to address subtle changes in proliferation.  
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4.1.5 Pooled overexpression screen in vivo mostly suﬀers from low 
transducOon eﬃciencies.  
As discussed above, a critical step for genetic screens in general is to maintain an 
unbiased representation of the library in order to observe real biological effects rather 
than stochastic noise. Most in vivo screens are performed in tumor models using cell 
lines as starting material. Due to the high number of available cells, these approaches 
even allow for genome-wide screens with tens of thousands of different BCs or 
shRNAs/sgRNAs (Chen et al., 2015; Crotty and Pipkin, 2015). In contrast, genetic screens 
that aim to elucidate the impact of e.g. gene-knockdown on engraftment or 
differentiation and self-renewal of stem and progenitor (HSPCs) cells are largely 
restricted by limited input material and poor engraftment. For example, a study that 
used molecular barcoding to track HSCs (LSK, CD34- CD150+ CD135-) after 
transplantation in mice showed that out of 9,000 only 50-80 HSCs stably engraft and 
propagate per mouse (Lu et al., 2011). Correspondingly, a study by Hope et al. (2010) 
focused on only 20 genes, each targeted by 2-3 shRNAs to identify new fate 
determinants of HSCs in vivo. Despite the small scale and high gene transfer efficiency of 
59% on average, the results still showed substantial variation. In another study from 
Holmfeldt et al. (2016), a total of 41 genes were screened, each represented by ≥2 
shRNAs. However, due to the large number of constructs, the authors had to transplant 
and analyze a very high number of >1,300 mice. In contrast to the RNAi screens, another 
group performed a gain-of-function cDNA overexpression screen on 104 candidates and 
3 mice for every cDNA (Deneault et al., 2009). However, it has to be noted that all of the 
above-mentioned screens did not pool the candidates but instead transplanted 
single-gene transduced cells into individual mice. Thus, engraftment, differentiation as 
well as self-renewal could be traced by FACS and fluorescent markers and did not 
require HT-seq detection of BCs. Thus, the tracking is more cost efficient and immediate. 
Moreover, the transduction efficiency can be drastically increased as double or triple 
integrations would refer to the same gene and not lead to the overexpression or 
knock-down of different genes in the same cell. However, these approaches also have 
downsides: Differences while handling or transplanting the cells or even differences 
between mice and irradiation can induce effects that are not attributable to the 
overexpressed or knocked-out gene (Deneault et al., 2009).  
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Considering the insights from the above mentioned studies, the results from the 
in vivo screen performed in this study have to be treated with caution. Assuming a 
maximum of 100 engrafted HSCs per mouse would naturally not allow for a proper BC 
representation, regardless of the library size. One has also to take into consideration, 
that only ∼20% of the transplanted cells are transduced, limiting the approach even 
further. Some of these limitations could probably be bypassed through larger cohorts of 
mice or fewer genes. On the other hand, not only HSCs contribute to blood production in 
the first weeks after transplantation, but also progenitor cells (Lu et al., 2011). 
Depending on the focus of the study, changes in the progenitor compartment can also 
be of interest. Hence, the approach itself has the capacity to generate usable results, 
however, has to be further improved with respect to the above mentioned limitations. In 
fact, using the same approach applied in the present study but focusing on 
overexpression of miRNA instead, did indeed generate robust results (data from Elias 
Eckert, published in Wünsche et al. (2018)). A uniformly sized miRNA overexpression 
library with fewer constructs and higher engraftment and transduction efficiency led to 
the identification of miR-10a and miR-335 as regulators of early hematopoiesis. Both 
miRNAs were validated individually in transplantation experiments, demonstrating that 
the approach can be sensitive and robust enough to pick up subtle changes in BC 
representation (Wünsche et al., 2018).  
4.1.6 γRV genotoxicity is probably less universal than expected. 
Albeit the fact that the data discussed above did not allow for detailed insights on 
how the candidate genes affect hematopoiesis, some conclusions can still be drawn from 
these experiments. Throughout all experiments, we never observed clonal expansion or 
neoplastic growth of transduced cells. This was partially unexpected, as the field of gene 
therapy postulates that large CIS occur due to clonal expansion of cells (Biasco et al., 
2012). Undeniably, this effect can certainly be observed for some well-characterized 
proto-oncogenes such as MECOM (EVI1/MDS1), LMO2, MN1, SETBP1, PRDM16 and 
CCND2 (Boztug et al., 2010; Braun et al., 2014). However, at this point, our candidate 
genes do not appear to fall into this category. Especially NRIP1 showed some of the 
largest clusters of ISs among all genes, yet its overexpression never caused an 
overproportional expansion of cells. Instead, the opposite was observed, ultimately 
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leading to the question, if there are other reasons why CIS are differently sized and what 
the location in the genome dictates. In fact, investigations on γRV integration preference 
have answered many questions and propose a directed integration mechanisms, which 
leads to a heterogeneous distribution of ISs in the genome, even without clonal selection 
(Kvaratskhelia et al., 2014). 
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The following paragraphs of the discussion contain text sections that have been taken 
from Wünsche et al., (2018) and have been originally written by myself. All literal quotes 
are indicated by quotation marks (” … “), following the guidelines of good scientific 
practice of the Ruperto-Carola University of Heidelberg. 
Reprinted figures from Wünsche et al., (2018) are indicated as such in the figure legend. 
 
 
4.2 Oncogenic γ-retroviral integraOon events are less common 
than expected  
The fact that not a single gene included in our screen led to a measurable clonal 
expansion neither in vitro nor in vivo experiments was rather unexpected. For many 
years, the general perception was that large CIS are most certainly a consequence of 
overproportionally expanding cells or clonal selection, respectively. Thus, genes that 
carry a lot of ISs were classically suspected to be causal for this overproportional 
expansion (Biasco et al., 2012). Yet, the complete picture appears more complex. In 
1993, Stocking and colleagues tried to estimate the frequency at which transforming 
events occur. Using in vitro growth-factor dependency assays, the proposed risk was 
only ∼2 x 10-7 (Stocking et al., 1993). Other studies suggested comparable rates, ranging 
from 10-8 to 10-6 (King et al., 1985; Moolten and Cupples, 1992). With increasing 
knowledge from insertional mutagenesis screens, the frequency at which ISs were 
thought to hit proto-oncogenes increased significantly to 10-5 to 10-2. However, the way 
these numbers were generated was still very theoretical and subject to many 
assumptions (Baum et al., 2003). Moreover, the rate at which proto-oncogenes are hit 
and the rate at which clonal outgrowth or malignant transformation occurs should be 
very different. First of all, gene activation or disruption due to viral integrants arise 
monoallelic, restricting a profound effect to dominant proto-oncogenes only. Recessive 
oncogenes are likely to require an additional mutation in the second allele to cause a 
phenotype. Moreover, human carcinogenesis is usually a multistep process and requires 
for example additional genetic lesions, maintenance of Telomerase Reverse 
Transcriptase (TERT) expression to overcome oncogene-induced senescence, or immune 
escape (Baum et al., 2004). This is in line with “[…] a study from Howe et al. (2008), 
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showed that clonal outgrowth often depends on combinatorial processes between 
somatic mutations, deletions, or translocations and retroviral overexpression, restricting 
the pool of transformed clones dramatically.” 
The theory of multiple cooperating hits required for malignant transformation 
also supports our notion of rarely transforming IS. Using our IS data in comparison to 
other IS data, “[…] we neither observed a striking difference in the global number of 
clusters, cluster sizes or dimensions, nor a significant enrichment of genes contained 
within leukemia related gene sets.” Also, the analysis of cumulative ISs per gene only 
revealed 13 genes that were statistically noticeable. Moreover, “[…] despite the high 
prevalence of leukemia observed in the WAS GT trial, the global pattern of ISs remained 
stable, again indicating that γRV-mediated transformation is restricted to only few loci. 
In fact, across various γRV gene therapy trials all patients presented with only a small 
number of dominant clones, driven by the same limited set of recurrent genes (Braun et 
al., 2014; Hacein-Bey-Abina et al., 2003b; Ott et al., 2006).” In summary, “[…] the 
genotoxic potential of γRV insertions appears to take effect only under certain 
circumstances, whereas the vast majority of ISs leave the cells unchanged. Of course, 
one must keep in mind that the IS pattern might be indeed skewed for known 
leukemogenic drivers such as MECOM and LMO2. However, regardless of the skewing, 
these genes may still play an important role during normal hematopoiesis, as inactive 
genes are unlikely to be targeted by γRV insertions and consequently would not carry 
any IS. In fact, many of the known leukemogenic drivers identified in gene therapy 
studies and γRV screenings in mice have also been implicated in normal HSC regulation 
or were shown to be specifically active in HSCs (Aguilo et al., 2011; Yamada et al., 1998; 
Zhang et al., 2011).” Given the non-detectable incidence of clonal outgrowth upon 
transduction with our candidate genes and the low probability of a genome-wide 
skewed γRV IS pattern, we hypothesized that γRV IS from patients can be harnessed for 
other purposes. 
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4.3 Using γ-retroviral integraOon sites from long-term 
repopulaOng clones to map acOve gene-regulatory regions in 
HSCs 
An essential assumption made in the present study is the post-transplant 
enrichment of HSCs. Historically, HSCs were defined as cells that have the capacity to 
repopulate the entire blood system of an organisms through self-renewal and 
differentiation into all blood-cell lineages (multipotency, see 1.1.1). Later, the discovery 
of surface marker combinations enabled the prospective enrichment of phenotypic HSC 
(see 1.1.2). Both names are often used interchangeably, although functional and 
phenotypic HSCs are not exactly the same. While phenotypic markers only enrich for 
HSCs, functional experiments can usually prove the aforementioned characteristics. 
Although we were able to address the self-renewal capacity of IS-tagged cells through 
positive association matrices and a mathematical model, our data does not provide the 
necessary lineage information required to analyze the multipotency. To infer that 
IS-tagged cells originated from HSCs using only information on self-renewal capacity 
(time after transplantation and recurrence of clones), it is important to discuss the 
current state of research regarding the definition of phenotypic and functional HSCs. 
4.3.1 HSCs diﬀer in their capacity to diﬀerenOate and self-renew  
To date, countless studies have conducted functional experiments to investigate 
HSC biology. While HSCs were historically regarded as a homogenous population of cells 
that can be separated from committed downstream progenitors, results from recent 
experiments suggest that the transition from HSCs to MPPs to progenitors is not as sharp 
as previously imagined. In fact, the contrary was observed – a multitude of stages 
between multipotent HSCs and oligopotent or lineage restricted progenitors, 
respectively, ultimately questioning our current definition of HSCs (Haas et al., 2018; 
Laurenti and Göttgens, 2018). However, given the focus on HSCs in this study, the 
following paragraphs discuss the key findings regarding HSC biology and nomenclature 
to elaborate more on our concept of post-transplant HSC enrichment.  
Many studies, both in humans and in mice could show that a substantial 
proportion of phenotypic and also functional HSCs are lineage biased (Haas et al., 2018; 
Laurenti and Göttgens, 2018). In functional experiments, this manifests through a shifted 
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output of long-term clones towards either lymphoid or myeloid cells. Importantly, 
lineage-biased cells are different from lineage-restricted cells. Lineage-biased cells can 
still be regarded as multipotent, as they contribute to both lineages although to different 
quantities. Lineage-restricted cells in contrast are oligopotent and only contribute to 
either lymphoid or myeloid cells. One of the pioneering studies that experimentally 
addressed HSC heterogeneity in more detail was conducted by Dykstra et al. (2007). 
Here, flow cytometry sorted murine phenotypic HSCs were transplanted into sublethally 
irradiated mice as single cells or single cell derived clonal cultures. The output of 
individual cells was followed over time focusing on lineage contribution and self-renewal 
capacity. Interestingly, four HSC-subtypes with differing self-renewal and differentiation 
capacity were identified, termed α-, β-, γ-, and δ-cells. Out of these four, only β-cells 
showed a balanced output, while α-cells showed a strong myeloid bias and γ-cells a 
corresponding lymphoid bias. In contrast, δ-cells were almost completely 
lineage-restricted to only lymphoid cells. Importantly, the majority of HSCs were found 
to be β-cells (39%) and α-cells (27%), which also exhibited the highest self-renewal 
capacity. In contrast, γ- and δ-cells were not capable of reconstituting secondary or 
tertiary recipients. In conclusion, this study demonstrated the presence of 
lineage-restricted cells (δ-cells) within the HSC pool, however, these cells showed the 
lowest percent of donor blood contribution (<10%) and were not serially transplantable 
(Dykstra et al., 2007). In contrast, ∼60% of the recipient blood was reconstituted by 
balanced β-cells. Similar results were generated without single-cell transplantation 
experiments but instead using viral genetic barcoding. Here, two different HSC 
sub-populations were identified, one biased towards B and T cells, and one biased 
towards B cells and granulocytes. Importantly, both sub-populations were biased but not 
restricted, indicating multipotency (Glimm et al., 2011; Lu et al., 2011).  
So far, only lineage-balanced or lineage-biased cells were shown to possess 
long-term repopulating capacity. Lineage-restricted cells, on the other hand, which 
would not fulfill the HSC-criterion of multipotency only showed short-term but not 
long-term self-renewal capacity. Another study that demonstrated short-term 
repopulation capacity of lineage-restricted progenitors came from Yamamoto et al. 
(2013). Here, the authors describe the presence of myeloid-restricted progenitors 
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(MyRPs) within the pool of phenotypic HSCs. MyRPs contain common myeloid 
repopulating progenitor (CMRP), megakaryocyte-erythroid repopulating progenitor 
(MERP) and megakaryocyte repopulating progenitors (MkRP) that are derived from HSCs 
by asymmetric cell division. Tracking of MyRPs showed that MERPs and MkRPs only 
self-renew for about 20 weeks and were not serially transplantable, similar to CMRPs, 
which vanished latest 4 weeks after re-transplantation. Interestingly, the repopulation 
kinetics were very comparable to those of short-term HSCs, the equivalent to human 
MPPs. To date, MkRPs were also identified by many others, that show that these highly 
lineage-restricted stem-like cells indeed exhibit short-term self-renewal capacity and 
reside within the pool of phenotypic LT-HSCs (Carrelha et al., 2018; Grinenko et al., 2018; 
Haas et al., 2015; Sanjuan-Pla et al., 2013; Shin et al., 2014). A comprehensive study 
from Carrelha et al. (2018) investigated systematically cells of the 
megakaryocyte/platelet, erythroid, myeloid and B and T cell lineages after single cell 
transplantation at an unpreceded resolution. Interestingly, Carrelha and colleagues also 
identified a distinct class of megakaryocyte/platelet-restricted HSCs, however claim that 
these cells maintain their multipotency albeit lineage-restriction. Importantly, no other 
HSC sub-class was observed that contributed to one lineage only. Moreover, 
lineage-biased HSCs retained their multipotency.  
In summary, these insights into the murine hematopoiesis clearly indicate that 
long-term self-renewal capacity almost always coincides with multipotency. Because of 
the tight connection between these two properties, it is safe to assume that long-term 
repopulating cells are equivalent to HSCs. 
The tight connection between long-term self-renewal capacity and multipotency 
in mice is in fact also in line with insights from studies in non-human primates. Clonal 
tracking studies in rhesus macaque revealed that already after one month uni-lineage 
progenitors were replaced by myeloid, then by myeloid-B and later by stable 
myeloid-B-T multipotent HSCs (Wu et al., 2014). This is partially in line with another 
study in primates, which shows that after 7-13 months uni-lineage progenitors were 
replaced by long-term multipotent clones, contributing to >80% of the total blood cell 
population (Kim et al., 2014). Interestingly, similar observations were made in a human 
lentiviral gene therapy trial, which showed the greatest overall multilineage output over 
time by HSCs followed a lesser extent by MPPs (Biasco et al., 2016). These studies again 
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suggest that it is safe to assume that long-term repopulating cells are equivalent to HSCs 
and to a lesser extent by MPPs. 
While all of the aforementioned studies addressed blood reconstitution and 
maintenance after transplantation, new in situ genetic barcoding techniques also 
enabled researchers to study clonal dynamics in an unperturbed or naïve state (Busch et 
al., 2015; Rodriguez-Fraticelli et al., 2018; Sun et al., 2014; Yu et al., 2016). Intriguingly, 
these studies observed a much higher contribution of phenotypic MPPs to steady-state 
hematopoiesis than HSCs, indicating that post-transplant and naïve or unperturbed 
hematopoiesis differ at least in some aspects. Importantly however, HSC heterogeneity 
regarding lineage-bias or restriction were shown to be both features of reconstitution 
after transplantation as well as naïve hematopoiesis (Carrelha et al., 2018; Rodriguez-
Fraticelli et al., 2018).  
Taken together, the new insights into HSC heterogeneity and lineage biases are 
challenging the classical linear tree-model of hematopoiesis. Moreover, the presence of 
self-renewing lineage-restricted MkPRs within the pool of phenotypic HSCs is 
questioning our current definition of HSCs even more. Nevertheless, the current 
literature clearly shows that the capacity of clones to reconstitute an entire organism 
over a period of up to 6 years, at least in the context of post-transplant hematopoiesis, 
can be regarded as a feature that is unique to HSCs only. In other word, multipotency 
hence HSC properties can be inferred from the time information alone. This is of great 
importance, as we lack the lineage information of ISs to show multipotency of clones 
during steady long-term hematopoiesis by demonstrating both myeloid and lymphoid 
output.  
4.3.2 The post-transplant enrichment of HSCs can be also be visualized 
using ATAC-seq signal intensity and gene set enrichment analysis 
Apart from inferring HSC-specificity of ISs using only the time information, we 
also analyzed the ATAC-seq signal intensity at ISs from three independent studies across 
13 primary human blood cell types (ISs from the WAS GT study, from Aiuti et al. (2007) 
and from De Ravin et al. (2014)). “We detected a striking difference between CD34+ ISs 
and WAS ISs or pre- and post-transplantation IS pattern, respectively. This indicates that 
cells with long-term engraftment capabilities, thus with HSC-like chromatin structure, 
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are selected after transplantation, while displacing short-lived progenitors. The fact that 
this phenomenon was observed across three separate studies clearly suggests that this 
selection occurs independently of disease background or transduction or cultivation 
protocols. Intriguingly, the enrichment of HSC-specific ATAC-seq peaks is very 
comparable between early and late IS, thus occurs much faster than the switch observed 
using pairwise positive association. However, the CD34+ pool contains a high number of 
cells that do not engraft upon transplantation, hence ISs in these cells are lost from the 
pool very fast and consequently could also cause a change in the ATAC-seq signal 
intensity at ISs after transplantation. Secondly, the ATAC-seq data is derived from 
immunophenotypically defined HSCs, which are still relatively heterogeneous and 
moreover were almost indistinguishable from MPPs (Corces et al., 2016). In contrast, 
murine HSCs can be sorted to much higher purities. Recently, high resolution gene 
expression data of murine LT-HSCs and their immediate progenitor populations (MPP1-
4) has been published (Cabezas-Wallscheid et al., 2014). Strikingly, genes that are 
significantly up-regulated in murine LT-HSCs compared to any of the downstream MPP 
populations were also significantly enriched in our human dataset, not only implying 
conserved functions of these genes across species, but also further supporting our 
hypothesis of tagging long-term specific regulatory regions.”  
In summary, the enrichment of HSC-specific ATAC-seq peaks and LT-HSC specific 
genes after transplantation strongly supports the notion that long-term engraftment 
naturally selects for HSCs and thus endorses our approach of using γRV ISs to map active 
regulatory regions in human repopulating HSCs. 
4.3.3 γ-retroviral integraOon might also point towards super-enhancers 
The puzzle of how and where γRV ISs locate in the genome has slowly been 
deciphered in the last decades. Researchers came a long way from the assumption that 
ISs spread out completely random in the genome to the concept of directed integration. 
Just recently, “[…] γRVs have been shown to preferentially integrate in active regulatory 
elements such as enhancers through tethering of the viral intasome to chromatin 
through the interaction with BET proteins” (Cattoglio et al., 2010; De Ravin et al., 2014; 
De Rijck et al., 2013; Gupta et al., 2013; Kvaratskhelia et al., 2014; LaFave et al., 2014; 
Larue et al., 2014; Sharma et al., 2013). Due to the stable integration, sequencing of γRV 
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ISs reveals the location of strong enhancers and active promoters. In fact, γRV ISs have 
already been used to successfully map regulatory regions in HSPCs, MPPs and EPPs to 
address epigenetic changes associated to HSPC lineage commitment, prior to our study 
(Romano et al., 2016). Interestingly, in that study Romano and colleagues found a highly 
significant enrichment of γRV clusters at super-enhancers (SE) compared to normal 
enhancers (53% vs. 12%), raising the question whether our IS clusters point more 
specifically to SEs rather than normal enhancers in human HSCs. However, as only one 
study reported this coherence so far, it is probably not yet save to generalize this 
observation for other cells types as well (enrichment of γRV ISs at strong enhancers and 
active promoters has been shown by multiple independent studies). One way to address 
this question could be to re-analyze existing data sets with matching samples of ChIP-seq 
against at least H3K4me3, H3K4me1 and H3K27ac and γRV ISs with a focus on SEs. 
Moreover, the ever-improving understanding of histone modifications and their 
associated chromatin states as well as newly available technologies might even refine 
the current concept of γRV integration preference, this way also improving the 
interpretation of the regulatory regions mapped in this study. 
4.3.4 PredicOon of enhancer acOvity during early hematopoiesis using the 
Ome point of IS detecOon 
“In addition to the investigation of IS-tagged genes we also demonstrated the 
HSC-specificity of ISs on cluster level, by analyzing the recently reported blood enhancer 
cluster (BENC), which has been functionally dissected with enhancer sub-module 
resolution. Strikingly, we were not only able to recapitulate the results from Bahr et al. 
(2018), but also identified three additional sub-modules with equal or even higher HSC 
specificity. These results indicate that our IS data has sufficient resolution to identify 
enhancer modules and that the information about the time point of detection allows to 
predict the activity of these enhancers in the early hematopoietic hierarchy.” 
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4.4 Conclusion and perspecOves 
“In summary, we show that γRV ISs can be used as molecular tags not only for 
clonal tracking, but also to mark regulatory regions in functionally defined cell 
populations. Unlike sequencing approaches of phenotypically defined cell populations, 
our method exploits the natural selection process enriching for long-term repopulating 
HSCs after transplantation. This approach may be even extended to other vector types 
such as lentiviruses (active gene bodies) or adeno-associated viruses (AAV5: 
transcriptional activity) (Janovitz et al., 2014). Likewise, γRVs may also be used to tag 
regulatory regions in other rare cell types. Using our strategy, we were able to detect 
>79,000 genomic tags from 10 patients which point towards >3,000 regulatory regions in 
human long-term repopulating HSCs. These data provide new insights into active regions 
and regulatory mechanisms of repopulating HSCs and represent a solid basis and 
comprehensive resource for functional studies investigating stem cell self-renewal and 
differentiation.” Although we did not observe a striking phenotype of the IS-tagged 
protein-coding genes analyzed with the pooled over-expression approach, future 
experiments with improved robustness or sensitivity might provide further insights into 
if and how these potential HSC regulators could affect hematopoiesis.  
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5 MATERIAL AND METHODS 
5.1 Material 
5.1.1 Technical equipment 
Table 6 | Overview of technical equipment and devices 
Instrument Manufacturer 
Agarose gel electrophoresis chambers VWR Peqlab 
Agarose gel electrophoresis power supply Elchrom Scientific 
Avanti J-30I Ultracentrifuge Beckman Coulter 
Bacteria incubator Sanyo 
Bacteria shaker Infors 
Benchtop centrifuges Eppendorf 
Benchtop centrifuges, cooling Heraeus 
Cell culture centrifuge Heraeus 
Cell culture hood Thermo Scientific 
Cell culture incubator Thermo Scientific 
Cell sorter FACS Aria II BD Biosciences 
ChemiDoc XRS Imaging System Bio-Rad 
Cobas z 480 Roche 
cOmplete EDTA-free Protease Inhibitor Cocktail Roche 
Flow cytometer LSRII BD Biosciences 
Freezer -20 °C Liebherr 
Freezer -80 °C Sanyo 
Fridge 4 °C Liebherr 
Fume hood WALDNER  
Gel documentation station VWR Peqlab 
Hotplate stirrer VWR 
Ice machine Hoshizaki 
L8-55M Ultracentrifuge Beckman Coulter 
Liquid nitrogen tank German-Cryo 
Microscope Axiovert 40C Zeiss 
Microwave Bartscher 
Mr. Frosty freezing containers Thermo Scientific 
NanoDrop Spectrophotometer ND-1000 Thermo Scientific 
PAGE running chambers Bio-Rad 
pH meter Mettler Toledo 
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Pipetboy Integra Biosciences 
Pipettes Eppendorf 
Qubit 2.0 Fluorometer Invitrogen 
SDS-PAGE power supply Bio-Rad 
Thermocycler peqSTAR VWR Peqlab 
Thermomixer Eppendorf 
Trans-Blot Turbo Transfer System Bio-Rad 
Vacuum pump VACUUBRAND 
Vortex IKA 
Water purification system (for ddH2O) Thermo Scientific 
 
5.1.2 Commercial kits 
Table 7 | Commercial kits 
Kit Manufacturer 
DNeasy Blood & Tissue Kit Qiagen 
EasySep™ Mouse Hematopoietic Progenitor Cell Isolation Kit Stem Cell Technologies 
GeneJET Plasmid Maxiprep Kit Thermo Scientific  
GeneMATRIX Plasmid Miniprep DNA Purification Kit EURx 
QIAquick Gel Purification Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
Qubit dsDNA HS Assay Kit Thermo Scientific 
RNase-Free DNase Set Qiagen 
RNeasy Micro or Mini Kit Qiagen 
SuperScript® III First-Strand Synthesis SuperMix Invitrogen 
 
5.1.3 Reagents  
Table 8 | Reagents 
Reagent Manufacturer 
10x Tris/Glycine/SDS Running Buffer Bio-Rad 
2-Mercaptoethanol Sigma-Aldrich 
ACK Lysing Buffer Thermo Scientific 
Agar  Sigma-Aldrich 
Agarose for DNA Electrophoresis Serva 
Ammonium chloride Sigma 
Ammonium persulfate (APS) Biorad 
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Ampicillin sodium salt Sigma-Aldrich 
Bovine Serum Albumin (BSA) Linaris 
cOmplete EDTA-free Protease Inhibitor Cocktail Roche 
Cytokines: mIl3, mFlt3-L, mTPO, mSCF R&D systems 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
DNA Gel Loading Dye Thermo Scientific 
DNase I, RNase-frei Epicentre 
dNTPs Genaxxon 
Dulbecco's Phosphate-Buffered Saline (PBS) Gibco 
Ethanol Sigma-Aldrich 
Ethidium Bromide solution 0.07 % AppliChem 
FACS Flow Sheath Fluid BD 
Fetal bovine serum (FBS) GE Healthcare 
Fluoro-Gold™ (Hydroxystilbamidine bis(methanesulfonate)) Sigma-Aldrich 
GeneRuler DNA Ladders 100 bp, 1 kb Thermo Scientific 
IGEPAL CA-630 (NP40 substitute) Sigma-Aldrich 
Iscove's Modified Dulbecco's Medium (IMDM) Invitrogen 
Laemmli Sample Buffer, 4x Concentrate Bio-Rad 
Luria Broth Base powder Invitrogen 
Magnesiumchloride, MgCl2 Sigma-Aldrich 
Methanol Sigma-Aldrich 
MethoCult™ M3434 Stemcell Technologies 
Penicillin-Streptomycin (P/S) Gibco 
Phusion High-Fidelity DNA Polymerase NEB 
Polybrene Chemicon 
Polyethylenimine, branched Sigma-Aldrich 
Precision Plus Protein Standards (Dual Color) BioRad 
Protamine Sulfate Sigma-Aldrich 
Proteinase K Qiagen 
REDTaq® ReadyMix™ PCR Reaction Mix Sigma Aldrich 
Restriction enzymes (BamHI, SbfI, ClaI + Cut Smart buffer) New England Biolabs 
RNase A Qiagen 
RNaseOUT™ Recombinant Ribonuclease Inhibitor Thermo Scientific 
RoboSep Buffer Stem Cell Technologies 
Roswell Park Memorial Institute (RPMI)-1640 Medium Gibco 
S.O.C. Medium Invitrogen 
Sodium chloride Sigma-Aldrich 
StemSpan SFEM Stem Cell Technologies 
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T4 DNA Ligase + buffer New England Biolabs 
T4 Polynucleotide Kinase + buffer New England Biolabs 
Taq DNA polymerase + PCR reaction buffer Qiagen 
TBE buffer (10X) Genaxxon 
Titanium Taq DNA polymerase + PCR reaction buffer Takara 
Trans-Blot Turbo Midi PVDF Transfer Packs Bio-Rad 
Tris powder Bio-Rad 
Trypan blue Gibco 
Trypsin-EDTA Gibco 
TWEEN 20 Sigma-Aldrich 
Western Lightning Plus-ECL PerkinElmer 
 
5.1.4 Consumables 
Table 9 | Consumables 
Consumable Manufacturer 
Cell Counting Chambers Neubauer 
Cell culture dishes 10 cm, 15 cm Corning 
Cell culture flasks T25, T75, T225 Fisher Scientific 
Cell culture plates 6-well, 12-well, 24-well, 48-well, 96-well Greiner Bio-One 
Cell strainer 40 µm, 70 µm, 100 µm Corning 
Conical tubes 15 mL, 50 mL BD 
Cryo tubes 2.0 mL (sterile) Genaxxon 
FACS tubes, 4.5 mL conical bottom polystyrene test tube Greiner Bio-One 
FACS tubes, 5 mL round bottom polystyrene test tube BD 
Filter foil, 85 µm, SEFAR NITEX 03-85/35 Sefar 
Filter pipette tips 10 µL, 20 µL, 200 µL, 1,000 µL Greiner Bio-One 
Microvette CB 300 K2E Sarstedt 
PCR plate sealing foil Steinbrenner 
PCR reaction plate, 96-well Greiner Bio-One 
PCR strips Biozym 
Petri dishes Corning 
Pipettes 2 mL, 5 mL, 10 mL, 25 mL, 50 mL Corning 
Plastic flasks 125 mL, 250 mL Nunc 
Polyallomer Centrifuge Tubes (Ultracentrifuge) Beckman Coulter 
qPCR plate sealing foil Biozym 
qPCR reaction plate, 96-well Biozym 
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Qubit Assay Tubes Invitrogen 
SafeSeal reaction tubes 0.5 mL, 1.5 mL, 2 mL Sarstedt 
 
5.1.5 Plasmids 
Table 10 | Plasmids 
Handling name Full name/Elements Reference 
LV101 3rd generation lentiviral plasmid (gag-pol) In house plasmid stocks 
LV102 3rd generation lentiviral plasmid (rev) In house plasmid stocks 
LV103 3rd generation lentiviral plasmid (vsv-g) In house plasmid stocks 
p602 pCCL.SIN.cPPT.PGK.IRES.eGFP.wPRE Luigi Naldini, (Herbst et al., 2012) 
p612 pCCL.SIN.cPPT.pTight.IRES.eGFP.wPRE 
Cloned using p602 backbone with  
pTight (pLVX) promoter 
P902 pCCL.SIN.cPPT.BC.pTight.IRES.eGFP.wPRE 
Cloned from p612 backbone with  
Barcode cassette (BC) 
pMA-RQ 
pMA-RQ transfer vector with 
 Ampicillin resistance 
Invitrogen (GeneArt) 
pMA-T 
pMA-T transfer vector with 
 Ampicillin resistance  
Invitrogen (GeneArt) 
pMK-RQ 
pMA-RQ transfer vector with 
 Kanamycin resistance 
Invitrogen (GeneArt) 
pRSI9 pRSI9-U6-(sh)-HTS3-UbiC-TagRFP-2A-Puro Cellecta, Inc. 
P612 plasmid was originally cloned by Shayda Hemmati.  
5.1.6 Western blot AnObodies 
Table 11 | Westernblot Antibodies 
Antibody Host Supplier Cat. no. Dilution 
Anti Igf2bp2 Rabbit Antibodies-Online ABIN502002 1:1,000 
Anti-rabbit-HRP Goat Abcam ab6721 1:10,000 
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5.1.7 Flow cytometry anObodies and staining panels 
Table 12 | Antibodies used for sorting of LSK and LSK-SLAM cells 
Antibody Format Clone Host Supplier Cat. no. Dilution 
CD117 PE 2B8 Rat IgG2b BD 553355 1:200 
CD150 PE-Cy5 17A2 Rat IgG2b BD 555276 1:500 
CD48 AlexaFlour700 HM48-1 Armenian Hamster Biozol B188338 1:200 
Lineage Cocktail APC mix Isotype Cocktail BD 558074 1:100 
Ly-6A/E (Sca-1) PE-Cy7 D7 Rat IgG2a BD 558162 1:200 
Establishment of color combinations and antibody dilutions for the detection of indicated cell populations 
were jointly established with Elias Eckert.  
Table 13 | Antibodies used for sorting of HSCs 
Antibody Format Clone Host Supplier Cat. no. Dilution 
CD117 APC 2B8 Rat IgG2b BD 553991 1:200 
CD135 PE A2F10.1 Rat IgG2a BD 553930 1:100 
CD150 PE-Cy5 17A2 Rat IgG2b BD 555276 1:500 
CD34 FITC RAM34 Rat IgG2b BD 560238 1:30 
CD48 AlexaFlour700 HM48-1 Armenian Hamster Biozol B188338 1:400 
Lineage Cocktail PE-Cy7 mix Isotype Cocktail 
See 
below 
See 
below 
1:00 
Ly-6A/E (Sca-1) APC-Cy7 D7 Rat IgG2a BD 552770 1:200 
Establishment of color combinations and antibody dilutions for the detection of indicated cell populations 
were jointly established with Elias Eckert.  
Table 14 | Lineage cocktail used for the HSC sort staining 
Antibody Format Clone Host Supplier Cat. no. Dilution 
CD11b PE-Cy7 M1/70 Rat IgG2b BD 552850 - 
CD3 PE-Cy7 17A2 Rat IgG2b BD 552849 - 
CD45R PE-Cy7 RA3-6B2 Rat IgG2a BD 552772 - 
Ly6G/C (Gr-1) PE-Cy7 RB6-8C5 Rat IgG2b BD 552894 - 
Ter119 PE-Cy7 Ter-119 Rat IgG2b BD 553673 - 
Antibodies in Table 14 are mixed to equal proportions and used in at a final dilution of 1:400. 
Establishment of color combinations and antibody dilutions for the detection of indicated cell populations 
were jointly established with Elias Eckert.  
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Table 15 | Antibodies used for detection or sort of progenitor cells 
Antibody Format Clone Host Supplier Cat. no. Dilution 
CD117 APC 2B8 Rat IgG2b BD 553991 1:200 
CD127 (IL7R) PE-Cy5 A7R34 Rat IgG2a eBioscience 15-1271-82 1:200 
CD16/32  
(FcγR) 
PE 93 Rat IgG2a BioLegend 101308 1:200 
CD34 FITC RAM34 Rat IgG2b BD 560238 1:30 
Lineage Cocktail PE-Cy7 mix Isotype Cocktail See below See below 1:300 
Ly-6A/E (Sca-1) APC-Cy7 D7 Rat IgG2a BD 552770 1:200 
Establishment of color combinations and antibody dilutions for the detection of indicated cell populations 
were jointly established with Elias Eckert.  
Table 16 | Antibodies used for analysis of HSCs with presents of GFP+ cells 
Antibody Format Clone Host Supplier Cat. no. Dilution 
CD117 PE 2B8 Rat IgG2b BD 553355 1:200 
CD150 PE-Cy5 17A2 Rat IgG2b BD 555276 1:500 
CD34 AlexaFlour700 RAM34 Rat IgG2a BD 560518 1:30 
CD45.2 PacificBlue 104 Mouse IgG2a BioLegend 109819 1:100 
CD48 PE-Cy7 HM48-1 Armenian Hamster BD 560731 1:200 
Lineage Cocktail APC mix Isotype Cocktail BD 558074 1:100 
Ly-6A/E (Sca-1) APC-Cy7 D7 Rat IgG2a BD 552770 1:200 
Establishment of color combinations and antibody dilutions for the detection of indicated cell populations 
were jointly established with Elias Eckert.  
Table 17 | Antibodies used for analysis and sort of differentiated lymphoid and myeloid cells 
Antibody Format Clone Host Supplier Cat. no. Dilution 
CD11b PerCP-Cy 5.5 M1/70 Rat IgG2a BD 550764 1:200 
CD3 PE-Cy7 17A2 Rat IgG2b BD 560591 1:200 
CD45.1 PE A20 Rat IgG2a BD 553930 1:200 
CD45.2 APC-Cy7 04 Rat IgG2a BD 550882 1:200 
CD45R  AlexaFluor700 RA3-6B2 Rat IgG2a BD 557957 1:200 
Ly6G APC 1A8 Rat IgG2a BD 560599 1:200 
Establishment of color combinations and antibody dilutions for the detection of indicated cell populations 
were jointly established with Elias Eckert.  
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5.1.8 OligonucleoOdes 
Table 18 | Genotyping primers for B6.Cg-Gt(ROSA)26Sor tm1(rtTA*M2)Jae/J mice 
Name Sequence (5’-3’) 
Rosa A aaagtcgctctgagttgttat 
Rosa B gcgaagagtttgtcctcaacc 
Rosa C ggagcgggagaaatggatatg 
Amplicon lengths: Wildtype ∼330bp; Mutant ∼550bp. 
Table 19 | Primers for amplifying the barcode cassette from the pRSI9 cellecta library and introducing 
the ClaI restriction enzyme cutsite 
Name Sequence (5’-3’) 
PW_C_Bar_Cla1_f ttacagatcgatttttttggcaagcaaaagacg 
PW_C_Bar_Cla1_r atctatatcgattgccatttgtctcgaggtcg 
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Table 20 | qPCR primers for endogenous expression of candidate genes 
Gene  Primer name Forward primer (5’-3’) Reverse primer (5’-3’) Amplicon  
Amica1 mAmica1_a atgaaaaagcccgtggaact gttgtatcacctactcggactctg 74 
Amica1 mAmica1_b agcctggagaacaaagagaagat  ctctgtcgtctcccacgtagt 75 
Ccnd3 mCcnd3_a ggcatactggatgctggag ccaggtagttcatagccagagg 77 
Ccnd3 mCcnd3_b attgagaagctttgcatctatacg gaccagcacctcccactc 72 
Evl* Evl atgagtgaacagagtatctgcc  tctttgccacagacggggtt  - 
Fbxl18 mFbxl18_a tgtacatgcctgctcttgct aagtagggctgctccaacc 76 
Fbxl18 mFbxl18_b ggctagctccggagagga tcatcggagaagccaagc 87 
Igf2bp2 mIgf2bp2_a gctggtgcctccatcaag tgaccatcctctcactgacatc 61 
Igf2bp2 mIgf2bp2_b tgacaagagaagaggcaaagc catcggggatgtaggaaatc 90 
Irf2bpl* Irf2bpl agatgctagctgtcccatgc  tgttcctcaccgagcttcag  - 
Lair1 mLair1c aatctagctactaatggcctggag ttgaaggtctcctgcaactg 108 
Lair1L mLair1l_a ggtgatcaaagaaaatgtcatcc gctgtatgtctttagccaagatgtat 76 
Lair1L mLair1l_b gtgcctgggatggaaaatta tcataagacttgaattagggaagatg 77 
Lair1S mLair1s tcatccagttatcctgctggt gccaagatgtatcctcctgtg 74 
Mbnl1 mMbnl1_a aacatctgccacaagtgttcc tgttcggcagatattatgggta 72 
Mbnl1 mMbnl1_b ttgattcagcagaagaacatgg ggtgcaactgaaaacattgg 107 
Ninj2 mNinj2_a caggacctccagcaatccta acaaaggctgaagtggctcta 74 
Ninj2 mNinj2_b ccctagtcaccctcatcattg tggcagcattgttgagcttat 132 
Nrip1 mNrip1_a gcttttcaacagccttctcag tcatctttcgttgctcacca 97 
Nrip1 mNrip1_b cctttaacattcgggaggaa ggctgttgaaaagcaactctg 103 
Plcb4* Plcb4 atgcgggtaccttctcaagc tttccgtatggtgtcggtgg  - 
Prkcb mPrkcb_a gggatgaaatgcgacacct cgttccgtgtggtcagtg 89 
Prkcb mPrkcb_b gaaactcgaacgcaaggaga accggtcgaagttttcagc 77 
Slx4ip mSlx4ipc gaggaacgctctgaaggaaa cactagatcttcccacgaggtc 98 
Slx4ipSL mSlx4ipsl attgccacaaggttcaaaca tgtgatctgaaagccataacctc 75 
Slx4ipSL mSlx4ipsl attgccacaaggttcaaaca tgtgatctgaaagccataacctc 113 
Swap70 mSwap70_a acctttgaaatcagtgcctca tgcccagcttcaacagatg 88 
Swap70 mSwap70_b cggcaggatgaagagactg ccagctctgccctcttagaa 76 
Xbp1 mXbp1_a ctgacgaggttccagaggtg gcagaggtgcacatagtctgag 96 
Xbp1 mXbp1_b agcaagtggtggatttggaa ccgtgagttttctcccgtaa 76 
Znf217* Znf217 tgaggatggactccctgacg  gctgcggcatactcacagaa  - 
Primers/Genes marked with an asterisk were originally designed by Shayda Hemmati. m, amplifies murine 
gene; L, long isoform; S, short isoform; l, primer that amplifies long isoform; s, primer that amplifies short 
isoform; c, primer that amplifies both isoforms (“common”).  
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Table 21 | qPCR primers for expression of codon optimized candidate genes 
Gene  Primer name Forward primer (5’-3’) Reverse primer (5’-3’) Amplicon  
Amica1 mAmica1co cgtgaccaaagtgaactgga gtcgtagctcagcacggttt 70 
Ccnd3 mCcnd3co gaaagctgaagtgggacctg cacgagggcctgtctgtc 98 
Evl* Evl_opt atctaccacaacaccgccag aggtggtggcttcctctttg - 
Fbxl18 mFbxlco_a cctagctacggcgtggtg tggttctgtccaggatctca 76 
Fbxl18 mFbxlco_b ccctagagccgatagagcac gcactttcttgccgaagc 71 
Igf2bp2 mIgf2co_a gccctcctcacagagctagag agtgggaagtcgatctgtctg 76 
Igf2bp2 mIgf2co_b ctgtacccccaccaccact ttgggatgaacagagacacg 82 
Irf2bpl* Irf2bpl_opt aaacagagccgaggaatggg gccggtgggatactcgatg - 
Lair1L mLair1lco gcccgacatcaccatctt cgctgtagctgcacacga 80 
Lair1S mLair1sco tcaacacccaggaagatacca cctctgctgctgtctcttgtt 164 
Lrrc33* Lrrc33_opt ccgacaacagactgagcgag tcgaagatgctgtcgtccag - 
Mbnl1 mMbnl1co ctgccttcaacccttacctg gattgcctgtcacgagcat 90 
Ninj2 mNinj2co actacaccaccctcgtgacc caggttcaggatggcgataa 92 
Nrip1_a mNrip1co_a aggaaaacggccagaaagac tagcctgtccgttcaggtg 75 
Nrip1_b mNrip1co_b tgaacagccaccagaaagtg     
Nrip1_c mNrip1co_c tcaggacttcagcttcagca tgtgggacttgtcctgctc 95 
Plcb4* Plcb4_opt gaagtccgagggcaaagagg caccatgtaggtgaagccga - 
Prkcb_a mPrkcbco_a agggcgagtacttcaacgtg ccgatcttggctctctcg 88 
Prkcb_b mPrkcbco_b gcaagtgggcagattcaaag ccctgtagatgatgcccttg 98 
Slx4ipL mSlx4co_l ccgcgtgaaagaatacgtg gctgcttctggtgaactcg 70 
Slx4ipS mSlx4co_s ggttcagcgagcagaaaaa gttctggacacggtgaaggt 88 
Swap70 mSwap70co aggcggaaagagctgagaa ctgctgtttgttctcgttgg 96 
Xbp1 mXbp1co cagaacatcttcccttggaca gtgtccagctggtccagaa 88 
Xbp1S mXbp1Sco tcatcgtgtccgtgaagaaa ctcaggcagtgggagctg 91 
Znf217* Znf217_opt accccgaagtgctgatgatg acttgctgtgagggctgaaa - 
Primers/Genes marked with an asterisk were originally designed by Shayda Hemmati. m, amplifies murine 
gene; L, long isoform; S, short isoform; l, primer that amplifies long isoform; s, primer that amplifies short 
isoform; c, primer that amplifies both isoforms (“common”).   
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Table 22 | Barcoding sequencing primers 
Name Sequence (5’-3’) 
deltaP5_1stPCR_R gagaggttcagagttctacagtccgaaac 
Multiplex Primer 
aatgatacggcgaccaccgaggatcggaagagcacacgtctgaactccagtcac (N)8 gagaggttcagagtt
ctacagtccg 
pRSI9_FwdGex caagcagaagacggcatacgaga 
pRSI9_FwdHTS ttctctggcaagcaaaagacggcata 
pRSI9_GexSeqN acagtccgaaaccccaaacgcacgaa 
The multiplex primer contains an eight nucleotide index sequence, indicated by (N)8. The index sequence 
is listed below in Table 23. Primers were jointly designed with Elias Eckert. 
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Table 23 | High throughput multiplexing primers 
Name Index Name Index Name Index 
NuGene_Ind_A01 TAGACGTG NuGene_Ind_A05 ATCGCCAT NuGene_Ind_A09 GCTTCTTG 
NuGene_Ind_B01 CACTAGCT NuGene_Ind_B05 AAGGCGTT NuGene_Ind_B09 CTCATCAG 
NuGene_Ind_C01 GCGATAGT NuGene_Ind_C05 CACCTTAC NuGene_Ind_C09 TGTTCGAG 
NuGene_Ind_D01 TGATACGC NuGene_Ind_D05 AGTCGACA NuGene_Ind_D09 CTTGTCGA 
NuGene_Ind_E01 TGGAGAGT NuGene_Ind_E05 CTCAGAGT NuGene_Ind_E09 GATGCACT 
NuGene_Ind_F01 AATGGACG NuGene_Ind_F05 ACTCCATC NuGene_Ind_F09 TGTAGCCA 
NuGene_Ind_G01 TTACGGCT NuGene_Ind_G05 TGAGCTAG NuGene_Ind_G09 TTGTGTGC 
NuGene_Ind_H01 CTCTACTC NuGene_Ind_H05 TGGTACAG NuGene_Ind_H09 GACTATGC 
NuGene_Ind_A02 AACGACGT NuGene_Ind_A06 TTGACAGG NuGene_Ind_A10 AGCGTGTT 
NuGene_Ind_B02 AACAGGAC NuGene_Ind_B06 ATACGACC NuGene_Ind_B10 TCCGTGAA 
NuGene_Ind_C02 AGGCTTCT NuGene_Ind_C06 TATCAGCG NuGene_Ind_C10 TCACAGCA 
NuGene_Ind_D02 GGATCTTC NuGene_Ind_D06 GGAAGCTA NuGene_Ind_D10 ATTCGAGG 
NuGene_Ind_E02 CTCAGCTA NuGene_Ind_E06 ACGACTTG NuGene_Ind_E10 AAGCCACA 
NuGene_Ind_F02 TTGGACGT NuGene_Ind_F06 GATGAGAC NuGene_Ind_F10 TACCACAG 
NuGene_Ind_G02 GATGTGTG NuGene_Ind_G06 TGCTTGGT NuGene_Ind_G10 TCGAGTGA 
NuGene_Ind_H02 TTGATCCG NuGene_Ind_H06 ACCTGACT NuGene_Ind_H10 GTAGGAGT 
NuGene_Ind_A03 AAGGCTGA NuGene_Ind_A07 TCGCGATA NuGene_Ind_A11 TGTTGTGG 
NuGene_Ind_B03 AGAGCCTT NuGene_Ind_B07 TCCTGCTA NuGene_Ind_B11 TTAAGCGG 
NuGene_Ind_C03 ACGGAACA NuGene_Ind_C07 GTCCTTCT NuGene_Ind_C11 CATACCAC 
NuGene_Ind_D03 GACATTCC NuGene_Ind_D07 ACAGCTCA NuGene_Ind_D11 TGTACACC 
NuGene_Ind_E03 CTTGGATG NuGene_Ind_E07 TCACTCTG NuGene_Ind_E11 CTCCTAGA 
NuGene_Ind_F03 CTGTTGAC NuGene_Ind_F07 AGGAACCT NuGene_Ind_F11 TGCTTCCA 
NuGene_Ind_G03 GATAGCGA NuGene_Ind_G07 CAAGGTCT NuGene_Ind_G11 GTGGTGTT 
NuGene_Ind_H03 GATAGGCT NuGene_Ind_H07 GAAGGAAG NuGene_Ind_H11 TCCGTATG 
NuGene_Ind_A04 GAATCCGA NuGene_Ind_A08 TGAACCTG NuGene_Ind_A12 TCTGAGAG 
NuGene_Ind_B04 ATACTCCG NuGene_Ind_B08 ACACCAGT NuGene_Ind_B12 ACCAGCTT 
NuGene_Ind_C04 GAAGGTTC NuGene_Ind_C08 GTGAATCC NuGene_Ind_C12 AAGGACAC 
NuGene_Ind_D04 CATCCTCT NuGene_Ind_D08 GAATCGTG NuGene_Ind_D12 ACAGACCT 
NuGene_Ind_E04 AGAAGCGT NuGene_Ind_E08 GCATGTCT NuGene_Ind_E12 GACGAATG 
NuGene_Ind_F04 TTCCTGTG NuGene_Ind_F08 ACTGTGTC NuGene_Ind_F12 TTGGTGAG 
NuGene_Ind_G04 GGATTCGT NuGene_Ind_G08 TCAACTGG NuGene_Ind_G12 TCGTAGTC 
NuGene_Ind_H04 ATGGAAGG NuGene_Ind_H08 GATCCATG NuGene_Ind_H12 CTGCGTAT 
Multiplexing strategy and primer design was jointly established with Elias Eckert.  
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Table 24 | Cellecta barcode sequences  
# Gene 18nt-BC Sequence # Gene 18nt-BC Sequence 
1 miR_10a_oe_1 ACACACACTGGTCATGCA 49 Mbnl1_1 TGACGTTGGTACCAGTCA 
2 miR_10a_oe_2 GTGTCAACGTGTTGGTCA 50 Mbnl1_2 GTCATGACCAACGTGTGT 
3 miR_26a-1_oe_1 ACTGACGTACGTTGCATG 51 Ninj2_1 CAACACGTCAGTACCATG 
4 miR_26a-1_oe_2 GTTGCACACAGTACCATG 52 Ninj2_2 GTACACACTCACCAGTTG 
5 miR_101_oe_1 ACGTACTGTGACACCAAC 53 Nrip1_1 TGTGGTGTTGCAACGTGT 
6 miR_101_oe_2 TGACTGTGCAGTACCATG 54 Nrip1_2 TGCACATGGTCAACCAAC 
7 miR_146a_oe_1 ACTGACTGGTACACGTAC 55 Prkcb_1 ACTGACCATGCAGTGTGT 
8 miR_146a_oe_2 ACACTGACTGGTACGTCA 56 Prkcb_2 TGTGGTCATGTGACCAGT 
9 miR_148b_oe_1 TGGTGTTGGTTGACGTTG 57 Slx4ipL_1 ACACGTGTGTGTTGCATG 
10 miR_148b_oe_2 GTCAGTGTCAACGTCACA 58 Slx4ipL_2 GTACTGACGTACCAGTCA 
11 miR_326_oe_1 ACACGTCAACGTGTCAGT 59 Slx4ipS_1 GTACACTGTGACACCATG 
12 miR_326_oe_2 ACGTTGCAGTACGTGTTG 60 Slx4ipS_2 GTCATGCACATGACGTCA 
13 miR_335_oe_1 CACATGGTACACCAGTCA 61 Swap70_1 GTCACATGTGTGTGCATG 
14 miR_335_oe_2 TGTGTGCAGTGTACCAGT 62 Swap70_2 GTGTGTTGTGTGCATGAC 
15 miR_342_oe_1 ACCATGCAGTACACGTAC 63 Xbp1_1 GTCATGGTCAGTCAGTAC 
16 miR_342_oe_2 ACGTGTACTGCAACGATG 64 Xbp1_2 TGGTGTTGTGACACCACA 
17 miR_eGFP_1 GTCACATGGTTGTGCACA 65 Xbp1S_1 GTACTGACACACTGGTGT 
18 miR_eGFP_2 CACACAACCAACACGTTT 66 Xbp1S_2 GTGTGTACACCAACCAAC 
19 miR_eGFP_3 ACGTCATGCACATGGTCA 67 Evl_1 CATGTGGTACCATGCACA 
20 miR_eGFP_4 GTGTCATGGTTGACCACA 68 Evl_2 GTGTCAGTACTGACCAGT 
21 miR_eGFP_5 TGGTTGACTGCATGCACA 69 Irf2bp2_1 ACGTCACATGTGCAGTTG 
22 miR_eGFP_6 TGCAACACCATGCATGCA 70 Irf2bp2_2 GTGTCACATGACTGCAGT 
23 miR_eGFP_7 ACTGACTGGTGTCAGTCA 71 Lrrc33_1 ACTGCAACTGGTTGCAGT 
24 miR_eGFP_8 ACACTGTGTGACCAGTTG 72 Lrrc33_2 ACCAGTGTTGCACATGGT 
25 miR_eGFP_9 CATGACTGTGTGCATGAC 73 Plcb4_1 TGGTTGTGCACACATGGT 
26 miR_eGFP_10 TGACGTCATGGTACCAGT 74 Plcb4_2 ACCATGTGGTTGCATGTG 
27 miR_eGFP_11 ACCAGTTGTGTGTGGTGT 75 Znf217_1 ACACCATGACTGCAGTCA 
28 miR_eGFP_12 ACACTGCAGTTGCATGTG 76 Znf217_2 GTGTCACATGACGTCATG 
29 miR_eGFP_13 TGTGCACAGTGTTGGTGT 77 GFPctrl_1 GTCACATGACGTACCAGT 
30 miR_eGFP_14 ACACCAGTGTGTCATGCA 78 GFPctrl_2 TGCAACACTGACTGGTTG 
31 miR_eGFP_15 TGACACGTGTTGTGGTGT 79 GFPctrl_3 GTGTTGACGTGTGTGTAC 
32 miR_eGFP_16 CAGTTTTGCATGACGTGT 80 GFPctrl_4 TGTGGTGTTGTGCATGCA 
33 miR_eGFP_17 ACCAACCAGTCAGTGTGT 81 GFPctrl_5 TGACCACATGCAACCAGT 
34 miR_eGFP_18 GTCATGGTGTCAACCAGT 82 GFPctrl_6 ACGTCATGCAACACGTTG 
35 add_BC_1 GTACGTGTACGTTGGTAC 83 GFPctrl_7 GTACTGGTGTACTGCACA 
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36 add_BC_2 TGCATGGTCAGTACCAGT 84 GFPctrl_8 ACTGCATGTGACCAGTAC 
37 Amica1_1 TGTGCACAGTTGACCACA 85 GFPctrl_9 CAACTGACACGTTGCAAC 
38 Amica1_2 CATGACGTTGCAACCAGT 86 GFPctrl_10 ACTGACACTGACGTGTTG 
39 Ccnd3_1 GTCATGACGTGTTGGTGT 87 add _BC_3 GTACTGTGGTTGACGTGT 
40 Ccnd3_2 TGCAGTCAGTCAGTGTTG 88 add _BC_4 TGTGTGCATGTGTGCAGT 
41 Fbxl18_1 TGGTTGGTGTGTTGCATG 89 add _BC_5 TGTGGTTGACCAACCAAC 
42 Fbxl18_2 TGTGTGTGCATGTCCATG 90 add _BC_6 TGGTGTGTTGTGACCAGT 
43 Igf2bp2_1 ACGTACACGTTGACGTCA 91 add _BC_7 ACCATGTGACTGACCAAC 
44 Igf2bp2_2 TGACACACTGGTTGCATG 92 add _BC_8 ACCATGGTGTACACCAAC 
45 Lair1L_1 TGCAGTTGACGTACCATG 93 add _BC_9 GTGTACACACACGTCATG 
46 Lair1L_2 ACACTGACTGACTGCATG 94 add _BC_10 CATGTGCATGGTTGGTCA 
47 Lair1S_1 TGGTTGTGTGACCAGTAC 95 add _BC_11 CAGTACTGGTACACGTCA 
48 Lair1S_2 GTCAACACTGCACAGTAC 96 add _BC_12 GTACGTACCATGACCAGT 
Barcode sequences were randomly picked from the Cellecta libray through bacterial transformation 
followed by colony PCR. Barcodes starting with “miR_” were cloned by Elias Eckert. Barcodes starting with 
“add_” were jointly cloned with Elias Eckert.  
5.1.9 Mouse Strains 
Table 25 | Mouse strains  
Abbreviation Full name Allogenic marker Supplier 
BoyJ B6.SJL-Ptprca-Pep3b-/BoyJ CD45.1 Charles River Italia 
Bl6Rosa rtTA B6.Cg-Gt(ROSA)26Sor tm1(rtTA*M2)Jae/J CD45.2 In house breeding 
 
5.1.10 So_ware 
Table 26 | Software 
Software Company Application 
FACS Diva V8 BD FACS analysis 
FlowJo V10 FlowJo FACS analysis 
Lasergene V12.2 DNASTAR Cloning and sequencing analysis 
LightCycler 480 Software V1.5 Roche qRT-PCR analysis 
R version 3.4.2 R Foundation Statistical analysis 
RStudio Desktop 1.0.143 RStudio Statistical analysis 
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Table 27 | R packages and Unix programs 
Name 
Versio
n OS Link 
bigWigToBedGraph - U 
http://hgdownload.soe.ucsc.edu/admin/exe/linux.x86_64/bigW
igToBedGraph  
ClusteredMutations 1.0.1 W 
https://cran.r-
project.org/web/packages/ClusteredMutations/index.html  
ComplexHeatmap 1.14.0 W 
https://bioconductor.org/packages/release/bioc/html/Complex
Heatmap.html  
data.table 1.10.4 W https://cran.r-project.org/web/packages/data.table/index.html  
dplyr  0.7.1 W https://cran.r-project.org/web/packages/dplyr/index.html  
GenomicRanges 1.28.3 W 
http://bioconductor.org/packages/release/bioc/html/GenomicR
anges.html  
ggplot2 2.2.1 W https://cran.r-project.org/web/packages/ggplot2/index.html 
ggrepel 0.6.5 W https://cran.r-project.org/web/packages/ggrepel/index.html  
ggsignif 0.3.0 W https://cran.r-project.org/web/packages/ggsignif/index.html  
gplots 3.0.1 W https://cran.r-project.org/web/packages/gplots/index.html 
HOMER 4.9 U/O http://homer.ucsd.edu/homer/index.html  
MACS2 2.2.1 U https://github.com/taoliu/MACS  
piano 1.16.1 W 
https://bioconductor.org/packages/release/bioc/html/piano.ht
ml 
scales 0.4.1 W https://cran.r-project.org/web/packages/scales/index.html  
seriation 1.2-2 W https://cran.r-project.org/web/packages/seriation/index.html  
wigToBigWig - U 
http://hgdownload.soe.ucsc.edu/admin/exe/linux.x86_64/wigT
oBigWig  
OS, Operating System; W, Windows 7; U, Unix/Linux; O, OS X Yosemity; Note: MACS2 was used python version 2.7 
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5.2 Methods 
5.2.1 Molecular cell biology 
5.2.1.1 RNA isolaOon 
Isolation of total cellular RNA was performed using either the RNeasy Mini or 
Micro Kit (Qiagen) according to the manufacturer protocol for RLT-Buffer lysis and 
homogenation with the Qiagen Shredder Columns. RNA was either directly reversely 
transcribed (5.2.1.4) or stored at -80°C until further processing.  
5.2.1.2 DNA isolaOon for mouse genotyping 
Genomic DNA was isolated from mouse tails using the DNeasy Blood & Tissue Kit 
(Qiagen) following the manufacturers protocol for rodent tails. DNA was either directly 
used for the genotyping PCR (5.2.1.3) or stored at -20°C until further usage.  
5.2.1.3 Genotyping PCR 
For genotyping of B6.Cg-Gt(ROSA)26Sor tm1(rtTA*M2)Jae/J mice, DNA was 
isolated as described in 5.2.1.2. For the PCR reaction, 5uL of DNA with a concentration of 
5-100ng/µL was used. The Primer-Mix was produced using 50 µL of Rosa A, 35µL of Rosa 
B and 50µL of Rosa C primers (Table 18) and mixed with 1215µL of distilled water. PCR 
mix and amplification conditions are listed below.  
Table 28 | Master Mix composition and PCR conditions for genotyping PCR of B6.Cg-Gt(ROSA)26Sor 
tm1(rtTA*M2)Jae/J mice 
Reagent Volume [µL]  Step Temp [°C] time [s] # 
Template (DNA) 5  Initial denaturing 95 45 1 
H2O 3.95  Denaturing 95 45 2 
Red-Tag-Mix 11  Annealing 55 45 3 
MgCl2 0,7  Elongation 72 60 4 
Primer-Mix (see above) 1.35  ----------- Repeat #2-4 30x ----------- 
   Final Elongation 72 420 5 
   Storage 4 Infinite 6 
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5.2.1.4 Reverse transcripOon and QuanOtaOve real-Ome PCR (qRT-PCR) 
mRNAs were reverse transcribed into cDNA using the SuperScript® III First-Strand 
Synthesis SuperMix (Invitrogen) with the addition of RNaseOUT™ Recombinant 
Ribonuclease Inhibitor following the manufacturers protocol. Next, cDNA was diluted 
1:10 in case 1µg of total RNA was used and 1:20 when 2µg of RNA was used during 
reverse transcription. Finally, a master mix was prepared and aliquoted into wells of a 
96-well plate followed by dispensing cDNA into the well. All primers were design to 
anneal at 60°C, in order to facilitate to grouping of different amplifications on the same 
96-well plate. 
Table 29 | Master Mix composition and PCR conditions for qPCR reactions 
Reagent Volume [µL]  Step Temp [°C] time [s] # 
Template (cDNA) 2  Initial denaturing 95 600 1 
H2O 7  Denaturing 95 15 2 
SYBR green 10  Annealing 60 30 3 
Forward Primer 0.5  Elongation 72 30 4 
Reverse Primer 0.5  ----------- Repeat #2-4 40x ----------- 
   Storage RT Infinite 6 
 
5.2.1.5 Protein isolaOon and semi dry Western blot for the detecOon of 
Igf2bp2 
1 x 107 cells were lyzed in 200µL RIPA buffer (conditioned with 1 cOmplete™ 
ULTRA Tablets, Mini, EASYpack Protease Inhibitor Cocktail tablet per 10mL of RIPA 
buffer) for 30 minutes at 4°C while shaking. Next, suspension is centrifuged at 
13,000rpm and 4°C in a benchtop centrifuge for 15min and supernatant is transferred to 
a fresh tube. After protein isolation, concentration is measured using the Pierce™ BCA 
Protein Assay Kit according to the manufacturers’ protocol. For Igf2bp2, a 5% resolving 
gel and a 10% stacking gel was casted according to Table 30 and Table 31. 10µg of total 
protein was mixed with 4x Laemmli-buffer and incubated at 95°C for 5min, followed by 
centrifugation at 4°C and maximum speed and incubation on ice before loading. 
Denatured protein was loaded and separated at 120V for 1.5h in running buffer. Gel was 
blotted onto a PVDF, which was active for 1 minute in 100% methanol, for 1.5h at 25V. 
Finally, membrane was blocked in 5% low fat milk powder dissolved in TBS-T for 60min 
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at RT before incubation with primary antibody against mouse Igf2bp2 over night at 4°C. 
To this end, the antibody was diluted 1:1,000 in 5% low fat milk powder dissolved in 
TBS-T and 0.01% NaN3. 
After incubation with the primary antibody, membrane was washed thoroughly 
in TBS-T, followed by incubation with secondary antibody coupled to horse-reddish 
peroxidase, raised against host species of first antibody at a dilution of 1:10,000 for 1 
hour at room temperatur. Finally, membrane was washed and secondary antibody was 
detected by incubation with Western Lightning Plus-ECL for 1min using the Gel 
documentation station.  
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Table 30 | Reagents and concentrations for the production blotting buffer as well as the resolving and 
stacking gel for Western blot 
Puffer Reagent Final concentration 
RIPA buffer NaCl 150mM 
 Tris 50mM 
 Nonident P-40 1% 
 Na-Deoxycholate 0.5% 
 SDS 1% 
Blotting buffer Tris 25mM 
Glycin 150mM 
(methanol) 10% 
(20% SDS) 1% 
10x PBS-T-buffer KCl 27mM 
NaCl 1,37M 
Tween 20 0,5% 
Na2HPO4 100mM 
KH2PO4 20mM 
2x Loading Dye 20% SDS 4% 
Glycerol 20% 
Beta-Mercaptoethanol 10% 
Bromphenolblau 0,004% 
Tris 125mM 
10x TBS-T-buffer 1M Tris/HCL pH 7,5 100mM 
 NaCl 1,5M 
 Tween 20 0,5% 
LGP (lower gel buffer): Tris 1,5M 
 20% SDS 0,4% 
UGP (gel buffer):upper  Tris 0,5M 
 20% SDS 0,4% 
10xSDS Running buffer Tris 25mM 
 Glycin 190mM 
 20% SDS 1% 
10% APS 1g per 10mL 10% 
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For the western blot of Igf2bp2, a 10% resolving gel was used. 
5.2.1.6 Cloning of the barcode casseXe containing p902 target vector 
The p902 target vector was cloned from the p612 vector by inserting the barcode 
cassettes upstream of the pLVX promoter. Barcode cassettes were amplified from the 
Cellecta pRSI6 shRNA library using the PW_C_BAR_Cla1_f/r primers, followed by 
purification with the PCR purification kit (Qiagen). Next, PCR products were digested 
with ClaI and ligated into ClaI-linearized p612 vectors. Finally, ligation product was 
transformed and spread on LB-Agar plate to pick single colonies. (Note that every colony 
represents a unique barcode). Successful insertion as well as barcode sequence was 
monitored by sanger sequencing. 
5.2.1.7 Synthesis of candidate gene cDNAs and cloning into p902 target 
vector 
The cDNA sequences were accessed for the GRCm38 mouse genome from 
Ensemble (https://www.ensembl.org/index.html), choosing those isoforms with 
available protein (CCDS) sequence. All cDNA sequences were equipped with a BamHI 
recognition sequence followed by a Kozak sequence ultimately before the start codon as 
well as a Sbf1 recognition site ultimately after the stop codon. (cDNAs with colour coded 
recognition sites as well as start and stop codons are supplied in the Appendix. All cDNAs 
were synthesized by GeneArt (ThermoFisher) and codon optimized for enhanced 
transcription and translation using a software implemented algorithm. Next, cDNAs 
were amplified from transfer vector (Table 10) using standard protocols for bacterial 
transformation, cultivation and plasmid isolation. cDNAs were extracted from plasmids 
through digestion with BamH1 and Sbf1, followed by gel extraction using the QIAquick 
Gel extraction Kit (Qiagen). Finally, p902 plasmids were linearized using BamHI and SbfI 
Table 31 | Volumes used for resolving and stacking gel 
1x resolving gel 5% 7,5% 10% 13% 15% 18% 1x stacking gel 5% 
LGB (Lower Gel Buffer) in mL 2 2 2 2 2 2 UGB (Upper Gel Buffer) in mL 1,2 
H2O in mL 4,6 4 3,3 2,5 2 1,2 H2O in mL 3 
30% Acrylamid in mL 1,3 2 2,6 3,4 4 4,8 30% Acrylamid in mL 0,8 
10% APS in µL 50 50 50 50 50 50 10% APS in µL 50 
TEMED in µL 5 5 5 5 5 5 TEMED in µL 5 
Material and Methods 
123 
 
restriction enzymes and cDNA fragments were ligated into the vector. Correct insertion 
and sequence integrity was monitored through sanger sequencing. 
5.2.1.8 Barcode ampliﬁcaOon followed by high-throughput sequencing 
In order to assess barcodes in transduced cells, cells were isolated and washed in 
PBS followed by centrifugation at 10,000 rpm for 10 minutes. After quantitative removal 
of supernatant, cells were directly lysed in a PCR compatible buffer (10mM Tris-HCl at 
pH7.5-pH7.5, 50mM NaCl, 6.25mM MgCl2, 0.045 % IGEPAL CA-630, 0.45% Tween-20, 
freshly added proteinase K to 1μg/μL) at 56°C for 60 minutes followed by a proteinase K 
inactivation step at 98°C for 10 minutes. Samples were either used directly or stored at -
80°C until further usage. To amplify the barcode sequence, two nested PCRs were 
conducted as displayed in Figure 17, using the volumes and condition depicted in 
Table 32 and Table 33. After both nested PCRs, multiplexed samples were pooled and 
purified using the QIAquick Gel extraction Kit (Qiagen). Finally, samples adjusted to a 
molar concentration of 10nM (~1ng/µL) using the Qubit (Thermo Fisher) along with the 
DNA high sensitivity detection kit and subsequently sequenced using the Illumina HiSeq 
2000 platform with V4 reagents at the DKFZ Genomics and Proteomic Core Facility using 
the pRSI9_GexSeqN primer and Illumina standard sequencing primers. FASTA files were 
de-multiplexed by the DKFZ Genomics and Proteomic Core Facility and barcode 
sequences were retrieved and counted using the edgeR package (Dai et al., 2014). 
Table 32 | 1st PCR during nested PCR for barcode amplification 
Reagent Volume [µL]  Step Temp [°C] time [s] # 
H2O 30.5  Initial denaturing 94 180 1 
10x Ti-Taq Buffer 5  Denaturing 94 30 2 
FwdHTS (10µM) primer 1.5  Annealing 60 10 3 
deltaP5_1stPCR_R primer 1.5  Elongation 72 20 4 
dNTPmix (10µM each) 1  ----------- Repeat #2-4 18x ----------- 
Titanium Taq polymerase 0.5  Elongation 68 120 5 
Sample (direct lysis) 10  Storage 8 Infinite 6 
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Table 33 | 2nd PCR during nested PCR for barcode amplification 
Reagent Volume [µL]  Step Temp [°C] time [s] # 
H2O 26  Initial denaturing 94 180 1 
10x Ti-Taq Buffer 5  Denaturing 94 30 2 
FwdGex (10µM) primer 2.5  Annealing 60 10 3 
Illu_pRSI9_X (2.5µM) primers  10  Elongation 72 20 4 
dNTPmix (10µM each) 1  ----------- Repeat #2-4 22x ----------- 
Titanium Taq polymerase 0.5  Elongation 68 120 5 
Sample (direct lysis) 5  Storage 8 Infinite 6 
Illu_pRSI9_X is one of 96 multiplexing primers from Table 23. 
5.2.1.9 Cell culture 
Culturing and passaging 
HL60rtTA cells were cultured in RPMI supplemented with 10% FBS and 1% 
glutamine and passaged through centrifugation at 150g for 5min at room temperature 
(RT). HEK293T cells were cultured in IMDM supplemented with 10% FBS and 1% 
glutamine (complete medium) and passaged by gently washing the plates with PBS, 
followed by incubation with 0.025% trypsin at 37°C until cells were fully detached. Next, 
trypsin was block using complete medium and centrifuged at 150g for 5min at room 
temperature (RT). LSKRosa26 rtTA or LSK-SLAMRosa26 rtTA cells were cultured in StemSpan 
medium supplemented with 1% P/S, 100ng/mL rmSCF, 100ng/mL Flt3 Ligand, 100ng/mL 
rmTPO and 20ng/mL rmIL3 and passaged through centrifugation at 150g for 5min at 
room temperature (RT). All cells were cultured in humidified incubators at 37°C and 5% 
CO2.  
Freezing and storage 
Vital freezing of HEK293T cells was performed after washing, detaching and 
centrifugation as described above, followed by re-suspension in complete medium with 
the addition of 10% DMSO. Subsequently, cell suspension is cooled down gradually in 
a -80°C freezer inside a MrFrosty container. HL60rtTA cells were frozen as described 
above, without the detaching step. Fully frozen samples were transferred to liquid 
nitrogen tanks for long-term storage. 
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5.2.1.10 Virus producOon 
Production of lentiviral particles for candidate gene overexpression was usually 
performed in 15 x 15cm plates seeded with 1 x 107 low-passage HEK293T cells at day 1. 
After 24h, medium was replaced with fresh medium, followed by transient 
co-transfection of cells. To this end, plasmids were mixed according to Table 34 and 
topped off with IMDM without supplements to a total volume of 500µL. Plasmid/IMDM 
solution was filtered sterile using a 0.22µm filter. Separately, 500 µL IMDM was mixed 
with polyethylenimine (PEI) at a concentration that the final ratio between µg DNA and 
µg PEI is 1:3. Plasmid/IMDM and PEI/IMDM solutions were mixed and thoroughly 
vortexed before incubation for 15-30 minutes. Subsequently, DNA/PEI/IMDM solution 
was applied dropwise to 15cm plates with as little disturbance of PEI:DNA complexes as 
possible through i.e. additional mixing etc. After 12h, medium was replaced. Virus 
containing supernatant was harvested 24h, 48h and 72h after changing the medium and 
filtered through a 0.22µm filter. Up to 35mL of supernatant were transferred to an 
ultra-centrifuge tube and centrifuged for 2h at 20,000 rpm at RT. After centrifugation, 
supernatant was discarded and viral pellets were carefully resuspended in 50uL PBS or 
StemSpan without supplements and pooled into a 1.5mL Eppendorf tube. Finally, the 
virus concentrate was mixed on a rotary stand for 20 minutes at RT, aliquoted into 0.5 
mL Eppendorf tubes and stored at -80°C until use. 
Table 34 | µg plasmids used per 15cm dish. 
Plasmid  Genes  μg 
LV101  gag-pol  12.5  
LV102  rev  6.25  
LV103  vsv-g  9  
p902  GOI  32  
 
5.2.1.11 LenOviral Oter calculaOon 
In order to calculate the number of transducing units (TU) particles per volume, 
5 x 104 HL60rtTA cells were re-suspended in 500µL RPMI with supplements and plated 
into 6-well plates. 500µL virus dilution were made in 1:10 steps using RPMI with 
supplements plus 16µg/mL protamine sulfate and 2 µg/mL doxycycline (DOX), resulting 
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in dilutions of 1:200, 1:2,000, 1:20,000 and 1:200,000. Next, 500µL virus dilutions were 
placed into each well resulting in a 1:2 dilution. After 12-16h, 1mL of fresh medium was 
added to each well and GFP was measured 48 after transduction. Finally, the number of 
infectious viral particles per mL is calculated using Equation 1, considering only GFP+ 
percentages below 20%.  
 
Equation 1 | Calculation of virus titer 
Titer 	
⁄  = 50,000 ×%100 × 	 !"# 
 
5.2.1.12 LenOviral transducOon of LSKRosa26 rtTA or LSK-SLAMRosa26 rtTA cells 
Before transduction, LSKRosa26 rtTA or LSK-SLAMRosa26 rtTA cells were cultured as 
described above, or re-suspended in transduction media (see below) after sorting. The 
multiplicity of infection (MOI) ranged between 20-80, however was kept below 25% 
GFP+ cells to prevent multiple integrations per cell. Cells were transduced in U-bottom 
96-well plates with approx. 100,000 cells per well and re-suspended in 200µL IMDM plus 
supplements and 8µg/mL protamine sulfate. Culture medium was changed by 
centrifugation of the 96-well plate at 150g and RT for 5 minutes, followed by careful 
aspiration of the supernatant. Cells were cultured at least for another 24h before cell 
counting or flow cytometry analysis and proceeding with subsequent experiments 
(5.2.1.13, 5.2.1.14, 0).  
5.2.1.13 Colony forming unit assay 
For colony forming unit (CFU) assays promoting erythro-myeloid differentiation 
(MethoCult™ GF M3434, Stem Cell Technologies) LSK-SLAMRosa26 rtTA cells were 
transduced as described in (0). Subsequently, cells were washed with StemSpan medium 
including supplements and cultured for additional 72h in the presence of 1µg/mL DOX. 
Next, cells were flow cytometry sorted sorted for GFP directly into StemSpan medium 
without supplements, pelleted at 150g for 5min at RT and re-suspended in MethoCult™ 
GF M3434 supplemented with 1% P/S and 1µg/mL DOX at a concentration of 1,200 cells 
per 3mL. Cells were cultured for seven days. Subsequently, cells were washed off the 
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plates by diluting the semisolid medium with PBS and FACS sorted again for GFP+ cells. 
For the second culture period, 10,000 GFP+ cells were plated per 3mL dish and culture as 
described above and cultured for another 8 days. For the third culture period, cells were 
again re-suspended in PBS, not sorted for GFP because of the near-100% GFP positivity, 
re-plated again at a concentration of 100,000 cells per 3mL of MethoCult™ GF M3434 
and cultured for another 13 days. Colonies were counted before every replating under a 
light microscope at 40x magnification. Cell leftovers were kept before 1st plating and for 
every re-plating step for BC amplification and sequencing.  
5.2.1.14 Cell trace assay 
For the cell trace assay, 4 x 105 LSKRosa26 rtTA cells from donor Rosa26 rtTA mice 
were transduced as described above (0) after splitting the cells into 1/3 GFP pool and 2/3 
GOI pool cells. Next, transgene expression was initiated by adding 1µg/mL DOX to 
StemSpan with supplements and cells were stained with CellTrace™ violet according to 
the manufacturers protocol. Stained cells were cultured for 3 or 5 days, respectively, and 
finally sorted into fast (weakest signal intensity) intermediate fast, intermediate slow 
and slow (highest signal intensity) cycling cells. Lastly, cell were lyzed and BCs were 
amplified and sequenced. 
5.2.1.15 Fluorescence acOvated cell analyzing and sorOng 
Cell populations were sorted and analyzed using either the LSR II or Aria II from 
Becton Dickinson (BD). To this end, cells were labelled using FACS antibodies and 
fluorochrome combinations as described in 5.1.7 for 30min on ice with the addition of 
1µg/mL FluoroGoldTM (Hydroxystilbamidine bis(methanesulfonate). Before sorting, cells 
were washed and re-suspended in Hanks balanced salt solution containing 2% FBS and 
filtered through a 85µm strainer. LSKRosa26 rtT or LSK-SLAMRosa26 rtT cells were either sorted 
directly into StemSpan or Hanks balanced salt solution containing 2% FBS. Cell 
populations were distinguished using the following surface marker combinations listed 
in Table 35. 
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Table 35 | Surface marker combinations for the identification of immunophenotypic cell populations 
Abbreviation Cell type Source Cell surface combinations 
LSK 
Hematopoietic stem and progenitor 
cells 
BM Lineage+, CD117+, Ly6A/E+ 
LSK-SLAM Hematopoietic stem cells BM 
Lineage+, CD117+, Ly6A/E+, 
CD150+, CD48- 
Granu Granulocytes PB CD11b+, Ly6G+ 
Macro/Mono/DC 
Macrophages, Monocytes, Dendritic 
cells 
PB CD11b+, Ly6G- 
Ery Erythroid progenitor cells PB Ter119+ 
T cells T cells, peripheral blood PB CD3+ 
CD4 
CD4 positive T cells (mature T helper 
cells) 
PB CD3+, CD4+ 
CD8 CD8 positive T cells (cytotoxic T cells) PB CD3+, CD8+ 
B cells B cells, peripheral blood PB CD45R+ 
 
5.2.2 Mouse experiments 
5.2.2.1 HarvesOng of bone marrow samples for the isolaOon of 
hematopoieOc stem and progenitor cells 
After mice were euthanizing the mice by cervical dislocation, hind legs, hip and 
spine bones (femur, tibia; ilium; spina) were harvested and cleaned from muscle tissue. 
Next, bones were crushed in Hanks balanced salt solution containing 2% FBS using pistil 
and mortar. Bones were rinsed until white and cell suspension was filtered through a 
70µm strainer. Cells were depleted from differentiated lineage cells using the EasySep™ 
Mouse Hematopoietic Progenitor Cell Isolation Kit (StemCellTechnologies) according to 
the manufacturers’ protocol and finally stained with antibodies according to Table 15 
flow cytometry sorted.  
5.2.2.2 Acquiring of blood samples from transduced mice 
Approx. 200µL of peripheral blood samples were taken every four weeks from 
transduced mice by punctuation of the vena saphena and collected in EDTA tubes 
(Microvette CB 300 K2E). Before staining for FACS or aliquotation for direct lysis and BC 
amplification, erythrocytes were lysed twice by incubation with red blood cell lysis buffer 
for 5minutes each at RT. Cells were washed with Hanks balanced salt solution containing 
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2% FBS and ¼ was pelleted at 10,000 rpm for 5min and 4°C and subjected to direct lysis. 
The remainder was stained for flow cytometry sorting according to Table 17 
5.2.2.3 Bone marrow transplantaOons 
Approx. 24h before bone marrow transplantations, mice were lethally irradiated 
with 950cGy separated into two irradiation sessions. Transduced LSK cells were injected 
into the tail vein, which was dilated beforehand using infra-red light. In order to prevent 
immunogenic reactions against the transplant, cells were thoroughly washed with pure 
PBS to eliminate potential traces of FBS or cytokines. 
5.2.3 PaOent integraOon site data sample collecOon from WiskoX-Aldrich 
syndrome gene therapy study 
For biosafety reasons, integration site (IS) data for all patients in the 
Wiskott-Aldrich syndrome (WAS) study was collected over a period of 6 years (Sample 
collection, ISs retrieval and mapping performed in the group of Manfred Schmidt, DKFZ 
and Genewerk, Heidelberg, Germany) (Boztug et al., 2010; Braun et al., 2014). In brief, 
10 male patients between 2 to 14 years old received autologous bone marrow 
transplants using rhG-CSF and plerixafor (n = 8) or G-CSF (n = 2) mobilized CD34+ cells. 
The number of infused cells ranged from 9.7 x 106 to 24.9 x 106 cells/kg for 9 out of 10 
patients. Only patient 3 received significantly less cells (2.9 x 106 cells/kg) due to 
inefficient mobilization and leukopheresis. Depending on the patients weight, the total 
amount of infused CD34+ cells varied between 2.05 x 109 to 6.99 x 109 cells (patient 3: 
3.3 x 106 cells, median all patients: 3.5 x 109). This equals to approx. 20,565 to 69,877 
LT-HSCs per patient (median: 35,633; sum: 369,686), assuming a LT-HSC frequency of 
0.01% within CD34+ cells (Biasco et al., 2016; Kim et al., 2014). Amplification and 
detection of γRV ISs from genomic DNA was done by linear-amplification-mediated PCR 
(LAM-PCR) as described before (Boztug et al., 2010; Schmidt et al., 2007). For more 
detailed information about patients see Braun et al. (2014) and Boztug et al. (2010). 
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The following paragraphs on computational analysis of the material and methods part 
contain text sections that have been taken from Wünsche et al. (2018) and have been 
originally written by myself. All literal quotes are indicated by quotation marks (” … “), 
following the guidelines of good scientific practice of the  
Ruperto-Carola University of Heidelberg. 
 
5.2.4 ComputaOonal analysis 
5.2.4.1 AcquisiOon of datasets used in this study 
“Pre-transplant ISs positions from CD34+ cells as well as post-transplant positions 
from CD34+ cells transplanted into NSG mice and analyzed 2 month later were 
downloaded as supplemental data from the original publication (De Ravin et al., 2014). 
Pre and post-transplantation ISs positions from the ADA-SCID gene therapy trail on five 
patients followed up to 47 months after transplantation were acquired from the 
supplement from the original publication (Aiuti et al., 2007). IS positions from K562 and 
HepG2 cells were taken from (LaFave et al., 2014) and downloaded from 
https://research.nhgri.nih.gov/software/GeIST/download.shtml. Fast ATAC-seq as well 
as RNA-seq data of 13 primary cell types were downloaded as supplementary tables 
from (Corces et al., 2016). RNA-seq raw counts were converted to transcripts per million 
(TPM) using a custom python script and normalized using the R package DEseq2 (Love et 
al., 2014). Significant Capture Hi-C interactions were downloaded from ArrayExpress 
database under accession E-MTAB-2323. ChIP-seq data from CD34+ cells were 
downloaded from NCBI GEO under the accession GSM706845, GSM772865, 
GSM772870, GSM772938, GSM772951, GSM773041. GWAS SNPs were downloaded 
from the NHGRI-EBI Catalog of published genome-wide association studies 
(https://www.ebi.ac.uk/gwas/) as “All associations v1.0”. Common SNPs with no 
reported phenotype were downloaded from NCBI Variation resource as SNPs in VCF 
format. Topologically associated domains were downloaded from NCBI GEO under the 
accession number GSE63525 as “Arrowhead_domainlist” and CTCF sites were 
downloaded from NCBI GEO under the accession number GSM2861703 as a BigWig file 
and further processed as described below. All datasets were downloaded for the hg19 
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(GRCh37) build or converted to hg19 using the liftOver utility with default settings from 
UCSC (https://genome.ucsc.edu/cgi-bin/hgLiftOver).” 
5.2.4.2 Cluster analysis for the selecOon of candidate genes 
Before the use of the ClusterCount function as described below, the local 
accumulation of patient ISs (common integration site; CIS) and their closest TSS was 
assessed using the Cyctoscape software (version 2.8.3; www.cytoscape.com) with the 
addition of a plugin which was kindly provided by Raffaele Fronza (NCT/DKFZ 
Heidelberg). Here, the threshold for the minimal distance between two ISs within the 
same CIS was set to 10kb and the maximum distance from the boundary of the CIS to 
the nearest TSS was set to 50kb.  
5.2.4.3 Centered distance of ISs to TSSs and percentage of genes 
tagged by IS 
Transcription start site (TSS) positions for protein-coding, lincRNA and miRNA 
genes for hg19 / GRCh37 were downloaded from Ensembl Biomart and distance for each 
IS to the nearest TSS was calculated. To calculate the percentage of genes tagged by IS, 
genes were segregated by gene class and genes with at least one IS in a 10 kb window 
around the TSS were considered tagged. Data for both analyses were visualized using 
ggplot2 for R. 
5.2.4.4 Rainfall plots 
Distance between patient ISs and number matched ISs from CD34+ cells was 
calculated using the imd function from the ClusteredMutations package for R. ISs 
contained in the 100 biggest clusters were labeled and results were plotted using 
ggplot2 for R (see Table 27). 
5.2.4.5 Cluster predicOon 
For all bioinformatical analysis except the candidate gene selection – the clusters 
were predicted using the ClusterCount function (provided with the Appendix) with the 
maximum distance between two consecutive ISs set to 2500 bp and the minimum 
amount of ISs per cluster to 10 IS, unless stated otherwise.  
5.2.4.6 Overlap of ChIP-seq signal and IS posiOons  
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“The enrichment of histone marks was calculated as the percentage of all 
ChIP-seq reads which contain at least one IS. Plots were drawn using ggplot2 for R.” 
5.2.4.7 Pearson correlaOon and PCA 
The similarity of all IS datasets was assessed using Pearson correlation and PCA. 
Therefore, the genome was divided into 10kb bins and ISs were counted for each bin. 
Because of the differently sized datasets CD34+, K562, and HepG2 cells, datasets were 
randomly sampled to match the number of WAS ISs (130,673) 1,000 times and ISs per 
bin were counted for each sampling. Subsequently, the mean for each bin was calculated 
and Pearson correlation using the cor function for R with missing values handled by 
casewise deletion (use=”complete”). Datasets were ordered according to the principle 
component 1 from the PCA analysis. For the PCA, data was scaled and centered and the 
calculation was performed using the prcomp function in R. Data was visualized with 
ggplot2 for R (see Table 27). 
5.2.4.8 EsOmaOon of hematopoieOc switch a_er transplantaOon using 
pairwise posiOve associaOon matrix 
“The calculation of the positive association matrices for each patient was 
adapted from (Biasco et al., 2016). In brief, odds ratios (OR) were calculated from 
binarized values for ISs (1 detected or 0 not detected) for each combination of two time 
points , $ per patient […]” as described below in Equation 2. 
 
Equation 2 | Calculation of odds ratios between patient samples  
%&'( = )*+' = 1 ∧ *+( = 1/)*+' = 1 ∧ *+( = 0).*+' = 0 ∧ *+( = 1//)*+' = 0 ∧ *+( = 0 
 
“Time points with positive correlation take OR indices from (1;∞) while negative 
associations range from (0;1). For heatmaps, only OR≥1 were used, infinite values 
(diagonal) and values below 1 were set 1. The heatmap was drawn with the R package 
gplots with color intensities being proportional to log2(OR). Note that data was not 
hierarchically clustered but ranked for sequencing time point, to allow for a visual 
identification of a change in association.” 
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5.2.4.9 Comparison of cluster dimension and sizes between IS datasets 
“Median cluster size (number of ISs per cluster) and cluster dimension (cluster 
span in bp) was determined for all in vitro data sets and WAS ISs using the ClusterCount 
function in R. For cluster prediction, the maximum distance (d) between the lagging and 
the leading IS in two consecutive cluster was set to 2.5kb and the minimum cluster size 
to 10 ISs per cluster. Datasets were randomly sampled 1,000 times to match the 
numbers of ISs between in vitro data sets or early and late WAS ISs. A two-sample 
Wilcoxon signed-rank test was performed to test for significant differences between 
WAS patients and each matched sampling of the corresponding in vitro dataset. 
Figure 31 shows cluster size and dimension for one representative sampling and the 
median p-value of 100 samplings.” 
5.2.4.10 Assessment of growth kineOcs to address the frequency of 
overproporOonal clonal expansion 
“The closest gene for every unique IS at a given sequencing time point was 
determined using 159,884 TSS positions (corresponding to 30,381 genes) that were 
downloaded from BioMart for hg19/GRCh37 for protein-coding genes, miRNAs and 
lincRNAs. Next, the area under the curve (AUC) was calculated for all genes with more 
than 50 ISs per gene as described […]” in Equation 3 “[…] below, where 3' , … , 35 
describes the sequencing time point and  3' the corresponding cumulative number of 
IS. To compensate for non-Gaussian distribution, AUCs were logarithmized and mean 
and standard deviation were calculated. Next, the 95% confidence interval was 
calculated and subsequently back transformed. Finally, genes with an AUC outside the 
95% confidence interval were marked and denoted with a red line. Plots were drawn 
with base R and ggplot2.” 
 
Equation 3 | Calculation of area under the curve 
AUC = 93': − 3' 3'
5<:
'=:
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5.2.4.11 Fisng the mean of the log2 odds raOo using a 4-parametric 
log-logisOc model 
“First, the mean of all log2 odds ratios (OR) between a given sample and all 
corresponding samples and/or time points was calculated for all patients (mean log2 OR 
for every column of the positive association heatmap). Next, curve fitting was performed 
using the “drm” function from the DRC package for R (Ritz et al., 2015). Next, the onset 
of stable hematopoiesis was estimated empirically for the most robustly sequenced 
patients 1 and 2 so that the turning point matches the onset observed in the heatmap 
and set to 30% of the functions maximum. Finally, the same 30% were applied to all 
remaining patients that had sufficient data for the curve fitting. The exact computed 
switch time points for patients with sufficient data are listed in Table 4. For patients 3, 6, 
7 and 10, the median switch date of 404 days was used, which was calculated from 
Patients 1, 2, 4, 5, 8, and 9.” 
5.2.4.12 Assessment of ATAC-seq signal and gene expression at sites of 
integraOon 
“Clusters of ISs were predicted as described above and assigned to its closest 
gene using 159,884 TSS positions (corresponding to 30,381 genes) that were 
downloaded from BioMart for hg19/GRCh37 for protein-coding genes, miRNAs and 
lincRNAs. Next all clusters belonging to the same gene were aggregated and the sum of 
ISs was plotted against TPM gene expression with ggplot2. For the median expression of 
all IS-tagged genes, TPMs were extracted for all 13 primary cell types and plotted as 
violin plot using ggplot2. Pairwise statistical comparison was performed using a 
two-sample Wilcoxon signed-rank test. For the median signal intensity at sites of 
integration, either all ATAC-seq signals or signature peak ATAC-seq signals were 
normalized using the “normalize.quantiles” function from the preprocessCore package 
for R, and extracted in a genomic window of 1kb around all IS. CD34+ ISs were randomly 
sampled 1,000 times to correct for the lower number of WAS IS. Signal intensities were 
plotted for all IS-containing ATAC-seq peaks as boxplots using ggplot2 and pairwise 
statistical comparison was performed using a two-sample Wilcoxon signed-rank test.” 
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5.2.4.13 DiﬀerenOally tagged Ggnes between CD34+ cells and paOents 
and gene set enrichment analysis 
“Differential number of ISs per gene was calculated by first determining cluster 
positions and number of ISs per cluster as described above for late occurring ISs and 
CD34+ cells (maximum distance: 2,500bp; minimum number of ISs per cluster: 10). ISs 
from CD34+ cells were randomly sampled 1,000 times to match the lower number of ISs 
from patients, and clusters were allocated to its closest gene for each iteration as 
described above, followed by aggregation of clusters marking the same gene. Next, 
genes were dismissed which were tagged by clusters at a lower frequency than the 
mean number of genes tagged for each iteration. Finally, pairwise comparison was 
performed by subtracting (difference) or dividing (fold change) the mean sum of CD34+ 
ISs from the sum of late occurring WAS ISs for each gene. In order to calculate fold 
changes for genes that have 0 ISs in either dataset, one pseudo IS was added to all 
genes. For gene set enrichment analysis (GSEA), only genes showing a difference > 10 or 
< -10 ISs were used to filter out genes that only show a minor difference between ISs 
from CD34+ cells and WAS IS. […] Next, the log2 fold changes were used and matched to 
the C2 curated gene set v6.0 from the Molecular Signatures Database (MSigDB) 
alongside with 20 custom gene sets generated from Cabezas-Wallscheid et al. (2014). 
The GSEA analysis was conducted using the piano package in R (Varemo et al., 2013) 
with arguments set to signifMethod = "nullDist", geneSetStat = "page", and adjMethod = 
"fdr". The network was generated using the piano package on HSC relevant gene sets 
using the standard parameters. Genes contained in network gene sets were extracted, 
sorted according to p-value of the gene set and log2 fold change and plotted as heatmap 
using ggplot2.” 
5.2.4.14 Assessment of acOvity of MYC enhancer modules using WAS ISs 
“Genomic positions of BENC modules were taken from Bahr et al. (2018) and 
slightly expanded to fit the ATAC-seq pattern of HSCs: A/B = chr8:130555999-
130575896; C/D = chr8:130592385-130606829; G/I = chr8:130675980-130700504. 
Genomic positions of modules X1, X2 and X3 were set to match the ATAC-seq signal in 
HSC and the IS pattern observed. X1 = chr8:130429984-130436953; X2 = 
chr8:130546989-130552736; X3 = chr8:130652912-130657000. ISs were extracted given 
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genomic ranges and duplicates were discarded by retaining the IS (clone) that was 
sequenced at the last time point. ISs were categorized into early and late with the 
patient specific cut off plotted according to their sequencing time point using ggplot2.” 
5.2.4.15 Enrichment of ISs in CHi-C interacOon fragments 
“As the CHi-C fragments from (Mifsud et al., 2015) were generated using the 
HindIII restriction enzyme, we first digested the hg19 genome in silico using the HindIII 
restriction enzyme, through a custom Java script and hg19 fasta files from 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/chromosomes/). Next, contingency 
tables were produced by determining the number of HindIII fragments that either 
interact but do not harbor any IS, harbor ISs but do not interact, neither interact nor 
harbor any IS, or harbor both, interaction and IS. Expected values and significance were 
calculated using a Chi-square test with Yates’s correction for continuity for R and plotted 
using ggplot2.” 
5.2.4.16 GWAS and common SNP enrichment analysis 
“In total 33,044 GWAS SNPs and 38,138,476 common SNP were downloaded as 
described above. GWAS SNPs from non-European studies as well as chromosomal 
translocations and abnormalities were filtered out in order to match the genetic 
background of the patients with the data, yielding 24,434 remaining GWAS SNPs. Next, 
the overlap of GWAS SNPs and IS positions (±2.5kb) or the same quantity of randomly 
sampled common SNPs and the same IS positions, respectively. The significance of 
difference was estimated by Chi-squared test, using the mean overlap of 1,000 random 
samplings from common SNPs vs. the overlap of GWAS SNPs. Next, GWAS SNPs were 
classified into 17 categories, adapted from Mifsud et al. (2015) and Maurano et al. 
(2012) […]. The categorical enrichment was calculated as the percent overlap of the 
categorical GWAS SNPs subtracted by the mean percent of overlapping GWAS SNPs. 
Statistical significance was calculated using the Fisher's exact test by comparing the 
overlapping and the non-overlapping GWAS SNPs of each category with all 
un-categorized overlapping and non-overlapping GWAS SNPs.” 
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5.2.4.17 Circularized view of CD34+ capture Hi-C long-range interacOons 
and WAS ISs and WashU epigenome browser custom track 
For the publication (Wünsche et al., 2018), “circular plots including CHi-C 
interactions and patient ISs […]” were prepared and “[…] can be accessed using the 
Capture HiC Plotter (Schofield et al., 2016) (https://www.chicp.org/). Additionally, a 
Washington University EpiGenome Browser session (ID wgTns1P1rr) is available for 
displaying fully analyzed data for number matched patient and CD34+ IS, CD34+ CHi-C 
interactions, ATAC-seq peaks of 13 primary cell types and ChIP-seq data for selected 
histone modifications in CD34+ cells.” 
5.2.4.18 Sequence conservaOon at sites of integraOon 
“PhastCons and PhyloP scores for multiple alignments of 45 primates to the 
human genome (46way) were downloaded as fixed step wiggle files from UCSC for the 
hg19 genome build. First, files were converted to bigwig format using the wigToBigWig 
and subsequently converted to bedGraph file using the bigWigToBedGraph utilities 
(http://hgdownload.cse.ucsc.edu/admin/exe/). After converting all data into 1-based 
positions, both phastCons and phyloP scores were extracted chromosome wise for IS, 
GWAS SNP, as well as common SNP positions. Statistical differences were determined 
for each chromosome using a two-sample Wilcoxon signed-rank test comparing WAS ISs 
and GWAS SNPs, common SNPs as well as 1 x 106 randomly extracted scores. Likewise, 
scores for all positions 250 bp upstream as well as 250 bp downstream were extracted. 
Finally, the mean score for all IS, GWAS SNPs or common SNPs at every basepair 
coordinate was calculated and plotted. Statistical comparison was only performed at the 
actual position of ISs or SNPs and is presented as the median p-value for all 
chromosomes.” 
5.2.4.19 PermutaOon test to assess the enrichment of ISs at TAD 
boundaries 
“As a control 10,000 random TADs were created from the original TADs from Rao 
et al. (2014) using “shuffle” from bedtools 2.26.0 with arguments set to –excl –chrom –
noOverlapping –allowBeyondChromEnd, where –excl depicts all hg19 genome gaps 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/gap.txt.gz). Next, TAD 
boundaries were created by extending both, the start and the end coordinates of a TAD, 
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by ±2.5kb. Finally, the percentage of overlap for all 10,000 random TAD boundaries was 
assessed and plotted as a histogram using ggplot2. The p-value is calculated by dividing 
the number of events where the overlap is either greater (depletion) or smaller 
(enrichment) than the actual overlap, by the number of permutations.” 
5.2.4.20 PermutaOon test to assess the enrichment of ISs at CTCF sites 
from CD34+ cells 
“First, the bigwig file was converted to BedGraph using the bigWigToBedGraph 
binary from http://hgdownload.cse.ucsc.edu/admin/exe/linux.x86_64/bigWigToBedGra
ph and peak calling with MACS2.1.1 (Liu, 2014) was performed using the bdgpeakcall 
function with minimum gap (-l) set to 50bp and default max gap (-g; 30bp). Next, peaks 
were filtered for in silico predicted CTCF binding sites generated for hg19 using the 
probability matrix from JASPAR (http://jaspar.genereg.net/matrix/MA0139.1/) and FIMO 
(http://meme-suite.org/tools/fimo) with default settings, resulting in approx. 31,000 
high confidence CTCF peaks in CD34+ cells.” 
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9 APPENDIX 
9.1 List of ﬁgures 
Figure 1 | Hierarchical organization of the murine and human hematopoietic system. 5 
Figure 2 | Classical and modern models of the hematopoietic tree. 7 
Figure 3 | Model of clonal dynamics after HSPC transplantation. 8 
Figure 4 | Simplified view of the transcription initiation. 10 
Figure 5 | Gene regulation through enhancer mediated transcription. 12 
Figure 6 | Different modes of action of TADs in genome regulation. 14 
Figure 7 | TAD and TAD boundary properties including enrichment of various genomic features. 15 
Figure 8 | Overview of Roadmap Epigenomics 18-state expanded model ChromHMM chromatin states.
 19 
Figure 9 | Cell and nuclear entry paths of LV and γRV. 24 
Figure 10 | Specific chromatin states are deterministic of the location of viral ISs (Legend continued on 
next page). 25 
Figure 11 | Overview of retroviral insertional mutagenesis mechanisms. 27 
Figure 12 | Genetic correction of diseased hematopoietic stem cells and subsequent monitoring of the 
patients in a clinical gene therapy trial. 32 
Figure 13 | Schematic overview of genetic loci containing γRV ISs and terminology/parameters used for 
the characterization of clusters and statistic filtering for potential regulatory genes. 33 
Figure 14 | Top 100 largest CIS and their associated gene with indicated proportion of every patient. 34 
Figure 15 | Expression pattern of candidate genes. 36 
Figure 16 | Lentiviral-mediated candidate gene overexpression. 38 
Figure 17 | Detailed representation of the HT-seq barcode cassette with multiplexing PCR step. 39 
Figure 18 | Matrix experiment to evaluate any potential index bleeding (Legend continued on next 
page). 40 
Figure 19 | Evaluation of index bleeding. 41 
Figure 20 | Relation between construct size and virus titer. 42 
Figure 21 | Assessment of GFP and BC stability over time in vitro. 43 
Figure 22 | Serial replating of transduced LSK-SLAM cells in semisolid medium (Legend continued on 
next page). 46 
Figure 23 | CellTrace assay for the detection of changes in proliferation upon GOI OE (Legend continued 
on next page). 48 
Figure 24 | Relative proportions of read counts for each gene (mean of two BCs) per mouse over time. 51 
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9.4 AbbreviaOons 
Abbreviation Complete term 
3C chromatin conformation capture 
4C chromosome conformation capture-on-chip 
5C chromosome conformation capture carbon copy 
AB Antibody 
ADA-SCID Adenosin-Desaminase - Severe combined immunodeficiency 
AML Acute myeloid leukemia 
AmpR Ampicillin resistance 
ATAC-seq 
Assay for Transposase-Accessible Chromatin with high throughput 
sequencing 
AUC Area under the curve 
B cell B lymphocyte 
B-ALL B-cell acute lymphoblastic leukemia 
BC Barcode 
BENC Blood enhancer cluster 
BM Bone marrow 
bp Basepair 
CD Cluster of differentiation 
CD4 T cell CD4+ T lymphocyte 
CD8 T cell CD8+ T lymphocyte 
cDNA Complement DNA 
CFU Colony forming unit 
CHi-C Capture Hi-C 
ChIP-seq Chromatin immunoprecipitation combined with sequencing 
ChromHMM Machine-learning multivariate hidden Markov model 
CI Confidence interval 
CIS Common integration site 
CLOUD-HSPC 
Continuum of low-primed undifferentiated hematopoietic stem and 
progenitor cells 
CLP Common lymphoid progenitor 
CMP Common myeloid progenitor 
CMV Cytomegalovirus promoter 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CRM cis-regulatory module 
CTCF CCCTC-binding factor 
d  Days 
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DCE Downstream core element 
DHS DNase I-hypersensitive sites 
DKFZ German Cancer Research Centre 
DNA Deoxyribonucleic acid 
DOX Doxycycline 
Env Envelope 
Ery Erythrocytes  
ET domain Extraterminal domain 
ETP Earliest thymic progenitors 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FDR False discovery rate 
FSC Forward scatter 
gag Group specific antigen 
G-CSF Granulocyte-colony stimulating factor 
gDNA Genomic DNA 
GFP Green fluorescent protein 
GMP Granulocyte–monocyte progenitor 
GOI Gene of interest 
GT Gene therapy 
GTF general transcription factor 
GvHD Graft versus Host Disease 
GWAS Genome-wide association studies 
HBS Hank’s balanced salt solution 
Hi-C High-throughput sequencing chromosome conformation capture 
HIV Human Immunodeficiency virus 
HLA human leukocyte antigen 
HSC Hematopoietic stem cell 
HSPC Hematopoietic stem and progenitor cell 
HSZ Hämatopoetischen Stammzelle 
HT-seq High- throughput sequencing 
IL Interleukin 
IN Integrase protein 
Inr Initiator element 
IRES Internal ribosomal entry site 
IS Integration site 
IU Infectious units 
kb Kilobases 
Appendix 
165 
 
LAM-PCR Linear amplification mediated polymerase chain reaction 
LD linkage disequilibrium 
Lin- Lineage negative 
lincRNA Long intergenic non-coding RNA 
LMPP Lymphoid-primed multipotent progenitor 
LSK Lineage negative, Sca-1 positive, c-Kit positive 
LSK-SLAM LSK, CD48 negative, CD150 positive 
LT-HSC Long-term hematopoietic stem cell 
LTR Long terminal repeat 
LV Lentivirus 
MACS Magnetic cell separation 
MEP Megakaryocyte–erythroid progenitor 
miRNA micro RNA 
MLV Murine leukemia virus 
MOI Multiplicity of infection 
Mono Monocyte 
MPP Multipotent progenitor 
mRNA Messenger RNA 
MTW Motif ten element 
ncRNA Non-coding RNA 
NCT National Centre for Tumor Diseases 
ND Not disclosed / Not determined  
NGS Next generation sequencing 
NK cell Natural killer cell 
NPC Nuclear pore complex 
NSG NOD-Scid Il2γc-/- 
nt Nucleotide 
OE Overexpression 
PB Peripheral blood 
PBS Phosphate-buffered saline 
PCA Principle component analysis 
PCR Polymerase chain reaction 
PIC Pre-integration complex 
PrIC Pre-initiation complex 
qPCR Quantitative PCR 
RBC Relative barcode count 
RLD Relative lineage differentiation 
RNA Ribonucleic acid 
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RNAP I, II, III RNA polymerases I, II, III 
RRE Rev-responsive element 
RSV Rous sarcoma virus 
RT Room temperature 
RT-PCR Reverse transcription polymerase chain reaction 
rtTA reverse tetracycline-controlled trans-activator 
SCF Stem cell factor 
SD Standard deviation 
SEM Standard error of mean 
shRNA Short hairpin RNA 
SINE Short interspersed element 
SNP Single nucleotide polymorphisms 
SSC Side scatter 
STARR-seq self-transcribing active regulatory region sequencing 
ST-HSC Short-term hematopoietic stem cell 
T7 T7-RNA-polymerase promotor 
TAD Topologically associated domains 
T-ALL T-lymphoblastic leukemia/lymphoma 
TBP TATA-binding protein 
TF Transcription factor 
TFIIB Transcription factor II B 
TFIIH Transcription factor II H 
TPM Transcript per million 
TPO Thrombopoietin  
TSS Transcription start site 
TX Transplantation experiment 
UbiC Ubiquitin C promoter 
UTR Untranslated region 
WAS Wiskott-Aldrich-Syndrome 
WPRE Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element 
X-SCID X-linked severe combined immunodeficiency 
γRV γ-retrovirus 
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9.5 ClusterCount funcOon for R 
function (pos.is, d) { 
   
  # ClusterCount 
   
  # Counts the number of clusters contained in a vector of IS positions. 
  # ClusterCount has to be performed on single chromosomes. 
  # Clusters comprising identical IS are counted as well. 
  # A cluster must contain at least 2 IS. 
   
  # Args: 
  # pos.is:      A vector of IS positions 
  # d:           Threshold for differences in neighboring IS position used for 
  #                 defining clusters (unit=b) 
   
  # Returns: 
  # A list with five elements: 
  # 1, the number of clusters 
  # 2, the number of IS contained in clusters.  
  # 3, a vector which elements are the length (number of IS) of each cluster 
  # 4, a vector which elements are the dimension of each cluster 
  # 5, a list containing vectors representing all clusters in pos.is 
   
  #----------------------------------------------------------------------------- 
  # Check input: 
  if (length(pos.is) == 0) stop("The IS vector must have length >0.") 
   
  # Initialize: 
  pos.is <- sort(pos.is) 
  nis <- length(pos.is) 
  cluster.new <- pos.is[1] 
  list.cluster <- list() 
  length.new <-1 
  # length of present cluster (at this point, clusters may contain only one IS) 
  # N.B. "length means number of IS! 
  v.length <- numeric(0) 
  v.dimension <- numeric(0) 
   
  if (nis > 1) { 
    # Loop over IS positions (This code generates all clusters except the last one): 
     
    for (i in (2:nis))  { 
      if ((pos.is[i] - pos.is[i - 1]) <= d) { 
        length.new <- length.new + 1 
        cluster.new <- c(cluster.new, pos.is[i])  
      } 
      else { 
        if (length.new > 1) list.cluster <- c(list.cluster, list(cluster.new)) 
        v.dimension <- c(v.dimension, max(cluster.new) - min(cluster.new)) 
        cluster.new <- pos.is[i] 
        # pos.is[i] starts a new cluster, possibly of length 1 
        v.length <- c(v.length, length.new) 
        length.new <- 1 
      }   
    } 
  } 
   
  # Add last cluster: 
  v.length <- c(v.length, length.new) 
  v.dimension <- c(v.dimension, max(cluster.new) - min(cluster.new)) 
  v.dimension <- v.dimension[v.length > 1] 
  v.length <- v.length[v.length > 1] 
  if (length.new > 1) list.cluster <- c(list.cluster, list(cluster.new)) 
   
  # Evaluation: 
  n.cluster <- length(v.length) 
  n.is.cluster <- sum(v.length) 
   
  return(list(n.cluster, n.is.cluster, v.length, v.dimension, list.cluster)) 
} 
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9.6 Condon opOmized cDNA sequences of candidate genes 
9.6.1 Amica1 
GGATCCGCCACCATGCTGTGCCTGCTGAAGCTGATCGTGATCCCCGTGATCCTGGCCCCCGTGGGATATCCTCAGGGA
CTGCCTGGCCTGACCGTGTCCTCTCCACAGCTGAGAGTGCACGTGGGCGAGAGCGTGCTGATGGGCTGTGTGGTGCAG
AGAACCGAAGAGAAGCACGTGGACAGAGTGGACTGGCTGTTCAGCAAGGACAAGGACGACGCCAGCGAGTACGTGCTG
TTCTACTACAGCAACCTGAGCGTGCCCACCGGCAGATTCCAGAACAGATCTCACCTCGTGGGCGACACCTTCCACAAC
GACGGAAGCCTGCTGCTGCAGGACGTGCAGAAGGCTGACGAGGGCATCTACACATGCGAGATCAGACTGAAGAACGAG
AGCATGGTCATGAAGAAACCCGTGGAACTGTGGGTGCTGCCCGAGGAACCCAAGGACCTGCGCGTCAGAGTGGGCGAT
ACCACCCAGATGAGATGCAGCATCCAGTCCACCGAAGAAAAACGCGTGACCAAAGTGAACTGGATGTTCTCCAGCGGC
AGCCACACCGAAGAGGAAACCGTGCTGAGCTACGACTCCAACATGAGAAGCGGCAAGTTCCAGAGCCTGGGCAGGTTC
AGAAACAGGGTGGACCTGACCGGCGACATCAGCAGAAACGACGGCAGCATCAAGCTGCAGACCGTGAAAGAGAGCGAC
CAGGGAATCTACACCTGTAGCATCTACGTGGGCAAGCTGGAAAGCAGAAAGACCATCGTGCTGCACGTGGTGCAGGAC
GAGTTCCAGCGGACCATCAGCCCTACCCCCCCTACAGATAAGGGCCAGCAGGGCATCCTGAACGGCAATCAGCTCGTG
ATCATCGTGGGAATCGTGTGTGCCACCTTTCTGCTGCTGCCCGTGCTGATCCTGATCGTGAAGAAAGCCAAGTGGAAC
AAGAGCAGCGTGTCCAGCATGGCCAGCGTGAAGTCCCTGGAAAACAAAGAGAAGATCAACCCCGAGAAGCACATCTAC
AGCAGCATCACCACCTGGGAGACAACCGAGAGAGGCATCAGCGGCGAGTCCGAGGGAACCTACATGACAATGAACCCC
GTGTGGCCCAGCAGCCCCAAGGCTAGTTCTCTCGTGCGAAGCAGCGTGCGGAGCAAGTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
9.6.2 Ccnd3 
GGATCCGCCACCATGGAACTGCTGTGTTGCGAGGGCACCAGACACGCCCCTAGAGCTGGCCCTGATCCTAGACTGCTG
GGCGACCAGAGAGTGCTGCAGAGCCTGCTGAGACTGGAAGAAAGATACGTGCCCAGAGCCAGCTACTTCCAGTGCGTG
CAGAAAGAAATCAAGCCCCACATGAGAAAGATGCTGGCCTACTGGATGCTGGAAGTGTGCGAGGAACAGAGATGCGAA
GAGGACGTGTTCCCCCTGGCCATGAACTACCTGGACAGATACCTGAGCTGCGTGCCCACCAGAAAGGCCCAGCTGCAG
CTGCTGGGCACCGTGTGTCTGCTGCTGGCCTCCAAGCTGAGAGAGACAACCCCCCTGACCATCGAGAAGCTGTGCATC
TACACCGACCAGGCCGTGGCCCCTTGGCAGCTGAGGGAATGGGAAGTGCTGGTGCTGGGAAAGCTGAAGTGGGACCTG
GCCGCCGTGATCGCCCACGATTTTCTGGCTCTGATTCTGCACAGACTGAGCCTGCCCAGCGACAGACAGGCCCTCGTG
AAGAAGCACGCCCAGACCTTTCTGGCCCTGTGCGCCACCGACTACACCTTCGCCATGTACCCCCCCAGCATGATCGCC
ACCGGCTCTATCGGAGCAGCCGTGCTGGGACTGGGCGCCTGTTCTATGTCTGCCGACGAGCTGACCGAGCTGCTGGCT
GGCATCACAGGCACCGAGGTGGACTGCCTGAGAGCCTGCCAGGAACAGATCGAGGCCGCCCTGAGAGAGTCTCTGAGA
GAGGCCGCTCAGACCGCCCCAAGCCCTGTGCCTAAAGCTCCTAGAGGCAGCAGCTCCCAGGGCCCTAGCCAGACCAGC
ACACCTACAGACGTGACCGCCATCCACCTGTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
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9.6.3 Evl 
GGATCCGCCACCATGAGCGAGCAGAGCATCTGTCAGGCCAGAGCCAGCGTGATGGTGTACGACGACACCAGCAAGAAA
TGGGTGCCCATCAAGCCCGGCCAGCAGGGCTTCAGCAGAATCAACATCTACCACAACACCGCCAGCAGCACCTTCAGA
GTCGTGGGCGTGAAGCTGCAGGACCAGCAGGTCGTGATCAACTACAGCATCGTGAAGGGCCTGAAGTACAACCAGGCC
ACCCCCACCTTTCACCAGTGGCGGGATGCCAGACAGGTGTACGGCCTGAACTTCGCCAGCAAAGAGGAAGCCACCACC
TTCAGCAACGCCATGCTGTTCGCCCTGAACATCATGAACAGCCAGGAAGGCGGCCCTAGCACCCAGAGACAGGTGCAG
AACGGCCCCAGCCCCGAGGAAATGGACATCCAGCGGCGCCAAGTGATGGAACAGCAGCACAGACAGGAAAGCCTGGAA
AGAAGAATCAGCGCCACCGGCCCCATCCTGCCACCTGGACATCCTAGCTCTGCCGCCAGCACCACACTGAGCTGTAGC
GGACCTCCTCCCCCTCCACCACCACCTGTGCCTCCACCTCCAACAGGCAGCACACCTCCCCCACCCCCCCCACTGCCA
GCAGGCGGAGCACAGGGAACAAACCACGACGAGTCTAGCGCCAGCGGCCTGGCTGCTGCTCTGGCTGGCGCAAAGCTG
AGAAGAGTGCAGAGGCCTGAGGACGCTAGCGGCGGCAGTAGCCCTTCTGGCACAAGCAAGAGCGACGCCAACAGAGCC
TCTTCCGGCGGAGGCGGAGGGGGACTGATGGAAGAGATGAACAAGCTGCTGGCCAAGAGAAGAAAGGCCGCCTCCCAG
ACCGACAAGCCCGCCGACAGAAAAGAGGACGAGAGCCAGACCGAGGACCCCAGCACATCTCCTAGCCCTGGCACCAGA
GCCACCAGCCAGCCTCCAAACTCTAGCGAGGCCGGCAGAAAGCCCTGGGAGAGAAGCAACAGCGTGGAAAAGCCCGTG
TCCAGCCTGCTGAGCAGAACCCCTAGCGTGGCCAAGTCCCCTGAGGCCAAGAGCCCTCTGCAGTCCCAGCCTCACAGC
AGAGTGAAGCCTGCCGGCTCCGTGAACGACGTGGGACTGGATGCCCTGGACCTGGACAGAATGAAGCAGGAAATTCTG
GAAGAGGTCGTGCGCGAGCTGCACAAAGTGAAAGAGGAAATCATCGACGCCATCCGGCAGGAACTGAGCGGCATCAGC
ACAACCTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
9.6.4 Fbxl18 
GGATCCGCCACCATGGCTAGCAGCGGCGAGGACATCAGCAACGACGACGATGACATGCACCCTGCCGCCGCTGGAATG
GCCGACGGAGTGCATCTGCTGGGCTTCAGCGACGAGATCCTGCTGCACATCCTGAGCCACGTGCCCAGCACCGACCTG
ATCCTGAACGTGCGGAGAACCTGCAGAAAGCTGGCCGCCCTGTGCCTGGACAAGAGCCTGATCCACACCGTGCTGCTG
CAGAAGGACTACCAGGCCAGCGAGGACAAAGTGCGGCAGCTCGTGAAAGAGATCGGCAGAGAGATCCAGCAGCTGAGC
ATGGCCGGCTGCTACTGGCTGCCTGGCTCTACCGTGGAACACGTGGCCAGATGCAGATCCCTCGTGAAAGTGAACCTG
AGCGGCTGCCACCTGACCAGCCTGAGACTGAGCAAGATGCTGAGCGCCCTGCAGCACCTGAGAAGCCTGGCCATCGAT
GTGTCCCCAGGCTTCGACGCCAGCCAGCTGTCTAGCGAGTGCAAGGCCACCCTGAGCAGAGTGCGCGAGCTGAAGCAG
ACCCTGTTCACCCCTAGCTACGGCGTGGTGCCTTGCTGCACCAGCCTGGAAAAGCTGCTGCTGTACTTTGAGATCCTG
GACAGAACCAGAGAGGGCGCCATCCTGTCCGGCCAGCTGATGGTGGGACAGAGCAACGTGCCCCACTACCAGAACCTG
AGAGTGTTCTACGCCAGACTGGCCCCTGGCTACATCAACCAGGAAGTCGTGCGGCTGTACCTGGCCGTGCTGAGCGAC
AGAACCCCCCAGAATCTGCACGCCTTTCTGATCAGCGTGCCCGGCAGCTTCGCTGAGTCTGGCGCCACAAAGAACCTG
CTGGACAGCATGGCCAGAAACGTGGTGCTGGACGCTCTGCAGCTGCCCAAGTCTTGGCTGAACGGCAGCTCCCTGCTG
CAGCACATGAAGTTCAACAACCCCTTCTACTTCAGCTTCAGCCGGTGCACCCTGTCTGGCGGACACCTGATTCAGCAA
GTGATCAACGGCGGCAAGGACCTGAGATCCCTGGCCTCCCTGAACCTGTCCGGATGCGTGCACTGTCTGAGCCCCGAC
AGCCTGCTGAGAAAGGCCGAGGACGACATCGACAGCAGCATCCTGGAAACCCTGGTGGCCAGCTGCTGCAACCTGAGA
CACCTGAATCTGTCTGCCGCCCACCACCACAGCTCTGAGGGACTGGGCAGACACCTGTGTCAGCTGCTGGCCAGACTG
AGACATCTGCGGAGCCTGAGCCTGCCCGTGTGTTCTGTGGCCGACTCTGCCCCTAGAGCCGATAGAGCACCAGCCCAG
CCTGCCATGCACGCTGTGCCTAGAGGCTTCGGCAAGAAAGTGCGCGTGGGCGTGCAGTCCTGCCCCAGCCCTTTTAGC
GGACAGGCTTGCCCTCAGCCCAGCTCCGTGTTTTGGTCCCTGCTGAAGAATCTGCCCTTCCTGGAACACCTGGAACTG
ATCGGCAGCAACTTCAGCAGCGCCATGCCTAGAAACGAGCCCGCCATCAGAAACAGCCTGCCCCCTTGTAGCAGAGCC
CAGAGCGTGGGCGATTCTGAGGTGGCCGCTATCGGGCAGCTGGCTTTCCTGAGGCATCTGACCCTGGCCCAGCTGCCA
AGTGTGCTGACAGGCAGCGGCCTCGTGAACATCGGCCTGCAGTGTCAGCAGCTGCGGTCCCTGTCTCTGGCCAACCTG
GGCATGATGGGAAAGGTGGTGTACATGCCCGCCCTGTCCGACATGCTGAAGCACTGCAAGAGACTGAGGGACCTGAGG
CTGGAACAGCCTTACTTCAGCGCCAACGCCCAGTTCTTCCAGGCCCTGAGCCAGTGTCCTAGCCTGCAGAGACTGTGT
CTGGTGTCCAGAAGCGGCACCCTGCAGCCTGATGCTGTGCTGGCCTTCATGGCCCGGTGTCTGCAGGTCGTGATGTGC
CACCTGTTCACAGGCGAGAGCCTGGCTACCTGCAAAAGCCTGCAGCAGAGCCTGCTGCGGTCTTTCCAGGCCGAAAGA
CCCGCTCTGAACGTCGTGATCTTCCCACTGCTGCACGAGGGCCTGACCGACGTGATCAGAGATGTGCCCCTGGTGCAC
CTGGACGAGATCACACTGTTCAAGTCCAGAGTGGCCGAGGAACCCCCTAACCTGTGGTGGTAGCCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
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9.6.5 Igf2bp2 
GGATCCGCCACCATGATGAACAAGCTGTACATCGGCAACCTGAGCCCTGCCGTGACAGCCGACGATCTGAGACAGCTG
TTCGGCGACAGAAAGCTGCCCCTGGCTGGACAGGTGCTGCTGAAGTCTGGCTACGCCTTCGTGGACTACCCCGACCAG
AACTGGGCCATCAGAGCCATCGAGACACTGAGCGGCAAGGTGGAACTGCACGGCAAGATCATGGAAGTGGACTACAGC
GTGTCCAAGAAGCTGAGGTCCAGAAGAATCCAGATCCGGAACATCCCCCCACATCTGCAGTGGGAGGTGCTGGATGGA
CTGCTGGCCGAGTACGGCACCGTGGAAAACGTGGAACAAGTGAACACCGACACCGAGACAGCCGTCGTGAACGTGACC
TACATGACCAGAGAGGAAGCCAAGCTGGCTATCGAGAAGCTGTCCGGCCACCAGTTCGAGGACTACTCCTTCAAGATC
AGCTACATCCCCGACGAGGAAGTGTCCAGCCCCAGCCCTCCTCACAGAGCTAGAGAGCAGGGACACGGCCCTGGCAGC
AGCTCTCAGGCCAGACAGATCGACTTCCCACTGAGAATCCTGGTGCCCACCCAGTTCGTGGGCGCCATCATCGGCAAA
GAGGGCCTGACCATCAAGAACATCACCAAGCAGACCCAGAGCAGAGTGGACATCCACAGAAAAGAGAACAGCGGCGCT
GCCGAGAAGCCCGTGACAATCCACGCTACCCCTGAGGGCACAAGCGAGGCCTGCAGAATGATCCTGGAAATCATGCAG
AAAGAGGCCGACGAGACAAAGCTGGCCGAAGAGGTGCCCCTGAAGATCCTGGCCCACAACGGCTTCGTGGGCAGACTG
ATCGGAAAAGAAGGCCGGAACCTGAAGAAGATCGAGCACGAGACAGGCACCAAGATTACAATCAGCTCTCTGCAGGAC
CTGAGCATCTACAACCCCGAGAGAACCATCACCGTGCGGGGCACCATCGAGGCTTGTGCCAACGCCGAGATCGAGATC
ATGAAGAAACTGAGAGAGGCCTTCGAGAACGACATGCTGGCCGTGAACCAGCAGGCCAACCTGATCCCAGGCCTGAAC
CTGTCTGCCCTGGGCATCTTCAGCACCGGCCTGTCAGTGCTGCCACCTCCTGCTGGACCTAGAGGCGTGCCACCTAGC
CCTCCCTACCACCCTTTCGCCACACACAGCGGCTACTTCAGCTCCCTGTACCCCCACCACCACTTCGGCCCATTCCCT
CACCACCACAGCTACCCCGAGCAGGAAACCGTGTCTCTGTTCATCCCAACCCAGGCCGTGGGAGCTATCATTGGCAAG
AAGGGCGCCCACATCAAGCAGCTGGCCAGATTCGCTGGCGCCTCCATCAAGATCGCCCCTGCTGAAGGCCCTGACGTG
TCCGAGAGAATGGTCATCATCACCGGCCCTCCCGAGGCTCAGTTCAAGGCTCAGGGCAGAATCTTCGGCAAGCTGAAA
GAGGAAAACTTCTTCAACCCCAAAGAAGAAGTGAAGCTGGAAGCCCACATCCGGGTGCCAAGCAGCACAGCCGGAAGA
GTGATTGGCAAGGGCGGCAAGACCGTGAACGAGCTGCAGAACCTGACCAGCGCCGAAGTGATCGTGCCCAGGGACCAG
ACCCCTGACGAGAATGAGGAAGTGATTGTGCGGATCATCGGCCACTTTTTCGCCAGCCAGACCGCCCAGAGAAAGATC
CGCGAGATCGTGCAGCAAGTGAAGCAGCAGGAACAGAGATACCCCCAGGGCGTGGCCCCCCAGAGATCCAAATGACCT
GCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
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9.6.6 Irf2bpl 
GGATCCGCCACCATGTCTGCTGCCCAGGTGTCCAGCAGCAGAAGGCAGAGCTGCTACCTGTGCGACCTGCCCAGAATG
CCCTGGGCCATGATCTGGGACTTCAGCGAGCCTGTGTGCAGAGGCTGCGTGAACTACGAGGGCGCCGACAGAATCGAG
TTCGTGATCGAGACAGCCAGACAGCTGAAGAGAGCCCACGGCTGCTTCCAGGACGGCAGATCTCCTGGACCTCCTCCA
CCCGTGGGCGTGAAAACAGTGGCCCTGTCTGCCAAAGAGGCCGCTGCTGCAGCTGCTGCCGCCCAACAACAACAACAA
CAACAACAGCAACAGCAGCAGCAGCTGAACCACGTGGACGGCAGCACAAAGCCTGCCGTGCTGGCTGCTCCTAGCGGC
CTGGAAAGATACGGCCTGTCTGCAGCCGCCGCTGCCGCCGCAGCAGCCGCTGCAGTGGAACAGAGAAGCAGATTCGAG
TACCCCCCTCCCCCTGTGTCCCTGGGCTCTAGCTCTCACGCTGCCAGACTGCCTAACGGCCTGGGCGGACCTAACGGC
TTCCCTAAGCCTGCCCCTGAGGAAGGCCCTCCCGAGCTGAACAGACAGAGCCCCAACTCTAGCAGCGCCGCCACAAGC
GTGGCCAGCAGAAGAGGCACACACTCCGGCCTCGTGACCGGCCTGCCTAATCCTGGCGGAGGCGGAGGACCTCAGCTG
ACCGTGCCTCCAAATCTGCTGCCTCAGACCCTGCTGAACGGCCCTGCTTCTGCAGCTGTGCTGCCTCCTCCTCATGGA
CTGGGCGGCTCTAGAGGCCCTCCTACACCAGCTCCTCCAGGCGCACCTGGCGGACCTGCTTGTCTGGGAGGACCACCT
GGCGTGTCCGCCACAGTGTCTAGCGCCCCTAGCAGCACAAGCAGCACCGTGGCTGAAGTGGGCGTGGGCGCTGCTGGC
AAAAGACCTGGCTCTGTGTCCTCCACCGACCAGGAAAGAGAGCTGAAAGAAAAGCAGAGAAACGCCGAGGCCCTGGCC
GAGCTGTCTGAGAGCCTGAGAAACAGAGCCGAGGAATGGGCCAACAAGCCCAAGATGGTGCGAGACACACTGCTGACA
CTGGCCGGCTGCACCCCTTACGAAGTGCGGTTCAAGAAGGACCACAGCCTGCTGGGCAGAGTGTTCGCCTTCGACGCC
GTGTCCAAGCCCGGCATGGACTACGAGCTGAAGCTGTTCATCGAGTATCCCACCGGCTCCGGCAACGTGTACTCTAGC
GCTTCTGGGGTGGCCAAGCAGATGTACCAGGACTGCATGAAGGACTTCGGCAGAGGCCTGAGCAGCGGCTTCAAGTAC
CTGGAATACGAGAAGAAGCACGGCTCTGGCGATTGGAGACTGCTGGGCGACCTGCTGCCAGAGGCTGTGCGGTTCTTC
AAAGAAGGCGTGCCAGGCGCCGATATGCTGCCCCAGCCTTACCTGGACGCCAGCTGCCCTATGCTGCCTACCGCTCTG
GTGTCCCTGAGCAGAGCCCCTTCTGCTCCTCCTGGAACAGGCGCTCTGCCACCAGCTGCACCTACTGGAAGGGGAGCC
GCCAGCTCCCTGAGAAAGAGAAAGGCCAGCCCCGAGCCTCCTGACTCTGCCGAGTCTGCTCTGAAGCTGGGCGAGGAA
CAGCAGAGACAGCAGTGGATGGCCAACCAGTCTGAGGCCCTGAAGCTGACCATGAGCGCTGGCGGATTTGCCGCCCCT
GGACATTCTGCAGGCGGACCTCCACCCCCTCCACCTCCACTGGGACCTCACTCCAACAGAACCACCCCCCCTGAGAGC
GCCCCTCAGAACGGACCTTCTCCTATGGCCGCCCTGATGAGCGTGGCCGACACACTGGGAACAGCCCACAGCCCTAAG
GACGGCTCTAGCGTGCACAGCACAACAGCCAGCGCCAGAAGAAACAGCTCCAGCCCAGTGTCCCCTGCCTCTGTGCCT
GGACAGAGAAGGCTGGCCTCCAGAAACGGCGACCTGAATCTGCAGGTGGCCCCACCACCACCTAGCGCTCACCCTGGA
ATGGACCAGGTGCACCCCCAGAACATCCCCGACAGCCCCATGGCTAACAGCGGCCCTCTGTGCTGCACCATCTGCCAC
GAGAGACTGGAAGATACCCACTTCGTGCAGTGCCCCAGCGTGCCCAGCCACAAGTTCTGCTTCCCTTGCAGCAGAGAG
TCCATCAAGGCTCAGGGCGCCACCGGCGAGGTGTACTGTCCTTCTGGCGAGAAGTGCCCCCTCGTGGGCAGCAATGTG
CCTTGGGCTTTCATGCAGGGCGAGATCGCCACAATCCTGGCCGGCGACGTGAAAGTGAAGAAAGAGCGGGACCCCTGA
CCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
9.6.7 Lair 1 long isoform 
GGATCCGCCACCATGTCTCTGCACCCCGTGATCCTGCTGGTGCTGGTGCTGTGTCTGGGCTGGAAGATCAACACCCAG
GAAGGCAGCCTGCCCGACATCACCATCTTCCCCAACAGCAGCCTGATGATCAGCCAGGGCACCTTCGTGACCGTCGTG
TGCAGCTACAGCGACAAGCACGACCTGTACAACATGGTGCGACTGGAAAAGGACGGCAGCACCTTCATGGAAAAGAGC
ACCGAGCCCTACAAGACCGAGGACGAGTTCGAGATCGGCCCCGTGAACGAGACAATCACCGGCCACTACAGCTGCATC
TACAGCAAGGGCATCACTTGGAGCGAGAGAAGCAAGACCCTGGAACTGAAAGTGATCAAAGAAAACGTGATCCAGACC
CCTGCCCCTGGCCCTACCAGCGACACAAGCTGGCTGAAAACCTACAGCATCTACATCTTCACCGTGGTGTCCGTGATC
TTCCTGCTGTGCCTGAGCGCCCTGCTGTTCTGCTTCCTGAGACACAGACAGAAGAAGCAGGGCCTGCCCAACAACAAG
AGACAGCAGCAGAGGCCCGAGGAAAGACTGAACCTGGCCACCAACGGCCTGGAAATGACCCCCGACATCGTGGCCGAC
GACAGACTGCCTGAGGACAGATGGACCGAGACATGGACACCCGTGGCCGGCGATCTGCAGGAAGTGACCTACATTCAG
CTGGACCACCACAGCCTGACCCAGAGGGCTGTGGGCGCTGTGACAAGCCAGAGCACAGACATGGCCGAGAGCAGCACC
TACGCCGCCATCATCAGACACTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
  
Appendix 
172 
 
9.6.8 Lair1 short isoform 
GGATCCGCCACCATGTCTCTGCACCCCGTGATCCTGCTGGTGCTGGTGCTGTGTCTGGGCTGGAAGATCAACACCCAG
GAAGATACCAGCTGGCTGAAAACCTACAGCATCTACATCTTCACCGTGGTGTCCGTGATCTTCCTGCTGTGCCTGAGC
GCCCTGCTGTTCTGCTTCCTGAGACACAGACAGAAGAAGCAGGGCCTGCCCAACAACAAGAGACAGCAGCAGAGGCCC
GAGGAAAGACTGAACCTGGCCACCAACGGCCTGGAAATGACCCCCGACATCGTGGCCGACGACAGACTGCCTGAGGAC
AGATGGACCGAGACATGGACACCCGTGGCCGGCGATCTGCAGGAAGTGACCTACATTCAGCTGGACCACCACAGCCTG
ACCCAGAGGGCTGTGGGCGCTGTGACAAGCCAGAGCACAGACATGGCCGAGAGCAGCACCTACGCCGCCATCATCAGA
CACTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
9.6.9 Lrrc33 
GGATCCGCCACCATGCAGGAACCTCTGGAAACCGGCAGCATCGAGAGCAGCGGCACAGGCAACGTGGTGGTGTCTCAC
CAGAGGGCCGTGCCCGAGATGGAATTCCCTCCTCTGTGGCTGTGCCTGGGCTTCCACTTCCTGATCGTGGAATGGCGC
AGCGGCCCTGGCACTGCTACAGCTGCTTCTCAGGGCGGCTGCAAGGTGGTGGATGGCGTGGCAGACTGCAGAGGCCTG
AACCTGGCCTCTGTGCCTAGCAGCCTGCCCCCCCACAGCAGAATGCTGATCCTGGACGCCAACCCCCTGAAGGACCTG
TGGAACCACTCTCTGCAGGCCTACCCCAGACTGGAAAACCTGAGCCTGCACAGCTGCCACCTGGACAGAATCAGCCAC
TACGCCTTCAGAGAGCAGGGCCACCTGAGAAACCTGGTGCTGGCCGACAACAGACTGAGCGAGAACTACAAAGAGAGC
GCCGCTGCCCTGCACACCCTGCTGGGACTGAGAAGGCTGGACCTGAGCGGCAACAGCCTGACCGAGGATATGGCCGCA
CTGATGCTGCAGAACCTGAGCAGCCTGGAAGTGGTGTCCCTGGCCAGAAACACCCTGATGAGACTGGACGACAGCATC
TTCGAGGGCCTGGAACACCTGGTGGAACTGGACCTGCAGAGGAACTACATCTTTGAGATCGAGGGCGGAGCCTTCGAC
GGCCTGACAGAACTGCGGAGACTGAATCTGGCCTACAACAACCTGCCTTGCATCGTGGACTTTAGCCTGACCCAGCTG
AGATTCCTGAACGTGTCCTACAATATCCTGGAATGGTTCCTGGCTGCCAGAGAAGAGGTGGCCTTCGAGCTGGAAATC
CTGGACCTGTCCCACAACCAGCTGCTGTTCTTCCCACTGCTGCCCCAGTGCGGCAAGCTGCATACACTGCTGCTGCAG
GACAACAACATGGGCTTCTACAGAGAGCTGTACAACACCAGCAGCCCCCAGGAAATGGTGGCCCAGTTTCTGCTGGTG
GACGGCAACGTGACCAACATCACCACCGTGAACCTGTGGGAGGAATTCAGCAGCAGCGACCTGTCCGCCCTGCGGTTC
CTGGACATGAGCCAGAACCAGTTCAGACATCTGCCCGACGGCTTTCTGAAGAAAACCCCCAGCCTGAGCCACCTGAAT
CTGAACCAGAACTGCCTGAAAATGCTGCACATCCGCGAGCACGAGCCTCCAGGCGCTCTGACAGAGCTGGATCTGAGC
CACAATCAGCTGGCCGAGCTGCACCTGGCCCCTGGACTGACAGGCTCTCTGAGGAACCTGAGAGTGTTCAACCTGTCC
TCTAATCAGCTGCTGGGCGTGCCCACCGGCCTGTTCGATAACGCCAGCAGCATCACCACAATCGACATGTCTCACAAT
CAGATCAGCCTGTGCCCCCAGATGGTGCCCGTGGATTGGGAGGGACCTCCTAGCTGCGTGGACTTCAGAAACATGGGC
AGCCTGAGATCCCTGTCCCTGGACGGCTGTGGCCTGAAGGCTCTGCAGGACTGCCCATTTCAAGGCACCTCCCTGACC
CATCTGGATCTGTCCAGCAACTGGGGCGTGCTGAACGGCTCCATCAGCCCTCTGTGGGCCGTGGCTCCTACACTGCAG
GTGCTGAGCCTGAGAGATGTGGGCCTGGGATCTGGCGCCGCTGAGATGGACTTCTCCGCCTTCGGCAACCTGAGGGCC
CTGGATCTGTCTGGCAACTCCCTGACCAGCTTCCCCAAGTTCAAGGGCTCCCTGGCCCTGAGGACCCTGGACCTGAGA
AGAAACTCTCTGACCGCCCTGCCCCAGAGGGTGGTGTCAGAACAGCCTCTGAGAGGACTGCAGACCATCTACCTGTCT
CAGAACCCCTACGACTGCTGCGGCGTGGAAGGATGGGGAGCACTGCAGCAGCACTTCAAGACCGTGGCCGACCTGAGC
ATGGTCACCTGTAACCTGTCTAGCAAGATCGTGCGGGTGGTGGAACTGCCCGAGGGACTGCCTCAGGGCTGCAAGTGG
GAACAGGTGGACACCGGACTGTTCTATCTGGTGCTGATTCTGCCCTCCTGTCTGACCCTGCTGGTGGCCTGTACCGTG
GTGTTCCTGACCTTCAAGAAACCCCTGCTGCAAGTGATCAAGTCCAGATGCCACTGGTCCAGCATCTACTGACCTGCA
GG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
  
Appendix 
173 
 
9.6.10 Mbnl1 
GGATCCGCCACCATGGCCGTGTCTGTGACCCCCATCAGAGACACCAAGTGGCTGACCCTGGAAGTGTGCAGAGAGTTC
CAGAGAGGCACCTGTAGCAGACCCGACACCGAGTGCAAGTTCGCCCACCCCAGCAAGAGCTGCCAGGTGGAAAACGGC
AGAGTGATCGCCTGCTTCGACAGCCTGAAGGGCAGATGCAGCAGAGAGAACTGCAAGTACCTGCACCCCCCTCCCCAC
CTGAAAACCCAGCTGGAAATCAACGGCCGGAACAACCTGATCCAGCAGAAAAACATGGCTATGCTGGCCCAGCAGATG
CAGCTGGCCAACGCCATGATGCCTGGCGCTCCTCTGCAGCCCGTGCCCATGTTTTCTGTGGCCCCTAGCCTGGCCACA
AGCGCCTCTGCTGCCTTCAACCCTTACCTGGGCCCTGTGTCCCCTTCCCTGGTGCCTGCTGAGATCCTGCCTACCGCC
CCCATGCTCGTGACAGGCAATCCTGGCGTGCCAGTGCCAGCTGCTGCCGCTGCTGCTGCCCAGAAACTGATGAGAACC
GACAGACTGGAAGTGTGCCGCGAGTACCAGCGGGGCAACTGCAACAGAGGCGAGAACGACTGCAGATTCGCTCACCCC
GCCGACAGCACCATGATCGACACCAACGACAACACCGTGACCGTGTGCATGGACTACATCAAGGGCCGGTGCTCCCGC
GAAAAGTGCAAGTACTTCCACCCTCCCGCCCATCTGCAGGCCAAGATCAAGGCCGCTCAGTACCAAGTGAACCAGGCC
GCTGCAGCCCAGGCTGCTGCTACTGCTGCAGCTATGGGCATCCCTCAGGCCGTGCTGCCCCCCCTGCCTAAAAGACCT
GCCCTGGAAAAGACCAACGGCGCCACCGCCGTGTTCAACACCGGCATCTTCCAGTACCAGCAGGCCCTGGCCAACATG
CAGCTGCAGCAGCACACCGCCTTTCTGCCCCCTGGCAGCATCCTGTGTATGACCCCTGCCACCAGCGTGGTGCCTATG
GTGCATGGCGCTACCCCAGCCACAGTGTCTGCCGCCACAACAAGCGCCACCTCTGTGCCTTTCGCCGCCACCGCTACA
GCCAACCAGATCCCCATCATCAGCGCCGAGCACCTGACCAGCCACAAATACGTGACCCAGATGTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
9.6.11 Ninj2 
GGATCCGCCACCATGGAAAGCGACAGAGAGACAATCCATCTGCAGCACAGACACAGCATGAGAGGCGGCAACCAGAGA
ATCGACCTGAACTTCTACGCCACCAAGAAAAGCGTGGCCGAGAGCATGCTGGACGTGGCCCTGTTCATGAGCAACGCC
ATGAGACTGAAGTCCGTGCTGCAGCAGGGCCCCTTCGCCGAGTACTACACCACCCTCGTGACCCTGATCATCGTGTCC
CTGCTGCTGCAGGTCGTGATCTCTCTGCTGCTGGTGTTTATCGCCATCCTGAACCTGAACGAGGTGGAAAACCAGAGG
CACCTGAACAAGCTGAACAACGCCGCCACAATCCTGGTGTTCATCACCGTCGTGATCAACATCTTCATCACAGCCTTC
GGCGCCCACCACGCCGCCTCTATGGCTGCCAGAACAAGCAGCAACCCAATCTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
  
Appendix 
174 
 
9.6.12 Nrip1 
GGATCCGCCACCATGACACACGGCGAGGAACTGGGCTCTGACGTGCACCAGGACAGCATCGTGCTGACCTACCTGGAA
GGCCTGCTGATGCACCAGGCTGCTGGCGGCTCTGGCACCGCCATCAACAAGAAGTCTGCCGGCCACAAAGAAGAGGAC
CAGAACTTCAACCTGAGCGGCAGCGCCTTCCCCAGCTGTCAGTCTAACGGCCCTACCGTGTCCACCCAGACCTACCAG
GGCAGCGGAATGCTGCACCTGAAGAAGGCCAGACTGCTGCAGAGCAGCGAGGACTGGAACGCCGCCAAGAGAAAGAGA
CTGAGCGACTCCATCGTGAACCTGAACGTGAAGAAAGAGGCCCTGCTGGCCGGCATGGTGGACTCTGTGCCTAAGGGC
AAGCAGGACTCCACACTGCTGGCCTCCCTGCTGCAGTCCTTCAGCAGCAGACTGCAGACCGTGGCCCTGAGCCAGCAG
ATCAGACAGAGCCTGAAAGAGCAGGGCTACGCCCTGTCCCACGAGTCCCTGAAGGTGGAAAAGGACCTGAGATGCTAC
GGCGTGGCCAGCTCCCACCTGAAAACCCTGCTGAAGAAGTCCAAGACCAAGGATCAGAAGTCCGGCCCCACCCTGCCT
GACGTGACCCCCAACCTGATCAGAGACAGCTTCGTGGAAAGCAGCCACCCCGCCGTGGGCCAGTCTGGCACAAAAGTG
ATGAGCGAGCCCCTGAGCTGCGCCGCTAGACTGCAGGCTGTGGCTTCCATGGTGGAAAAAAGAGCCAGCCCTGCCGCC
AGCCCCAAGCCTTCTGTGGCTTGTTCTCAGCTGGCACTGCTGCTGTCCAGCGAGGCCCATCTGCAGCAGTACAGCAGA
GAGCACGCCCTGAAAACACAGAACGCCCACCAGGTGGCCAGCGAGAGGCTGGCTGCTATGGCTAGGCTGCAGGAAAAC
GGCCAGAAAGACGTGGGCTCCAGCCAGCTGTCTAAGGGCGTGTCCGGCCACCTGAACGGACAGGCTAGAGCCCTGCCT
GCCTCTAAGCTGGTGGCCAACAAGAACAACGCCGCTACCTTCCAGAGCCCCATGGGCGTGGTGCCTAGCAGCCCTAAG
AACACCAGCTACAAGAACAGCCTGGAACGGAACAACCTGAAGCAGGCTGCCAACAACAGCCTGCTGCTGCATCTGCTG
AAGTCTCAGACCATCCCCACCCCCATGAACGGCCACAGCCAGAACGAGAGGGCCAGCAGCTTCGAGAGCAGCACCCCT
ACCACCATCGACGAGTACAGCGACAACAACCCCAGCTTCACCGACGACAGCAGCGGCGACGAGTCCAGCTACTCCAAC
TGCGTGCCCATCGACCTGTCCTGCAAGCACAGAATCGAGAAGCCCGAGGCCGAGAGGCCCGTGTCCCTGGAAAACCTG
ACCCAGAGCCTGCTGAACACCTGGGACCCCAAGATCCCCGGCGTGGACATCAAAGAGGATCAGGACACCAGCACCAAC
AGCAAGCTGAACAGCCACCAGAAAGTGACTCTGCTGCAGCTGCTGCTGGGCCACAAGAGCGAGGAAACCGTGGAAAGA
AACGCCTCCCCCCAGGACATCCACAGCGACGGCACAAAGTTCAGCCCCCAGAACTACACCAGAACCAGCGTGATCGAG
AGCCCCTCCACCAACAGAACCACCCCTGTGTCCACACCCCCCCTGTACACAGCCTCTCAGGCCGAGTCCCCTATCAAC
CTGTCCCAGCACTCCCTCGTGATCAAGTGGAACAGCCCCCCCTACGCCTGTAGCACCCCTGCTTCCAAGCTGACCAAC
ACCGCCCCCAGCCACCTGATGGACCTGACCAAGGGCAAAGAGAGCCAGGCCGAGAAGCCTGCCCCTTCTGAAGGCGCC
CAGAACAGCGCCACATTCAGCGCCTCAAAGCTGCTGCAGAACCTGGCCCAGTGTGGGCTGCAGAGTTCTGGCCCTGGC
GAAGAACAGCGGCCTTGCAAACAGCTGCTGAGCGGAAACCCCGACAAGCCCCTGGGCCTGATCGACAGACTGAATAGC
CCCCTGCTGAGCAACAAGACAAACGCTGCCGAGGAAAGCAAGGCCTTCAGCTCCCAGCCAGCCGGACCTGAACCTGGA
CTGCCTGGATGCGAGATCGAGAACCTGCTGGAAAGACGGACCGTGCTGCAGCTGCTGCTGGGAAACAGCAGCAAGGGC
AAGAATGAGAAGAAAGAAAAGACCCCCGCCAGGGACGAGGCCCCTCAGGAACATTCTGAGAGGGCCGCCAACGAGCAG
ATCCTGATGGTCAAGATCAAGTCCGAGCCCTGCGACGACTTCCAGACCCACAACACCAACCTGCCCCTGAACCACGAC
GCCAAGAGCGCCCCATTTCTGGGCGTGACACCCGCCATCCACAGAAGCACAGCTGCCCTGCCAGTGTCCGAGGACTTC
AAGTCTGAGCCTGCCAGCCCTCAGGACTTCAGCTTCAGCAAGAACGGCCTGCTGTCCCGGCTGCTGAGACAGAACCAG
GAAAGCTACCCTGCCGACGAGCAGGACAAGTCCCACAGAAACAGCGAGCTGCCTACCCTGGAATCCAAGAACATCTGC
ATGGTGCCCAAGAAGCGGAAGCTGTACACCGAGCCTCTGGAAAATCCCTTCAAGAAGATGAAGAACACCGCCGTGGAC
ACCGCCAACCACCACTCTGGACCAGAGGTGCTGTACGGATCACTGCTGCACCAGGAAGAACTGAAGTTCAGCAGAAAC
GAGCTGGACTACAAGTACCCAGCCGGCCACTCTAGCGCCTCTGACGGCGATCACAGAAGCTGGGCCAGAGAGTCCAAG
AGCTTCAACGTGCTGAAACAGCTGCTGCTGTCCGAGAACTGCGTGCGGGATCTGAGCCCCCACAGATCCGACAGCGTG
CCCGACACCAAGAAGAAGGGCCACAAAAACAACGCTCCCGGCAGCAAGCCCGAGTTCGGCATCTCTTCCCTGAATGGC
CTGATGTACAGCTCCCCTCAGCCCGGCTCTTGCGTGACCGACCACAGAACCTTCAGCTACCCCGGAATGGTCAAAACC
CCCCTGAGCCCTCCATTCCCCGAGCACCTGGGATGCGTGGGAAGCAGACCAGAGCCCGGACTGCTGAACGGCTGTTCT
GTGCCTGGCGAGAAGGGCCCCATCAAATGGGTCATCGCCGACATGGACAAGAACGAGTACGAGAAGGACAGCCCCAGA
CTGACAAAGACCAACCCCATCCTGTACTACATGCTGCAGAAAGGCGGCGGAAACAGCGTGACCACCCAGGAAACCCAG
GACAAGGACATTTGGAGAGAGCCCGCCTCCGCCGAGAGCCTGTCTCAAGTGACCGTGAAAGAGGAACTGCTGCCAGCC
GCCGAGACAAAGGCCAGCTTCTTTAACCTGAGAAGCCCCTACAACAGCCACATGGGCAACAACGCCAGCAGACCCCAC
AGCACAAACGGCGAGGTGTACGGGCTGCTGGGGAACGCCCTGACCATCAAGAAAGAATCCGAGTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
  
Appendix 
175 
 
9.6.13 Plcb4 
GGATCCGCCACCATGGCCAAGCCCTACGAGTTCAACTGGCAGAAAGAGGTGCCCAGCTTTCTGCAGGAAGGCGCCGTG
TTCGACAGATACGAAGAGGAATCCTTCGTGTTCGAGCCCAACTGCCTGTTCAAGGTGGACGAGTTCGGATTCTTCCTG
ACCTGGAAGTCCGAGGGCAAAGAGGGCCAGGTGCTGGAATGCAGCCTGATCAACAGCATCAGACAGGCCGCCATCCCC
AAGGACCCCAAGATCCTGGCTGCCCTGGAAGCTGTGGGCAAGAGCGAGAACGATCTGGAAGGCAGAATCCTGTGCGTG
TGCAGCGGCACCGACCTCGTGAACATCGGCTTCACCTACATGGTGGCCGAGAACCCCGAAGTGACCAAGCAGTGGGTG
GAAGGCCTGAGATCCATCATCCACAACTTCAGAGCCAACAACGTGTCCCCCATGACCTGCCTGAAGAAACACTGGATG
AAGCTGGCCTTCCTGACAAACACCACCGGCAAGATCCCCGTGCGGAGCATCACCAGAACATTCGCCAGCGGCAAGACA
GAGAAAGTGATCTTCCAGGCCCTGAAAGAGCTGGGCCTGCCCTCCGGCAAGAACGACGAGATCGAGCCTGCCGCCTTC
ACATACGAGAAGTTCTACGAGCTGACCCAGAAGATCTGCCCCAGAACCGACATCGAGGATCTGTTCAAGAAGATCAAC
GGCGACAAGACCGACTACCTGACCGTGGATCAGCTGGTGTCCTTCCTGAACGAGCACCAGAGGGACCCCAGACTGAAC
GAGATCCTGTTCCCATTCTACGACGCCAAGAGAGCCATGCAGATCATCGAGATGTACGAGCCCGACGAGGAACTGAAG
AAGAAGGGCCTGATCAGCTCCGACGGCTTCTGCAGATACCTGATGAGCGACGAGAACGCCCCCGTGTTCCTGGACAGA
CTGGAACTGTACCAGGAAATGGACCACCCCCTGGCCCACTACTTCATCAGCAGCAGCCACAACACCTACCTGACAGGC
AGACAGTTCGGCGGCAAGAGCAGCGTGGAAATGTACAGACAGGTGCTGCTGGCCGGCTGCAGATGCGTGGAACTGGAC
TGTTGGGACGGCAAGGGCGAGGACCAGGAACCCATCATCACACACGGCAAGGCCATGTGCACCGACATCCTGTTTAAG
GACGTGATCCAGGCCATCAAAGAAACCGCCTTCGTGACCAGCGAGTACCCCGTGATCCTGAGCTTCGAGAACCACTGC
AGCAAGTACCAGCAGTACAAGATGAGCAAGTACTGCGAGGACCTGTTCGGCGACCTGCTGCTGAAGCAGGCCCTGGAA
TCCCACCCTCTGGAACCCGGCAGACCTCTGCCTAGCCCCAACGACCTGAAGAGAAAGATCCTGATCAAGAACAAGCGG
CTGAAGCCCGAGGTGGAAAAGAAGCAGCTGGAAGCCCTGAAGTCCATGATGGAAGCCGGCGAGTCTGCCGCCCCTGCC
AGCATTCTGGAAGATGACAACGAGGAAGAGATCGAGAGCGCCGACCAGGAAGAGGAAGCCCACCCCGAGTACAAGTTC
GGCAACGAGCTGTCCGCCGACGACTACAGCCACAAAGAAGCCGTGGCCAACAGCGTGAAGAAAGGCCTCGTGACCGTG
GAAGATGAGCAGGCCTGGATGGCCAGCTACAAATACGTGGGCGCCACCACCAACATCCACCCCTACCTGAGCACCATG
ATCAACTACGCCCAGCCCGTGAAGTTCCAGGGCTTTCACGTGGCCGAGGAAAGAAACATCCACTACAACATGAGCAGC
TTCAACGAGTCCGTGGGCCTGGGCTACCTGAAAACCCACGCCATCGAGTTCGTGAACTACAACAAGAGACAGATGAGC
CGGATCTACCCCAAGGGCGGCAGGGTGGACAGCAGCAACTATATGCCCCAGATCTTTTGGAACGCTGGCTGCCAGATG
GTGTCCCTGAACTACCAGACACCCGACCTGGCCATGCAGCTGAACCAGGGCAAGTTCGAGTACAACGGCAGCTGCGGC
TACCTGCTGAAACCCGACTTCATGAGAAGGCCCGACAGAACCTTCGACCCCTTCAGCGAGACACCCGTGGATGGCGTG
ATCGCCGCCACATGTAGCGTGCAAGTGATCAGCGGCCAGTTCCTGAGCGACAAGAAAATCGGCACCTACGTGGAAGTG
GATATGTACGGCCTGCCCACCGACACCATCAGAAAAGAATTCAGAACCCGGATGGTCATGAACAACGGCCTGAACCCC
GTGTACAACGAAGAGTCTTTCGTGTTCCGCAAAGTGATCCTGCCAGACCTGGCCGTGCTGAGAATCGCCGTGTACGAC
GACAACAACAAGCTGATCGGCCAGAGAATCCTGCCCCTGGACGGACTGCAGGCTGGCTACAGACACATCAGCCTGAGA
AACGAGGGCAACAAGCCCCTGAGCCTGCCTACCATCTTCTGCAACATCGTGCTGAAAACCTACGTGCCAGACGGCTTC
GGCGACATCGTGGACGCTCTGAGCGACCCTAAGAAGTTCCTGTCCATCACCGAGAAGCGGGCCGACCAGATGAGGGCC
ATGGGCATCGAGACATCCGATATCGCCGACGTGCCAAGCGACACCTCTAAGAACGACAAGAAGGGCAAGGCTAACCCC
GCCAAGGCCAACGTGACACCCCAGTCTAGCAGCGAGCTGAGGCCTACCACAACAGCCGCTCTGGGCTCTGGCCAGGAA
GCCAAGAAGGGAATCGAGCTGATCCCCCAAGTGCGGATTGAGGACCTGAAGCAGATGAAGGCCTATCTGAAGCACCTG
AAAAAGCAGCAGAAAGAACTGAACTCTCTGAAGAAAAAGCACGCCAAAGAACACAGCACCATGCAGAAGCTGCACTGC
ACCCAGGTGGACAAGATCGTGGCCCAGTACGACAAAGAGAAGTCCACCCACGAGAAGATTCTGGAAAAGGCCATGAAG
AAGAAAGGCGGCTCTAACTGCCTGGAAATCAAGAAAGAGACTGAGATCAAGATCCAGACCCTGACCACCGACCACAAG
AGCAAAGTGAAAGAAATCGTGGCTCAGCATACCAAAGAATGGAGCGAGATGATCAACACCCACAGCGCCGAGGAACAG
GAAATCAGGGACCTGCACCTGAGCCAGCAGTGCGAGCTGCTGAGAAAGCTGCTGATTAACGCCCACGAGCAGCAGACC
CAGCAGCTGAAGCTGTCCCACGACCGCGAGAGCAAAGAGATGCGGGCTCACCAGGCCAAGATCAGCATGGAAAACTCC
AAGGCCATCAGCCAGGACAAGAGCATTAAGAACAAGGCCGAGCGCGAGCGGAGAGTGCGCGAGCTGAACAGCTCCAAC
ACCAAAAAGTTTCTGGAAGAACGGAAGCGGCTGGCCATGAAGCAGTCCAAAGAGATGGACCAGCTGAAGAAGGTGCAG
CTGGAACACCTGGAATTTCTGGAAAAGCAGAACGAGCAGGCCAAAGAAATGCAGCAGATGGTCAAGCTGGAAGCCGAG
ATGGACAGACGGCCTGCTACCGTGGTGTAACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
  
Appendix 
176 
 
9.6.14 Prkcb 
GGATCCGCCACCATGGCTGATCCTGCTGCTGGCCCTCCACCTAGCGAGGGCGAAGAAAGCACAGTCAGATTCGCCAGA
AAGGGCGCTCTGAGACAGAAAAACGTGCACGAAGTGAAGAACCACAAGTTCACCGCCCGGTTCTTCAAGCAGCCCACC
TTCTGCAGCCACTGCACCGACTTCATCTGGGGCTTCGGCAAGCAGGGATTCCAGTGCCAAGTGTGCTGCTTCGTGGTG
CACAAGAGATGCCACGAGTTCGTGACCTTCAGCTGCCCTGGCGCCGATAAGGGCCCTGCCTCTGACGACCCTAGAAGC
AAGCACAAGTTTAAGATCCACACCTACAGCTCCCCAACCTTCTGTGACCACTGCGGCAGCCTGCTGTACGGCCTGATC
CACCAGGGCATGAAGTGCGACACCTGTATGATGAACGTGCACAAACGCTGCGTGATGAATGTGCCCAGCCTGTGCGGC
ACCGACCACACCGAGAGAAGAGGCAGAATCTACATCCAGGCCCACATCGACCGCGAGGTGCTGATTGTGGTCGTGCGG
GACGCCAAGAACCTGGTGCCCATGGACCCTAACGGCCTGAGCGACCCCTACGTGAAGCTGAAGCTGATCCCCGACCCC
AAGAGCGAGAGCAAGCAGAAAACAAAGACCATCAAGTGCAGCCTGAACCCCGAGTGGAACGAGACATTCAGATTCCAG
CTGAAAGAGAGCGACAAGGACAGACGGCTGAGCGTGGAAATCTGGGACTGGGACCTGACCAGCAGAAACGACTTCATG
GGCAGCCTGAGCTTCGGCATCAGCGAGCTGCAGAAAGCTGGCGTGGACGGCTGGTTCAAGCTGCTGTCTCAGGAAGAG
GGCGAGTACTTCAACGTGCCCGTGCCTCCTGAGGGCAGCGAGGGAAACGAGGAACTGAGGCAGAAGTTCGAGAGAGCC
AAGATCGGCCAGGGCACCAAGGCCCCCGAGGAAAAGACCGCCAACACCATCAGCAAGTTCGACAACAACGGCAACAGG
GACAGAATGAAGCTGACAGACTTCAATTTCCTGATGGTGCTGGGCAAGGGCTCCTTCGGCAAAGTGATGCTGAGCGAG
AGAAAGGGCACCGACGAGCTGTACGCCGTGAAGATCCTGAAGAAAGACGTCGTGATCCAGGACGACGACGTGGAATGT
ACCATGGTGGAAAAGAGAGTGCTGGCTCTGCCCGGCAAGCCCCCATTCCTGACACAGCTGCACAGCTGCTTCCAGACC
ATGGACAGACTGTACTTCGTGATGGAATACGTGAACGGCGGCGACCTGATGTACCACATCCAGCAAGTGGGCAGATTC
AAAGAACCCCACGCCGTGTTCTACGCCGCCGAGATCGCTATCGGCCTGTTCTTCCTGCAAAGCAAGGGCATCATCTAC
AGGGACCTGAAGCTGGACAACGTGATGCTGGACAGCGAGGGCCACATCAAGATCGCCGACTTCGGCATGTGCAAAGAG
AACATCTGGGACGGCGTGACCACCAAGACATTCTGCGGCACCCCCGACTATATCGCCCCCGAGATCATTGCCTACCAG
CCCTACGGCAAGTCCGTGGATTGGTGGGCTTTCGGCGTGCTGCTGTATGAGATGCTGGCTGGCCAGGCCCCTTTCGAG
GGCGAGGATGAGGATGAGCTGTTCCAGAGCATCATGGAACACAACGTGGCCTACCCTAAGAGCATGAGCAAAGAAGCC
GTGGCCATCTGCAAGGGCCTGATGACCAAGCACCCCGGCAAGAGACTGGGCTGTGGACCCGAAGGCGAGAGAGATATC
AAAGAGCACGCCTTCTTCCGGTACATCGACTGGGAGAAGCTGGAACGGAAAGAGATCCAGCCCCCCTACAAGCCCAAG
GCCTGTGGCAGAAACGCCGAGAACTTCGACAGATTCTTCACCAGACACCCCCCCGTGCTGACCCCCCCAGATCAGGAA
GTGATCAGAAACATCGACCAGAGCGAGTTCGAGGGCTTTAGCTTCGTGAACAGCGAGTTCCTGAAGCCTGAAGTGAAG
TCCTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
9.6.15 Slx4ip long isoform 
GGATCCGCCACCATGGCCAGCAAGAAATTCGCCGTGAAGTGCGGCAACTTCGCCGTGCTGGTGGACCTGCATGTGCTG
CCTCAGGGCAGCAACAGAGACAGCAGCTGGTTCAGCGAGCAGAAAAAAGAGGAAGTGTGCCTGCTGCTGAAAGAGACA
ATCGACAGCCGCGTGAAAGAATACGTGGGCATCTACAAGCAGAGAAAGCCCAGCAGCGCCGAGTTCACCAGAAGCAGC
CCTCTGAGCCTGAAGGGCTACGGCTTCCAGATCACCGCCTACTTTCTGAAGAGAGGCATCCATCTGCACTGCATCCAG
AACAGCCAGAACACCGAGCTGAGAGTGTTCCCCGAGAGATTCGTCGTGTGCGTGTCCCAGCTGGCCTTCGGCCACGAT
ATCTGGGCCAACCAGAACGAGAAGTCCACCAAGAAAGCCCTGCACGGCGTGTCCGACTACTTCCCTGAGTGTGCCGAG
AGCAGCCCTAGCCCTGGCACCAAGCTGAAGAGAAACGCCCTGAAAGAAATCGTGCGGAGGACCAAGAGCAAGGGCACC
GACGTGTCCAAGCCTCAGCCTAGCGGAGATCTCGTGGGCAGATCCAGCGACAGCGTGATCACCGTGGTGCCTTGGAGA
AGAGATGCCAGCGCCATCCTGCTGAGCGAGTCTGTGGGACAGGCCCAGGACGATATCAGAGCCGCCAAGAGCCACCAG
GAACTGCCCGTGCAGAAACTGGAAAATGTGTCCCAGACCCAGCCCGGCGACACCAGATCACAGCAGCAGCTGCATCCT
GGCGAGTGGCTGAAAACCGGCCTGCTGTCTAGAAGCCCCGCCTACAACTACGAGAGCGCCAGCCCAGGCCCTAAGCAG
TCTCTGAGAGCCGCTAAGACCCAGCAGAAGCACAGAAACTGCGGCAGCGTGGAAGATTGCGACCACCGCAGAAGAGTG
TCCCTGGGCAACGAGGGACTGGTGCCTGAGGACGCTGACCGCGAGAGATCTACAGCTGTGCGGGTGCTGCCTGCCCTG
GAACTGTCTGATCCTGGACTGCTGCTGAAGCAGGACCTGGCCAAGGCCAAGGCTAAAGAGGAACTGCACGCCCTGGAA
AACCTGAGCAGCAGACACCTCGTGACCAACAACCCAGGCCAGGCCCAGCAGAGCGATAGCGCTGCTATCACCGAGCAG
CTGGCCACAGATCAGGGCGGACCTAGCAAGAAGAGAAAGAAGCTGCAGAGCTACAACAGAGGCTGCAGCGGCAAGAAG
AACTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
  
Appendix 
177 
 
9.6.16 Slx4ip short isoform 
GGATCCGCCACCATGGCCAGCAAGAAATTCGCCGTGAAGTGCGGCAACTTCGCCGTGCTGGTGGACCTGCATGTGCTG
CCTCAGGGCAGCAACAGAGACAGCAGCTGGTTCAGCGAGCAGAAAAAAGAAGTGATGGCCTTCAGGTCCCAGCTGATC
TCCAGCAGAGAGGGCTACACCTTCACCGTGTCCAGAACCCCCAGAATCCTGACCAAGAAAGCCCTGCACGGCGTGTCC
GACTACTTCCCTGAGTGTGCCGAGAGCAGCCCTAGCCCTGGCACCAAGCTGAAGAGAAACGCCCTGAAAGAAATCGTG
CGGAGGACCAAGAGCAAGGGCACCGACGTGTCCAAGCCTCAGCCTAGCGGAGATCTCGTGGGCAGATCCAGCGACAGC
GTGATCACCGTGGTGCCTTGGAGAAGAGATGCCAGCGCCATCCTGCTGAGCGAGTCTGTGGGACAGGCCCAGGACGAT
ATCAGAGCCGCCAAGAGCCACCAGGAACTGCCCGTGCAGAAACTGGAAAACGTGTCCCAGACCCAGCCCGGCGACACC
AGATCTCAGCAGCAGCTGCATCCTGGCGAGTGGCTGAAAACCGGCCTGCTGTCTAGAAGCCCCGCCTACAACTACGAG
AGCGCCAGCCCAGGCCCTAAGCAGTCTCTGAGAGCCGCTAAGACCCAGCAGAAGCACAGAAACTGCGGCAGCGTGGAA
GATTGCGACCACCGCAGAAGAGTGTCCCTGGGCAACGAGGGACTGGTGCCTGAGGACGCTGACCGCGAGAGATCTACA
GCTGTGCGGGTGCTGCCTGCCCTGGAACTGTCTGATCCTGGCCTGCTGCTGAAACAGGACCTGGCCAAGGCCAAGGCT
AAAGAGGAACTGCACGCCCTGGAAAACCTGAGCAGCAGACACCTCGTGACCAACAACCCAGGCCAGGCCCAGCAGAGC
GATAGCGCTGCTATCACAGAGCAGCTGGCCACCGATCAGGGCGGACCTAGCAAGAAGAGAAAGAAGCTGCAGAGCTAC
AACAGAGGCTGCAGCGGCAAGAAGAACTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
9.6.17 Swap70 
GGATCCGCCACCATGAGAGGCCTGAAGGACGAGCTGCTGAAGGCCATCTGGCACGCCTTCACAGCCCTGGACCTGGAC
AGATCCGGCAAGGTGTCCAAGAGCCAGCTGAAGGTGCTGAGCCACAACCTGTGCACCGTGCTGAAAGTGCCCCACGAC
CCTGTGGCCCTGGAAGAACACTTCAGGGACGACGATGAGGGCCCCGTGTCCAACCAGGGCTACATGCCCTACCTGAAC
AAGTTCATCCTGGAAAAGGTGCAGGACAACTTCGACAAGATCGAGTTCAACAGGATGTGCTGGACCCTGTGCGTGAAG
AAGAACCTGACCAAGAGCCCCCTGCTGATCACCGAGGACGACGCCTTCAAAGTGTGGGTCATCTTCAACTTTCTGAGC
GAGGACAAGTACCCCCTGATCATCGTGCCCGAGGAAATCGAGTACCTGCTGAAGAAACTGACCGAGGCCATGGGCGGA
GGCTGGCAGCAGGAACAGTTCGAGCACTACAAGATCAACTTCGATGACAACAAGGACGGCCTGAGCGCCTGGGAGCTG
ATCGAACTGATCGGCAACGGCCAGTTCAGCAAGGGCATGGACAGACAGACCGTGTCCATGGCCATCAACGAGGTGTTC
AACGAGCTGATCCTGGACGTGCTGAAGCAGGGCTATATGATGAAGAAGGGCCACAAGAGGAAGAACTGGACCGAGCGG
TGGTTTGTGCTGAAACCCAACATCATCAGCTACTACGTGTCCGAGGATCTGAAGGACAAGAAGGGCGACATCCTGCTG
GACGAGAACTGCTGCGTGGAAAGCCTGCCCGACAAGGATGGCAAGAAGTGCCTGTTCCTGATCAAGTGCTTCGATAAG
ACCTTCGAGATCAGCGCCAGCGACAAGAAAAAGAAACAGGAATGGATTCAGGCCATCTACAGCACCATCCATCTGCTG
AAGCTGGGAAGCCCCCCACCCCACAAAGAGGCCAGACAGAGGCGGAAAGAGCTGAGAAGAAAGCTGCTGGCCGAGCAG
GAAGAACTGGAAAGACAGATGAAGGAACTGCAGGCCGCCAACGAGAACAAACAGCAGGAACTGGAATCCGTGCGGAAG
AAGCTGGAAGAGGCCGCCTCTAGAGCCGCCGACGAGGAAAAGAAGAGACTGCAGACCCAGGTGGAACTGCAGACCAGA
TTCAGCACCGAGCTGGAAAGAGAGAAGCTGATCAGACAGCAGATGGAAGAACAGGTGGCCCAGAAGTCCAGCGAACTG
GAACAGTACCTGCAGAGAGTGCGCGAGCTGGAAGATATGTACCTGAAGCTGCAGGAAGCTCTGGAGGACGAGAGACAG
GCCAGGCAGGATGAGGAAACAGTGCGCAAGCTGCAGGCCAGACTGCTGGAAGAAGAGTCCAGCAAGAGGGCTGAGCTG
GAAAAGTGGCACCTGGAACAGCAGCAGGCCATCCAGACCACCGAGGCCGAAAAACAGGAACTGGAACAGCAGAGAGTG
ATGAAGGAACAGGCTCTGCAGGAAGCCATGGCCCAGCTGGAGCAGCTGGAACTGGAACGGAAGCAGGCCCTGGAACAG
TATGAGGGCGTGAAGAAAAAGCTGGAAATGGCCACCCACATGACCAAGTCCTGGAAGGACAAAGTGGCCCACCACGAG
GGACTGATCAGGCTGATCGAGCCCGGCAGCAAGAACCCTCACCTGATCACCAACTGGGGCCCTGCCGCTTTCACACAG
GCCGAACTGGAAGAGAGGGAAAAGTCTTGGAAAGAAAAGAAAACCACCGAGTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
  
Appendix 
178 
 
9.6.18 Xbp1 
GGATCCGCCACCATGGTGGTGGTGGCTGCTGCACCTTCTGCCGCCACAGCTGCTCCTAAGGTGCTGCTGCTGTCTGGC
CAGCCTGCTAGCGGAGGCAGAGCACTGCCACTGATGGTGCCTGGCCCTAGAGCTGCTGGCTCTGAGGCTTCTGGCACC
CCCCAGGCCAGAAAGAGACAGAGACTGACCCACCTGAGCCCCGAGGAAAAGGCCCTGAGAAGAAAGCTGAAGAACAGA
GTGGCCGCCCAGACCGCCAGAGACAGAAAGAAAGCCAGAATGAGCGAGCTGGAACAGCAGGTGGTGGACCTGGAAGAG
GAAAACCACAAACTGCAGCTGGAAAACCAGCTGCTGAGAGAAAAGACCCACGGCCTGGTGGTGGAAAATCAGGAACTG
AGAACCAGACTGGGCATGGACACCCTGGACCCTGACGAGGTGCCAGAGGTGGAAGCTAAGGGATCTGGCGTGCGGCTG
GTGGCCGGATCTGCTGAATCTGCCGCCCTGAGACTGTGCGCCCCTCTGCAGCAGGTGCAGGCTCAGCTGAGTCCCCCC
CAGAACATCTTCCCTTGGACACTGACCCTGCTGCCCCTGCAGATCCTGAGCCTGATCAGCTTCTGGGCCTTCTGGACC
AGCTGGACACTGTCCTGCTTCAGCAACGTGCTGCCCCAGAGCCTGCTCGTGTGGCGGAACAGCCAGAGAAGCACCCAG
AAAGACCTGGTGCCCTACCAGCCCCCATTCCTGTGTCAGTGGGGACCCCACCAGCCCAGCTGGAAGCCTCTGATGAAC
AGCTTCGTGCTGACCATGTACACCCCCTCACTGTAACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
9.6.19 Xbp1S 
GGATCCGCCACCATGGTGGTGGTGGCTGCTGCACCTTCTGCCGCCACAGCTGCTCCTAAGGTGCTGCTGCTGTCTGGC
CAGCCTGCTAGCGGAGGCAGAGCACTGCCACTGATGGTGCCTGGCCCTAGAGCTGCTGGCTCTGAGGCTTCTGGCACC
CCCCAGGCCAGAAAGAGACAGAGACTGACCCACCTGAGCCCCGAGGAAAAGGCCCTGAGAAGAAAGCTGAAGAACAGA
GTGGCCGCCCAGACCGCCAGAGACAGAAAGAAAGCCAGAATGAGCGAGCTGGAACAGCAGGTGGTGGACCTGGAAGAG
GAAAACCACAAACTGCAGCTGGAAAACCAGCTGCTGAGAGAAAAGACCCACGGCCTGGTGGTGGAAAATCAGGAACTG
AGAACCAGACTGGGCATGGACACCCTGGACCCTGACGAGGTGCCAGAGGTGGAAGCTAAGGGATCTGGCGTGCGGCTG
GTGGCCGGATCTGCTGAATCTGCTGCTGGCGCTGGCCCCGTCGTGACATCTCCTGAGCATCTGCCCATGGACAGCGAC
ACCGTGGCCAGCAGCGACAGCGAGAGCGATATCCTGCTGGGCATCCTGGACAAGCTGGACCCCGTGATGTTCTTCAAG
TGCCCCAGCCCTGAGAGCGCCAGCCTGGAAGAACTGCCCGAGGTGTACCCTGAGGGCCCTAGCTCTCTGCCTGCCAGC
CTGAGTCTGAGCGTGGGCACAAGCAGCGCCAAGCTGGAAGCCATCAACGAGCTGATCAGATTCGACCACGTGTACACC
AAGCCCCTGGTGCTGGAAATCCCCAGCGAGACAGAGTCCCAGACCAACGTGGTCGTGAAGATCGAGGAAGCCCCCCTG
AGCAGCAGCGAAGAGGACCACCCTGAGTTCATCGTGTCCGTGAAGAAAGAACCCCTGGAAGATGACTTCATCCCCGAG
CTGGGAATCAGCAACCTGCTGAGCAGCTCCCACTGCCTGAGGCCTCCAAGCTGTCTGCTGGACGCCCACAGCGACTGT
GGCTACGAGGGAAGCCCTAGCCCCTTCAGCGACATGTCTAGCCCTCTGGGCACCGACCACAGCTGGGAGGACACATTC
GCTAACGAGCTGTTCCCCCAGCTGATCTCAGTGTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
  
Appendix 
179 
 
9.6.20 Znf217 
GGATCCGCCACCATGCCTACACAGAGCCTGCTGGTGTACATGGACGGCCCCGAGGTGCTGTCTAGCAGCCTGGGCTCT
CAGATGGAAGTGGACGACGCCGTGCCCATCAAGGGCCCTGTGGCTGTGCCTTTCAGAGCCGCCCAGGAAAAGTCCATG
GCCGTGGCTGAGGGCCACATGCCCCTGGACTGCATGTTCTGTAGTCAAGTGTTCAGCCAGGCCGAGGACCTGAGCCAG
CATGTGCTGCTGCAGCATAGACCCACCCTGTGCGAACCCGCCGTGCTGAGAGTGGAAGCCGAGTACCTGTCCCCCCTG
GACAAGGCCCTGGAACCTACAGAGCCCGCTCTGGAAAAGAGCGGCGAGGACCCTGAGGAACTGAGCTGCGACGTGTGC
GGCCAGACATTCCCTGTGGCCTTCGACGTGGAATCCCACATGAAGAAGCACAAGGACAGCTTCACCTACGGCTGCTCC
ATGTGCGGCAGAAGATTCAAAGAGCCCTGGTTCCTGAAGAACCACATGAGAACCCACAACGGCAAGAGCGGCACCAGA
AGCAAACTGCAGCAGGGCATGGAAAGCCCCGTGACCATCAACGAGGTGGTGCAGCCTCACGCCCCTGGCAGCATCAGC
ACCCCCTACAAGATCTGTATGGTGTGCGGCTTCCTGTTCCCCAACAAGCAGAGCCTGATCGAGCACAGCAAGGTGCAC
GCCAAAGAAACCGTGCCCAGCGCCTCTAACGTGGCCCCTGACGACCACAGAGAGGAACCCACCAGCCCCAGAGAAGAA
CTGCTGCAGTTCCTGAACCTGAGGCCCAGAAGCACCGCCGGCAGCACCGTGAAGCCTATGACCTGCATCCCCCAGCTG
GACCCCTTCACCACCTACCAGGCTTGGCAGCTGGCCACCAAGGGAAAGGTGGCAGTGGCTCAGGAAGAAGTGAAAGAG
TCCGGCCAGGAAGGCTCCACCGACAACGACGACAGCTGCAGCGAGAAAGAGGAACTGGGCGAGATCTGGGTGGGAGGC
AAGGCTGAGGGAAGCGGCAAGTCCAAGACCAGCAAGAGCAGCTGCCCTGGCCTGTCCCAGGACAAAGAGAAGCCCAGA
CACGCCAACAGCGAGGTGCCAAGCGGCGACAGCGACCCTAAGCTGAGCAGCAGCAAAGAAAAGCCTACCCACTGCTCC
GAGTGCAGCAAGGCCTTCAGAACCTACCATCAGCTGGTGCTGCACAGCAGAGTGCACAGAAAGGACAGAAGAACCGAC
GCCCTGAGCCCCACCATGGCTGTGGATGCAAGACAGCCCGGCACCTGTAGCCCTGACCTGAGCACCACCCTGGAAGAT
AGCGGCGCTGGCGATAGAGAGGGCGGAAGCGAGGACGGCTCTGAGGATGGACTGCCTGATGGCCTGCACCTGGATAAG
AACGACGACGGCGGCAAGGCTAAGCCCCTGCCTAGCAGCAGAGAGTGCAGCTACTGCGGCAAGTTCTTCCGCAGCAAC
TACTACCTGAACATCCACCTGAGGACACACACCGGCGAGAAGCCCTACAAGTGCGAGTTCTGCGAGTACGCCGCTGCC
CAGAAAACCAGCCTGAGATACCACCTGGAAAGACACCACAAGGATAAGCAGCCCGTGGACGCTGCCGCCGAGTCTAAG
TCTGAGGGCAGAAGCCAGGAACCCCAGGACGCCCTGCTGACAGCCGCTGATTCTGCCCAGACCAAGAACCTGAAGAGA
TTCCTGGACGGCGCCAAGGACGTGAAGGGCAGCCCTCCTGCCAAGCAGCTGAAAGAAATGCCCAGCGTGTTCCAGTCC
GTGCTGTCCCCTGCCCACAGCAACGACACCCAGGACTTCCACAAGCACGCCGCCGACTCTGCCGAGAAGGCCAGAAAG
TCTCCCGCCCCTACCTACCTGGACATGCAGAGAAAGAAGGCCGGCGAGCCTCAGGCCAGCAGCCCTGTGTGTAGACTG
GAAGGCGTGGGCAGCCTGGCTAGAGAGGCTGGCCACAGAGAAAAGATGGACCAGGATGCCGACTACAGACACAAGCCT
GGCGCCGACTGCCAGGACAGACCTCTGAACCTGTCTCTGGGCCCTCTGCACGCCTGTCCTGCCATCAGCCTGAGCAAG
TGCCTGATCCCCAGTATCGCCTGCCCCTTCTGCACCTTCAAGACCTTCTACCCCGAAGTGCTGATGATGCACCAGAGG
CTGGAACACAGATACAACCCCGACCCCCACAAGAACGGCAGCTCCAAGAGCGTGCTGAGGAACAGAAGGACCGGCTGC
CCTCCAGCTCTGCTGGGCAAAGATGTGCCTCCTCTGAGCGGCCTGCACAAGCCCAAGGCCAAGACCGCTTTCAGCCCT
CACAGCAAGTCCCTGCACAGCGAGAAGGCTAGACAGGGCGCCAGCGGCCCTTCTAAGGCCCCTCAGACAAGCGGCCCT
GACAACAGCACACTGGCCCCCAGCAACCTGAAGTCCCACAGATCCCAGCCTAACGCTGGCGGCACAAGCGCCACAAGA
CAGCAGCAGTCCGAGCTGTTCCCAAAGGGCGGAGTGCCTGCCGCTATGGACAAAGTGAAGAGGCCCGAGCCCAAGCTG
AAGTCTCTGCCTGCCAGCCCTAGCCAGAGCCCCCTGTCCAGCAACAACAGCAACGGCAGCGTGGAATACCCCGTGAAG
GTGGACGGACCTTGGGCCCAGCAGGGAAGAGACTACTACTGCCACAGAAACTCCGGCAGCGCCGCAGCTGAGTACAGC
GAGCCACACCCCAAGAGACTGAAGTCCAGCGCCGTGTCCCTGGACACAGAGCACGCTGGCACAAACGGCAGACGGGGC
TTCGAGCTGCCCAAGTATCACGTCGTGCGGAGCATCACCAGCCTGCTGCCACCTGAATGCGTGCGGCCTCCTCCTGTG
CTGCCACACAAGGCCAGATTTCTGAGCCCTGGCGAGGTGGAATCTCCTAGCGTGCTGGCCGTGCAGAAGCCTTACTCT
GCTAGCGGCCCACTGTACACCTGTGGCCCAGTGGGACATGCCGGCGGATCTCCAGCACTGGAAGGGAAGAGGCCTGTG
TCCCACCAGCACCTGAGCAACTCCATGCTGCAGAAGAGAAGCTACGAGAACTTCATCGGCAACACCCACTACAGACCC
AACGACAAGAAGCCCTGACCTGCAGG 
BamHI cutsite | Kozac sequence | Start codon | Stop codon | Sbf1 cutsite 
